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Abstract
The drug-receptor binding kinetics are defined by the rate at which a given drug
associates with and dissociates from its binding site on its macromolecular receptor.
The lead optimization stage of drug discovery programs usually emphasizes optimiz-
ing the affinity (as described by the equilibrium dissociation constant, Kd) of a drug
which depends on the strength of its binding to a specific target. Since affinity is
optimized under equilibrium conditions, it does not always ensures higher potency
in vivo. There has been a growing consensus that, in addition to Kd, kinetic param-
eters (kon and koff ) should be optimized to improve the chances of a good clinical
outcome. However, current understanding of the physicochemical features that con-
tribute to differences in binding kinetics is limited. Experimental methods that are
used to determine kinetic parameters for drug binding and unbinding are often time
consuming and labor-intensive. Therefore, robust, high-throughput in silico meth-
ods are needed to predict binding kinetic parameters and to explore the mechanistic
determinants of drug-protein binding. As the experimental data on drug-binding
kinetics is continuously growing and the number of crystallographic structures of
ligand-receptor complexes is also increasing, methods to compute three dimensional
(3D) Quantitative-Structure-Kinetics relationships (QSKRs) offer great potential for
predicting kinetic rate constants for new compounds. COMparative BINding Energy
(COMBINE) analysis is one example of such approach that was developed to derive
target-specific scoring functions based on molecular mechanics calculations. It has
been used extensively to predict properties such as binding affinity, target selectivity,
and substrate specificity. In this thesis, I made the first application of COMBINE
analysis to derive Quantitative Structure-Kinetics Relationships (QSKRs) for the
dissociation rates. I obtained models for koff of inhibitors of HIV-1 protease and
heat shock protein 90 (HSP90) with very good predictive power and identified the
key ligand-receptor interactions that contribute to the variance in binding kinetics.
With technological and methodological advances, the use of all-atom unbiased
Molecular Dynamics (MD) simulations can allow sampling upto the millisecond
timescale and investigation of the kinetic profile of drug binding and unbinding
to a receptor. However, the residence times of drug-receptor complexes are usually
longer than the timescales that are feasible to simulate using conventional molec-
ular dynamics techniques. Enhanced sampling methods can allow faster sampling
of protein and ligand dynamics, thereby resulting in application of MD techniques
to study longer timescale processes. I have evaluated the application of τ -Random
Acceleration Molecular Dynamics (τRAMD), an enhanced sampling method based
on MD, to compute the relative residence times of a series of compounds binding to
Haspin kinase. A good correlation (R2 = 0.86) was observed between the computed
residence times and the experimental residence times of these compounds. I also per-
formed interaction energy calculations, both at the quantum chemical level and at
the molecular mechanics level, to explain the experimental observation that the res-
idence times of kinase inhibitors can be prolonged by introducing halogen-aromatic
π interactions between halogen atoms of inhibitors and aromatic residues at the
binding site of kinases. I determined different energetic contributions to this highly
polar and directional halogen-bonding interaction by partitioning the total inter-
action energy calculated at the quantum-chemical level into its constituent energy
components. It was observed that the major contribution to this interaction en-
ergy comes from the correlation energy which describes second-order intermolecular
dispersion interactions and the correlation corrections to the Hartree-Fock energy.
In addition, a protocol to determine diffusional kon rates of low molecular weight
compounds from Brownian Dynamics (BD) simulations of protein-ligand association
was established using SDA 7 software. The widely studied test case of benzamidine
binding to trypsin was used to evaluate a set of parameters and a robust set of op-
timal parameters was determined that should be generally applicable for computing
the diffusional association rate constants of a wide range of protein-ligand binding
pairs. I validated this protocol on inhibitors of several targets with varying complex-
ity such as Human Coagulation Factor Xa, Haspin kinase and N1 Neuraminidase,
and the computed diffusional association rate constants were compared with the
experiments. I contributed to the development of a toolbox of computational meth-
ods: KBbox (http://kbbox.h-its.org/toolbox/), which provides information about
various computational methods to study molecular binding kinetics, and different
computational tools that employ them. It was developed to guide researchers on the
use of the different computational and simulation approaches available to compute
the kinetic parameters of drug-protein binding.
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Zusammenfassung
Die Kinetik der Rezeptorbindung wird durch die Geschwindigkeit definiert, mit
der ein bestimmtes Medikament mit einem makromolekularen Rezeptor assoziiert
oder dissoziiert. Die Lead-Optimierungsphase von Drug-Discovery-Programmen
konzentriert sich in der Regel auf die Optimierung der Affinität (beschrieben durch
die Gleichgewichtsdissoziationskonstante, Kd) eines Medikaments, die von der Stärke
seiner Bindung an ein bestimmtes Ziel abhängt. Da die Affinität unter Gleichgewichts-
bedingungen optimiert wird, muss sie nicht unbedingt in vivo zu einer höheren Wirk-
samkeit führen. Es besteht ein wachsender Konsens darüber, dass neben Kd auch
die kinetischen Parameter (kon und koff ) optimiert werden sollten, um die Chan-
cen auf ein gutes klinisches Ergebnis zu verbessern. Allerdings ist das Verständnis
der physikalisch-chemischen Eigenschaften, die zu Unterschieden in der Bindungsk-
inetik beitragen, derzeit begrenzt. Experimentelle Methoden, die zur Bestimmung
kinetischer Parameter für die Bindung und Entbindung von Medikamenten einge-
setzt werden, sind oft zeitaufwendig und arbeitsintensiv. Daher werden robuste,
hochdurchsatzfähige In-silico-Methoden benötigt, um kinetische Bindungsparame-
ter vorherzusagen und die mechanistischen Determinanten der Wirkstoff-Protein-
Bindung zu untersuchen. Mit den kontinuierlich wachsenden experimentellen Daten
zur Arzneimittelbindungskinetik und der zunehmenden Anzahl kristallographischer
Strukturen von Liganden-Rezeptorkomplexen bieten Verfahren zur Berechnung drei-
dimensionaler (3D) Quantitativen-Struktur-Kinetik-Beziehungen (QSKRs) ein großes
Potenzial zur Vorhersage kinetischer Geschwindigkeitskonstanten für neue Verbindun-
gen. Die Comparative BINding Energy (COMBINE)-Analyse ist ein solcher Ansatz,
der entwickelt wurde, um zielgerichtete Scoring-Funktionen auf der Grundlage moleku-
larmechanischer Berechnungen abzuleiten. Es wurde umfassend genutzt, um Eigen-
schaften wie Bindungsaffinität, Zielselektivität und Substratspezifität vorherzusagen.
In dieser Arbeit habe ich die erste Anwendung der COMBINE-Analyse zur Ableitung
von Quantitative Structure-Kinetics Relationships (QSKRs) für die Dissoziation-
sraten durchgeführt. Ich erhielt Modelle für koff von Inhibitoren der HIV-1-Protease
und des Hitzeschockproteins 90 (HSP90) mit sehr guter Vorhersagekraft und iden-
tifizierte die wichtigsten Liganden-Rezeptoren-Interaktionen, die zur Varianz der
Bindungskinetik beitragen.
Mit technologischen und methodischen Fortschritten kann der Einsatz von All
Atomaren unbiased Molecular Dynamics (MD)-Simulationen bis in den Millisekun-
denbereich und die Untersuchung des kinetischen Profils der Medikamentenbindung
und -entbindung an einen Rezeptor ermöglicht werden. Die Lebensdauer vonWirkstoff-
Rezeptorkomplexen sind jedoch in der Regel länger als die Zeiten, die mit herkömm-
lichen molekularen Dynamikverfahren simuliert werden können. Verbesserte Ver-
fahren können eine schnellere Probenahme von Protein- und Ligandendynamik er-
möglichen, was zur Anwendung von MD-Techniken zur Untersuchung länger an-
dauernder Prozesse führt. Ich habe die Anwendung von τ -Random Acceleration
Molecular Dynamics (τRAMD), einer verbesserten Probenahmemethode auf MD-
Basis, zur Berechnung der relativen Verweilzeiten einer Reihe von Verbindungen, die
an die Haspin-Kinase binden, ausgewertet. Es wurde eine gute Korrelation (R2=
0,86) zwischen den berechneten Verweilzeiten und den experimentellen Verweilzeiten
dieser Verbindungen bestimmt. Ich habe auchWechselwirkungsenergieberechnungen
sowohl auf quantenchemischer als auch auf molekularmechanischer Ebene durchge-
führt, um die experimentelle Beobachtung zu erklären, dass die Verweilzeiten von
Kinase-Inhibitoren durch die Einführung von halogenaromatischen πWechselwirkun-
gen zwischen Halogenatomen von Inhibitoren und aromatischen Resten an der Bindestelle
von Kinasen verlängert werden können. Ich bestimmte verschiedene energetische
Beiträge zu dieser hochpolaren und gerichteten Halogen-Bindungswechselwirkung,
indem ich die auf quantenchemischer Ebene berechnete gesamte Wechselwirkungsen-
ergie in ihre konstituierenden Energiekomponenten aufteilte. Es wurde beobachtet,
dass der Hauptbeitrag zu dieser Interaktionsenergie aus der Korrelationsenergie
stammt, die intermolekulare Dispersionswechselwirkungen zweiter Ordnung und die
Korrelationskorrekturen zur Hartree-Fock-Energie beschreibt.
Darüber hinaus wurde mit Hilfe der SDA 7-Software ein Protokoll zur Bestim-
mung der Diffusions kon raten von niedermolekularen Verbindungen aus Brownian
Dynamics (BD)-Simulationen von Protein-Liganden-Assoziationen erstellt. Der aus-
führlich untersuchte Testfall der Benzamidinbindung an Trypsin wurde verwendet,
um eine Reihe von Parametern zu bewerten, und es wurde ein Satz optimaler Pa-
rameter bestimmt, der allgemein anwendbar sein sollten, um die Diffusionsratenkon-
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stanten für Assoziation einer breiten Palette von Protein-Liganden-Bindungspaaren
zu berechnen. Ich habe dieses Protokoll über Inhibitoren von mehreren Zielpro-
teine mit unterschiedlicher Komplexität wie Human Coagulation Factor Xa, Haspin
Kinase und N1 Neuraminidase validiert, und die berechneten Diffusionsratenkon-
stanten für Assoziation mit Experimenten verglichen. Ebenso habe ich an der En-
twicklung einer Toolbox von Berechnungsmethoden mitgewirkt: KBbox (http://
kbbox.h-its.org/toolbox/), die Informationen über verschiedene Berechnungsmeth-
oden zur Untersuchung der molekularen Bindungskinetik und verschiedene Berech-
nungswerkzeuge, die diese verwenden, liefert. Dieses Tool wurde entwickelt, um
Forscher bei der Suche nach neuen Simulationsmethoden unter der Berechnung von
kinetischen Parameter zu unterstützen.
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Chapter 1
Introduction
Drug binding can be considered as a bimolecular reaction where a drug binds to its
target receptor. Understanding the process of drug-receptor binding is crucial for
structure-based drug design and is of fundamental importance for pharmaceutical re-
search. The binding affinity, which determines the strength of drug-receptor binding,
is usually considered as the most important quantitative metric for estimating the
drug’s efficacy on the basis of strength of target binding. Therefore, drug discovery
programs mainly focus on the design of drug molecules with high receptor affinity
and selectivity. For this reason, several computational methods based on molecular
dynamics (MD) simulations have been developed to compute receptor-ligand bind-
ing affinities[1]. However, designing drug compounds to have high binding affinity
does not always result into higher potency in vivo. Over the past few years, it has
been becoming evident that drug binding kinetics may play a major role in efficacy.
Recently, it has been realized that the efficacy of a drug is sometimes more cor-
related with its residence time at the receptor than the affinity[2]. This has led to
widespread efforts in both industry and academia to consider the role of drug binding
kinetics in their drug discovery programs[3]. Therefore, the demand for both com-
putational and experimental methods for studying the drug-target binding kinetics
is expected to rise. With advances in the computational power and availability of
specialized architectures, now it is possible to apply simulation methodologies for
relatively longer time scales (upto a few milliseconds) and this has enabled studies of
the dynamics of ligand-receptor binding/unbinding using molecular simulations. In
addition, progress in machine learning technologies and the availability of datasets of
measured kinetic parameters has enabled the understanding of key ligand-receptor
1
features[3]. Since the experimental approaches that are commonly used to determine
binding kinetic parameters are often time-consuming, labour intensive and expen-
sive, there is a need to develop robust and improved in silico methods that can be
used to compute and predict kinetic parameters for drug-receptor binding and can
be used during the drug discovery and design process. With the growing level of
interest in drug-binding kinetics, it can be expected that there will be an increased
application of computational approaches to study drug-binding kinetics and that
new methods will be developed for this purpose.
1.1 Drug-binding kinetics and its importance
The binding of a ligand (L) to its target receptor (R) can be considered as a bi-
molecular reaction which can be characterized by standard kinetic parameters: kon,
the association rate constant (M−1s−1) that defines the rate of formation of receptor-
ligand complex (RL); koff , the dissociation rate constant (s−1), which measures the
rate of dissociation of a receptor-ligand complex (RL); τ , the residence time (s),
which describes the lifetime of a receptor-ligand complex and is given by the inverse
of the dissociation rate constant (τ = 1/koff ); and by a thermodynamic parameter,
also known as the equilibrium dissociation constant, Kd ≡ [L][R]/[LR], (units: [M]).
Kd is related to the binding free energy ∆G as:
Kd = e
+∆G
kBT (1.1)
The simple one-step binding model with the transition state RL# (see Figure
1.1 A) can be represented as:
R + L
k1−−⇀↽−
k−1
RL (1.2)
where k1 and k−1 are the rate constants for the association of receptor and ligand
to form the receptor-ligand complex (k1 = kon) and for the complex to dissociate
(k−1 = koff ), respectively (see Figure 1.1 A).
Under steady-state conditions:
Kd =
koff
kon
=
k−1
k1
(1.3)
In general, the process of ligand-receptor binding can be represented as a two-step
process with an intermediate state RL∗ (see Figure 1.1 B):
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Figure 1.1: Two models for describing bimolecular receptor-ligand (R-L) binding, (A) one-step
binding model and (B) two-step binding model. The plots show one-dimensional schemes of simpli-
fied energy landscapes where important free energy minima and maxima are marked; the heights
of these barriers are related to the kinetic parameters (see text). The figure is adapted from
Romanowska et al.[4]
R + L
k1−−⇀↽−
k−1
RL∗
k2−−⇀↽−
k−2
RL (1.4)
Here, the first step of the binding process describes the diffusion-controlled ap-
proach of the ligand (L) towards the receptor (R) to form a diffusional encounter
complex (RL∗) which is often characterized as a relatively stable, but not fully des-
olvated and ordered, arrangement of the ligand and receptor molecules[5, 6, 7]. The
equilibrium dissociation constant (K∗d) for this step can be given as K∗d = k1/k−1
[M]. The second step of the binding process involves overcoming an energetic barrier
(see RL## in Figure 1.1 B) to achieve a stable, low-energy bound state RL. This
step is often referred to as an induced-fit step as it is associated with the forma-
tion of short-range interactions (such as hydrogen bonds) between the interacting
molecules, the displacement of water molecules occupying the binding pocket, and
the conformational changes thereby allowing the ligand and receptor molecules to
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adapt to each other. This two-step model of binding leads to a more complicated
relationship between the rates of forward and reverse reactions and kon/koff . If the
second step is faster than the first step, the binding is considered to be diffusion-
limited, and in this case kon is mostly determined by the forward rate of the first
binding step (k1) and the ligand concentration, while koff is mostly determined from
the reverse rate of the second step (k−2) with τ ∼ 1/k−2[2, 8].
1.2 Current state-of-the-art in computing
drug-binding kinetics
In recent years, several promising computational methods have been developed for
the compution of rate constants for ligand-receptor binding and understanding the
mechanistic determinants of ligand-receptor binding processes[9] (see Figure 1.2);
for reviews see [1, 2, 3, 10, 11, 12, 13, 14]. These methods include different types of
enhanced sampling molecular dynamics simulations and the combination of energy-
based models with chemo-metric analysis. Some of these approaches are developed
for computing absolute association (kon) and/or dissociation (koff ) rate constants,
while others are developed for computing relative rate constants for a series of com-
pounds. While some of these methods provide detailed information on pathways
and binding/unbinding mechanisms, others just provide hints about the key deter-
minants of the rate constants. The choice of an appropriate computational method
depends on the level of complexity of the ligand-receptor binding process and the
specific challenges posed by the system of interest. The magnitude of the associa-
tion/dissociation rate constants, size and flexibility of the system are some of the key
factors that must be taken into account while making a choice of the appropriate
method[9]. Some of the computational methods make approximations that allow
increasingly challenging systems to be studied, while others are more computation-
ally rigorous and hence limited to certain classes of system (see following sections).
Recently Bruce et al.[9] assessed the key computational approaches to compute rates
for ligand-receptor binding processes, in terms of the classes of protein-ligand sys-
tems studied and the varying levels of complexity of the protein-ligand binding
processes (see Figure 1.3). The following sections discuss the examples of the ap-
plication of these computational methods to specific protein-ligand systems which
are categorized into 4 main categories (similar to categories described in Bruce et
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al.[9]) depending upon the level of flexibility of the proteins and ligands studied and
the complexity of the binding process simulated. While a few of the systems are
rather easier to simulate due to their low flexibility and faster binding, for others
simulating them might be very challenging as the binding might involve large con-
formational changes and therefore, the high flexibility of the interacting protein and
ligand molecules should be properly addressed.
Figure 1.2: Methods for computing ligand-receptor kinetics. The figure is taken from Bruce et
al.[9] and reproduced with permissions (Citations listed for recently published applications corre-
spond to cited articles in Bruce et al.[9]). The simulation time ranges correspond to those in these
applications. The simulation time depends on the properties of the system studied as well as the
methods used.
1.2.1 Fast binding of small, rather rigid ligands: the
trypsin–benzamidine complex and fragment binding
The relatively small size of both trypsin and benzamidine, their comparative rigid-
ity, as well as their relatively fast binding, have made the trypsin–benzamidine
complex a popular model system for developing and testing methods for computing
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protein–ligand binding kinetics (see Figure 1.3 A). In 2011, Buch et al.[15] applied
conventional molecular dynamics (CMD) simulations combined with Markov state
modelling (MSM) to identify multiple intermediate states for trypsin-benzamidine
binding and to compute the kinetics of an overall two-state binding model. In the
MSM approach, only partial binding or unbinding transitions are observed from a
simulated trajectory. These trajectories are first geometrically clustered in a prede-
fined conformational subspace from which a transition matrix (TM) of discretized
microstates is derived. Then, metastable states can be identified from the kinetic
clustering of the microstates by using eigenvectors of the TM. The kon and koff
values calculated by Buch et al.[15] using the MSM approach were 5-fold and 150-
fold greater than the respective experimental values. Recently, Plattner and Noe
[16] managed to compute kinetic rate constants closer to experimental values by
applying a more rigorous multiscale model for MSMs to trypsin-benzamidine bind-
ing. However, they needed three times (150 µs) more CMD sampling compared
to the CMD sampling (50 µs) required by Buch et al.[15]. Doerr and Fabritiis[17]
attempted to reduce this computational demand by demonstrating the application
of the Adaptive Markov state model (AMSM) method to trypsin-benzamidine bind-
ing and they managed to sample ligand binding one order of magnitude faster than
the classical sampling. AMSM methods iteratively perform multiple short trajecto-
ries of ensemble simulations. After each iteration, an MSM is constructed to learn
a simplified model of the simulations and provide information on the locations of
rarely sampled states. This information is then used to perform the next round of
simulations to facilitate the crossing of the transition barrier.
The trypsin-benzamidine system has also been studied using the metadynamics
(MetaD) approach[18]. In MetaD, a time-dependent biasing potential, represented
by a sum of Gaussian functions, is added along a particular geometric coordinate
(the so-called collective variable, CV) during a simulation, and this helps to sample
the regions that are separated by notable energy barriers. The CVs, to represent the
transition pathway or dissociation process (in the case of koff computation), must be
carefully chosen in MetaD. The method makes the critical assumption that the CVs
chosen, represent the dissociation process as a single rate-limiting transition between
two metastable states, and therefore the quality of the model can be evaluated by
a statistical analysis. The kon and koff rate constants calculated with MetaD were
2-fold and 70-fold lower, respectively, than the experiment[18].
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Teo et al.[19] applied the adaptive multistate splitting (AMS) method to com-
pute koff rates for the trypsin-benzamidine system and the computed koff values
were 2-fold slower than the experimental value. In the AMS method, an ensemble
of simulation trajectories is started from the bound state and they are periodically
pruned and restarted from the coordinates chosen so that the system progresses to-
wards the unbound state. Prior knowledge of the transition paths is however not
required in AMS. To enhance sampling of unbinding pathways for benzamidine from
trypsin, Dickson and Lotz[20] applied WExplore, a method based on Weighted en-
semble (WE) path sampling, and the computed koff values were 10 times higher
than experiment. The Weighted ensemble (WE) path sampling approach requires
defining a reaction coordinate which divides the progression from an initial (un-
bound) state to a target (bound) state into several bins. A number of trajectories
is started from the initial state having each trajectory assigned an equal weight
or probability. After a short time interval, the current bin of each trajectory is
recorded and the trajectories entering the new bins are either split or combined in
order to have a predetermined number of trajectories for each bin. In this way,
trajectories are periodically reweighted in a rigorous statistical manner, and the
whole process is iterated several times to generate a weighted trajectory ensem-
ble. This weighted ensemble provides information on transition probabilities and
the evolving configurational distribution. The Brownian dynamics (BD) is another
computationally inexpensive method that has recently been applied to compute dif-
fusional association rate constants for inhibitors, such as oseltamivir binding to the
neuraminidase[21]. BD is a stochastic method which uses an implicit continuum sol-
vent model and the diffusional motion of solutes is propagated by integration of the
overdamped Langevin equation. To account for solvent friction effects accurately,
the random collisions are modelled with the Langevin equation. Due to the use of
rigid structures, simplified force fields and an implicit solvent model in BD, it poses
significant limitations for small but flexible molecules, as well as conformation depen-
dent protein-binding. However, such limitations can be overcome by using multiscale
methods that combine BD with MD. In such multiscale approaches, BD simulations
can be used to model the initial diffusional association of two molecules, following
which an MD-based regime can be used to simulate the formation of the final bound
complex, thereby accounting for the flexibility of the molecules and the conforma-
tional changes. Votapka et al.[22] demonstrated the application of such a multiscale
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approach to the trypsin-benzamidine binding using their software SEEKR[22], which
uses a milestoning approach to combine BD and MD-based regimes. The kon rates
calculated from SEEKR were in good agreement with experiment whereas, the koff
value was within a factor of 10 of experimental values[22].
1.2.2 Unbinding with conformational changes: kinase and
heat shock protein 90 (HSP90) inhibitors
Both protein kinases and HSP90 are considered as challenging targets for comput-
ing drug-binding kinetics because of their high binding site flexibility (see Figure
1.3 B). Metadynamics (MetaD)[18], an approach that uses a time-dependent energy
function to enhance sampling of particular regions of configurational space, has been
applied to a number of protein kinases for computation of koff values. Tiwari et
al.[23] applied MetaD to compute the dissociation rates of dasatinib from c-Src ki-
nase. CVs used in this study were the distance between the ligand and the binding
pocket, and a term describing the solvation state of the binding pocket. Casasnovas
et al.[24] used MetaD to study the unbinding kinetics of a urea-based allosteric in-
hibitor from p38 MAP kinase. They have used two pathway-based CVs (along and
perpendicular to the pathway) which were identified from 8 snapshots from steered
MD (SMD) dissociation trajectories. The dissociation rates computed in both of
the studies were in good agreement with experiment. Callegari et al.[25] attempted
to estimate the relative koff values of a set of cyclin-dependent kinase 8 (CDK8)
inhibitors by proposing an alternative MetaD-based method. Seven CVs that en-
code both roto-translational and conformational motions of the ligand, were used
for driving the ligands to the point of dissociation. The authors managed to rank a
set of CDK8 inhibitors by their residence time, in good agreement with experiment.
Mollica et al.[26] proposed scaled or smoothed-potential MD, another simpler ap-
proach for ranking koff values, which does not involve the definition of CVs. This
approach involves smoothing the system’s potential energy with a constant scaling
parameter, resulting in the increased sampling of the conformational space. How-
ever, in applications to protein–ligand dissociation, a set of restraints is applied on
all protein heavy atoms outside the binding site to prevent protein unfolding and
keep the protein in its native conformation. The method was validated on several
ligands of HSP90, Glucose-Regulated Protein (Grp78), and adenosine A2A receptor
(A2A), and in all cases, method was able to rank these ligands correctly.
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Figure 1.3: Examples of protein–ligand systems for which binding kinetics have been computed,
illustrating some of the challenges posed for these calculations. The proteins are shown in cartoon
representation along with their ligands and selected residues in stick representation. The insets
show the molecular solvent accessible surface of the binding pockets as blue wireframes. (a) The
trypsin–benzamidine complex is a classic model system for studying ligand binding due to its fast
binding kinetics (PDB ID: 3PTB). Benzamidine binds in a surface exposed cleft, with the amidine
forming hydrogen bonds with the sidechain of D189 and the backbone carbonyl of G129 (inset).
(b) p38 MAP kinase with allosteric (upper inset, PDB ID: 1KV2) and orthosteric (lower insert,
PDB ID: 4ZTH) inhibitors and the kinase activation loop and the DFG motif highlighted (pink).
Computation of the binding kinetics of allosteric inhibitor binding to this and other kinases requires
consideration of a switch of the D and F positions in the DFG loop, which opens a concealed cavity
in the binding pocket that is otherwise blocked by the phenylalanine residue of the DFG loop. (c)
The A2A GPCR with a triazine derivative (PDB ID: 3UZC) bound in the orthosteric binding pocket
(inset). The dashed red line shows the location of a missing extracellular loop. The heterogeneous
membrane-bound environment of GPCRs poses additional challenges both to the determination
of accurate experimental structures and to simulation. (d) The HIV-1 protease homodimer with
ritonavir bound (PDB ID: 1HXW). HIV-protease has two β-hairpin loops (flaps) that exist in a
closed state (cyan) on ligand binding, but can also exist in semi-open (pink) or open (purple)
conformations in the unbound form. This protein flexibility, as well as the often high flexibility
of the ligands and the presence of a bridging water molecule (with H-bonds to the ligand and the
backbone amide nitrogen of I50), need to be treated in computations of binding kinetics (inset).
The figure is reproduced from Bruce et al.[9], with permissions.
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Niu et al.[27] proposed a computationally inexpensive approach by using random
acceleration molecular dynamics (RAMD) simulations and SMD to rank inhibitors of
B-RAF serine/threonine kinase by their residence time. RAMD[28, 29] simulations
were first used to obtain dissociation pathways of two inhibitors of B-RAF, followed
by application of SMD to generate potentials of mean force, which provided a struc-
tural rationale for the difference in transition state barrier in qualitative agreement
with the measured difference in binding kinetics. Recently Kokh et al.[29] developed
the τ -Random Acceleration Molecular Dynamics (τRAMD) procedure for estimation
of the relative residence times and demonstrated its application for sets of diverse
ligands of the N-terminal domain of HSP90. In τ -RAMD, an ensemble of MD sim-
ulations is run starting from the bound protein-ligand complex, and an artificial
randomly oriented force is applied to the centre of mass of the bound ligand. By
applying this artificial force, the unbinding of the ligands from the binding site can
be observed in short simulations of a few nanoseconds. The authors obtained a
good correlation between relative residence times computed from τRAMD and the
experimental residence times.
1.2.3 Binding to membrane proteins: G protein coupled
receptor (GPCR) ligands
GPCRs are considered challenging targets for computational studies due to their het-
erogeneous membrane-bound environments, and since GPCR ligands may partition
between the bilayer and solvent, it poses an extra challenge for their computer simu-
lation (see Figure 1.3 C). However, due to the increasing availability of experimental
structures of GPCR-ligand complexes over the past 10 years[30] and the importance
of engineering the residence times of GPCR-targeting compounds[31], there has been
increased interest in studying GPCRs computationally. Dror et al.[32] reported the
first computational study of GPCR binding kinetics using conventional molecular
dynamics (CMD), where they simulated the binding of antagonists and agonists to
the β2 adrenergic receptor (β2AR). The authors observed a total of 12 binding events
from 50 CMD simulations, each of up to 19 µs, of the membrane-bound receptors
with alprenolol or dihydroalprenolol antagonists. A total of 10 replicas of the al-
prenolol or dihydroalprenolol antagonists was used to improve the sampling. By
estimating the total time in which the ligand was available for binding, that is, in
aqueous solution, not penetrating the membrane, and modelling binding as a first-
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order Poisson process, the kon rate for alprenolol binding to β2AR was calculated to
be 3.1 x 107 M−1 s−1, which was in good agreement with the experimental value of
1.0 x 107 M−1 s−1. As mentioned in the previous section, Mollica et al.[26] applied
scaled MD to correctly rank a congeneric series of four A2A antagonists based on
their residence times.
Bortolato et al.[33] in 2015, reported a method that combines adiabatic bias MD
with metadynamics (aMetaD) to distinguish between short (residence time, τ < 20
min) and long (τ > 50 min) residence time compounds of 3 GPCRs, including 12
ligands of the corticotropin-releasing factor type 1 receptor (CRF1R). In adiabatic-
bias MD[34], a time-dependent harmonic energy barrier is used to drive a system
from an initial to a final state along a predefined reaction coordinate. The adiabatic-
bias metadynamics (aMetaD) approach combines a time-dependent harmonic energy
barrier to the ligand’s movements when it is not moving towards an unbound state
with MetaD using two CVs, the distance along an unbinding pathway and the dis-
tance perpendicular to the pathway. From each simulation, a score is computed that
describes the height of the traversed unbinding transition state barrier.
1.2.4 Binding of flexible ligands to flexible proteins: peptide
binding to MDM2 protein and HIV-1 protease
Several studies have been published recently that have successfully applied enhanced
sampling techniques to the calculation of rates of protein–peptide binding[35, 36].
Zwier et al.[36] computed the kon rate for the binding of the N-terminal peptide
fragment of p53 tumor suppressor to the MDM2 protein using a WE path sampling
method. In this study, the kon rate was calculated from 182 independent and con-
tinuous binding pathways obtained from a total of ≈120 µs of WE MD simulations,
from unbound to encounter complex and from encounter complex to bound state.
The computed kon value (7 ± 4 x 107 M−1 s−1) was within an order of magnitude
of the experimental value of 9.2 x 106 M−1 s−1[37]. Recently, the mechanism of
p53-MDM2 binding was studied in detail by Zhou et al.[38] using many unbiased
CMD simulations. The authors constructed MSMs from 831 µs of CMD simulations
for predicting p53 binding pathways, revealing both conformational selection and
induced-fit. The kon value (2.5 x 107 M−1 s−1) computed in this study was in good
agreement with the experimental value. However, compared to experiment[37] (2.1
s−1), the computed koff value (1.9 x 105 s−1) was strongly overestimated from tran-
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sition path theory analysis due to insufficient sampling of binding and unbinding
events.
HIV-1 protease is another challenging target known for its high flexibility and has
been studied extensively using computer simulations. It has two extended β-hairpin
loops, also known as flaps, that are known to exist in semi-open or open confor-
mations in the unbound form and these flaps close when the ligand is bound (see
Figure 1.3 D). For HIV-1 protease, the flap dynamics[39, 40] and the water-mediated
H-bonds between the flaps and the ligand[40, 41] have been shown to be important
for the binding and unbinding of its peptidomimetic inhibitors. Pietrucci et al.[35]
investigated the binding mechanism of a peptide substrate to HIV-1 protease us-
ing the bias-exchange MetaD (BEMD) approach. BEMD involves running several
replicas of metadynamics simulations for the same system at the same temperature,
with each replica biased by a time-dependent potential acting on a different set of
CVs. These replicas are then periodically allowed to exchange their configurations,
thereby allowing the biasing of a virtually unlimited number of CVs simultaneously.
The multidimensional nature of the bias makes it possible to explore a complex free
energy landscape with high efficiency. In this study, the authors sampled a total of 7
CVs which accounted for features such as flap opening, bridging water molecules, and
important physical interactions between the ligand and the protease. This conforma-
tional space was then used to construct a thermodynamic and kinetic model of the
binding process based on the weighted-histogram approach. The computed kon value
(1.26 x 106 M−1 s−1) was roughly 10 times the the experimental value[42] (≈ 0.16
x 106 M−1 s−1) whereas the computed koff value (57.1 s−1) was overestimated com-
pared to the experiment[42] (≈ 0.2-0.4 s−1). Since choosing correct CVs for BEMD
is a very difficult task, such methods cannot be applied on a high-throughput scale.
However, Sun et al.[43] recently demonstrated that for HIV-1 protease and several
other targets, it is possible to get a good agreement of koff with experiment for more
slowly dissociating drug-like compounds (koff ≈ 10−4 s−1) using standard MetaD
simulations even if the chosen set of CVs does not fully represent the slowest motion
with a single bottle-neck transition. The two CVs chosen by authors in this study
were the distance between the ligand and the binding pocket and the RMSD change
of the binding pocket. Authors were however not able to accurately calculate the
koff value for the kinase studied. But for the other 5 systems that they studied, they
managed to obtain the koff values within about an order of magnitude when using
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a single short (ns) MetaD simulation of each complex, starting from a minimized
crystal structure.
Several chemometric approaches have also been used to derive quantitative struc-
ture–kinetics relationships (QSKRs) for HIV-1 protease inhibitors. Qu et al.[44] at-
tempted to model the kinetic and thermodynamic properties of a series of HIV-1
protease inhibitors using Volsurf descriptors that were derived from Grid water and
hydrophobic probes. The three-fold cross-validation (Q2) coefficients for their opti-
mal koff and kon models were 0.695 and 0.549, respectively. Such models however
only include static structural characteristics and may not sufficiently capture the dy-
namic features of binding processes. Chiu and Xie[45] tried to address this problem
by constructing multi-target machine learning classification models integrating ener-
getic features with conformational variability features, derived from coarse-grained
normal mode analysis, to classify HIV-1 protease inhibitors into binding kinetic
classes.
1.3 Objectives and Motivation of the work
The computational studies to investigate protein-ligand interactions and to estimate
kinetics of protein-ligand binding are often addressed using biomolecular simulation-
based approaches. To reduce the computational complexity and to extend their ap-
plication to larger systems and longer timescales, these approaches often make use of
simplifications such as coarse-graining, use of implicit solvent and rigid body mod-
els, and enhanced sampling. But still, each of these methods has specific limitations
and they usually do not address some of the key aspects of protein-ligand binding.
For example, BD simulations can effectively model the diffusional encounter of pro-
tein and ligand molecules based on long-range electrostatic interactions but they
do not explain short-range effects such as desolvation effects, side-chain rearrange-
ments and conformational changes during the induced-fit step. The more detailed
MD simulations on the other hand, can address these important issues but due to
their high computational requirements, they cannot be applied to longer timescales
corresponding to drug residence times which usually range from a few seconds to
a few hours. Therefore, there is a need to develop and apply methods that allow
the more accurate prediction and effective investigation of protein-ligand binding
kinetics in a systematic manner and to address specific challenges in investigating
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protein-ligand binding kinetics. This current work aims to apply different physics-
based and bio- and chemoinformatics approaches to predict kon or koff rates for
protein-ligand binding and to investigate the mechanistic determinants of protein-
ligand binding kinetics. In such direction, the present thesis addresses the following
fundamental questions:
• Can high-throughput regression-based quantitative structure-kinetics relation-
ship (QSKR) models be derived for a series of compounds using only the struc-
tural information from their complexes with a specific protein or receptor?
• Can these QSKR models accurately predict kinetic parameters for novel com-
pounds?
• What are the key protein-ligand interactions that distinguish ligands with slow
and fast binding kinetics?
• How can residence times for drug molecules be prolonged by introducing specific
interactions such as halogen-aromatic interactions between halogenated drugs
and aromatic residues of kinases?
• How can continuum solvent and rigid-body based BD simulations be used to
assist high-throughput prediction of diffusional association rate constants for
binding of drug-like compounds to their receptors?
• How accurately can the τRAMD enhanced sampling procedure based on molec-
ular dynamics simulations predict relative residence times for a series of com-
pounds?
In addition to answering the above questions, I contributed to the development
of a toolbox of computational methods: KBbox (http://kbbox.h-its.org/toolbox/)
to help researchers to guide them to use different computational methods available
to study molecular binding kinetics. This toolbox consists of a collection of tutorials,
example cases and a theoretical overview of the current state-of-the-art methods and
tools used for computing the kinetic parameters of protein-ligand binding.
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1.4 Organization of the thesis
This thesis consists of 7 chapters. Chapter 2 provides the theoretical basis for the
different bio- and chemoinformatics and simulation-based approaches used in this
work. An overview and theoretical background of methods, such as COMBINE
analysis, Brownian dynamics and molecular dynamics is discussed. An introduction
to molecular mechanics force-fields and basic information about the continuum sol-
vent models used in this work is given. Also, the techniques commonly employed
in molecular simulations are briefly introduced and an introduction to MM/GBSA
free-energy calculations, and Møller–Plesset energy calculations is given. Further,
chapter 2 provides a short overview on different software and tools used in this thesis.
Chapter 3 describes the application of the COMBINE analysis approach to de-
rive Quantitative Structure-Kinetics Relationships (QSKRs) for koff rates of Heat
shock protein 90 (HSP90) and HIV-1 protease inhibitors. Results on predictive
QSKR models derived for inhibitors of these two therapeutically important targets
and the important protein-ligand interactions that distinguish slow and fast off-rate
compounds are presented and discussed.
Chapter 4 discusses the modulation of the residence times of inhibitors by tar-
geting the interactions between halogen atoms, commonly found in drugs, and the
aromatic residues typically found in the drug binding sites on proteins. Using haspin,
a serine/threonine kinase as a model system and halogen substituted tubercidin in-
hibitors (close analogues of ATP) as model inhibitors, it has been suggested that
residence times of inhibitors can be increased by introducing halogen-aromatic π in-
teractions between the halogen atom of the inhibitors and the aromatic gatekeeper
residues of kinases. Results from quantum chemical interaction energy calculations,
MM/GBSA free-energy calculations and τRAMD are compared to the experimental
findings and are discussed.
In Chapter 5, a protocol to compute diffusional associational rates for small
molecule binding to proteins, using BD simulations with SDA, is presented. Simula-
tion parameters that were optimized for setting up BD simulation runs for diffusional
association of protein and small molecules, are presented and a standard workflow to
analyse and compute diffusional kon rates from SDA is described. Results for valida-
tion of the protocol on inhibitors of different protein systems of varying complexity
are also discussed.
15
Chapter 6 describes the implementation and content of the KBbox (http://
kbbox.h-its.org/toolbox/), a toolbox of computational methods for studying the
kinetics of molecular binding. The software architecture and implementation of
KBbox is briefly introduced, followed by discussion on the organization of different
content in KBbox. Some of the use-cases are also described.
This thesis concludes with chapter 7 that consists of a brief conclusion and fu-
ture directions on the application of computational approaches to investigate kinetic
parameters of protein-drug binding.
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Chapter 2
Theoretical Methods and Software
This chapter gives a theoretical overview of the different chemoinformatics and
chemometric methods, as well as the methods based on bimolecular simulations,
that were employed in this work. The sequence of the methods described follows the
order in which they were employed in the subsequent chapters. In the end, a short
summary of each of the different software and tools that were employed is presented
along with the scope of their application for this study.
2.1 COMparative BINding Energy (COMBINE)
analysis
COMBINE analysis[46] is an approach for deriving quantitative structure-activity
relationships (QSAR) by exploiting the information contained in the 3D structures
of receptor-ligand complexes. In COMBINE analysis, the binding free energy, ∆G,
or a related property (such as Kd, koff , kon, pKi, pIC50) is correlated with a sub-
set of weighted interaction energy components determined from the structures of
energy-minimized receptor-ligand complexes. These interaction energy components
are typically Lennard-Jones (LJ) and Coulombic interaction energies decomposed
on a per amino acid residue basis. The binding free energies are calculated from
energy-minimized ligand-receptor complexes using a standard molecular mechanics
force field.
∆G =
nr∑
i=1
wLJi u
LJ
i +
nr∑
i=1
wCi u
C
i + C (2.1)
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Where ∆G is the binding free energy, uLJi and uCi are intermolecular Lennard-
Jones and Coulombic interaction energies calculated between each ligand and nr
amino acid residues of the protein, wLJi and wCi are weights or coefficients of these
LJ and Coulombic interaction energy terms. If, a sufficiently large number of
molecules with known activities and 3D structures of ligand-receptor structures for
these molecules is used in the training set, the weights of these interaction energy
terms can be estimated by linear fitting. Due to the fairly large number of residual
interaction terms used in the linear fitting, the use of standard multiple regression
techniques is avoided, and instead partial least squares (PLS) analysis is applied to
perform statistical analysis to determine the weights and constant C. If required,
the ligands can also be further divided into nl fragments, and thus the equation 2.1
can be rewritten as:
∆G =
nr∑
i=1
nl∑
j=1
wLJij u
LJ
ij +
nr∑
i=1
nl∑
j=1
wCiju
C
ij + C (2.2)
To perform COMBINE analysis, an energy matrix is generated where the columns
represent each of these interaction energy terms (independent variables) and the rows
correspond to each ligand in the training set. The inhibitory activities or binding
kinetics (dependent variable) of these ligands are added to the final column in the
matrix. Then, the PLS method [47][48] is used to maximize the linear correlation
between the independent and the dependent variables by performing rotations of
this matrix in the latent variables (LV) or the Principal Components (PC) space. In
order to exclude energy terms that do not contribute to binding from the QSAR, a
variable selection procedure is carried out. The variable selection procedure involves
evaluation of the effects of each independent variable on the model predictivity and
is carried out iteratively using a combination of D-optimal and fractional factorial
designs[49]. In this thesis, we did not perform variable selection procedure. Rather,
we have only used a pre-screening procedure where only those interaction energy
terms which have standard deviation higher than a specified threshhold value were
selected for PLS regression and the rest of the energy terms showing little or no
variance across the training dataset, were eliminated from statistical analysis.
The main advantages of correlating inhibitory activity or kinetics (∆G, Kd, koff ,
kon, pKi, pIC50 etc.) with residue-based interaction energy components over simply
correlating with total computed binding energy is that the resultant COMBINE
analysis model can help to highlight key interactions that are important to explain
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the observed variances in the biological activity. This information could help in
providing insights for predicting the effects of point mutations in the protein and for
designing compounds with improved binding properties. In addition, during PLS
analysis, errors either resulting from the modeled 3D structures or from force-field
parameterization can be at-least partly filtered out. The calculation of weights also
allow an implicit description of terms contributing to the dependent variable which
are not explicitly included in the model.
2.1.1 Partial least squares (PLS) regression
PLS regression [47, 48] is a statistical approach used to determine a linear regres-
sion model by projecting both the dependent and independent variables to a new
space. PLS combines features from both principal component analysis (PCA) and
multiple linear regression (MLR). As in PCA, orthogonal Principal Components
(PCs) are extracted and a fitting procedure similar to MLR is performed to describe
the response variable (biological activities of compounds). PLS is used to model
the fundamental relations between two matrices, X and Y , by finding the multidi-
mensional direction in the X space that explains the maximum multidimensional
variance direction in the Y space. In COMBINE analysis, the X matrix consists of
independent variables which are interaction energy terms and, optionally, additional
variables, such as desolvation energy terms.
X =

C11 C
1
2 ... C
1
M L
1
1 L
1
2 ... L
1
M
C21 C
2
2 ... C
2
M L
2
1 L
2
2 ... L
2
M
... ... ... ... ... ... ... ...
CN1 C
N
2 ... C
N
M L
N
1 L
N
2 ... L
N
M

where Cij and Lij are the Coulombic and Lennard-Jones variables, respectively.
N is the number of compounds and M is the number of residues in the protein.
The Y matrix consists of dependent variables i.e. the activities of the compounds.
Y =

y1
y2
...
yN

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where yi is the individual activity of compound i. In PLS, the X and Y matrices
are decomposed into one score matrix, T , and two different loading matrices, P and
Q (see equation 2.3)
X = TP T and Y = TQT (2.3)
The score matrix T contains information about the projections of compounds
onto the PCs. The PC space is normalized and has a mean of zero. The compounds
which behave as outliers usually have higher scores. The loading matrices P and Q
contain information about the variables in the so-called latent variables (LV) or PC
space. Latent variables are orthogonal vectors obtained as linear combinations of the
original variables in theX matrix. The coefficients in a given PC provide information
on the relative weights of the different terms and it can be useful to deduce the
importance of each individual ligand–residue interaction to explain the variance in
activity. The quality of the fit for the training set of compounds can be evaluated
using the regression coefficient (R2), cross-validation correlation coefficients (Q2),
average absolute errors (AAE) and root-mean squared errors (RME) (see equation
2.4 to equation 2.9).
R2 =
[∑N
i=1(yi − ȳ)(ŷi − 〈ŷi〉)
]2
∑N
i=1 (yi − ȳ)
2∑N
i=1 (ŷi − 〈ŷi〉)
2
(2.4)
Q2 = 1−
∑N
i=1 (yi − ŷi)
2∑N
i=1 (yi − ȳ)2
(2.5)
AAE =
1
N
N∑
i=1
|ŷi − yi| (2.6)
RME =
1
N
N∑
i=1
√
(ŷi − yi)2 (2.7)
Where, ȳ is the average value of the experimental activities (y1, y2, .., yN)
ȳ =
1
N
N∑
i=1
yi (2.8)
And, 〈ŷ〉 is the average value of the calculated activities (ŷ1, ŷ2, .., ŷN)
〈ŷ〉 = 1
N
N∑
i=1
ŷi (2.9)
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2.2 Brownian Dynamics
Brownian dynamics (BD) simulations are used to simulate the diffusional processes
and dynamics of particles, such as proteins, that undergo Brownian motion. In BD,
rigid body representations of interacting particles are used. The effect of solvent is
modelled using a continuum, implicit solvent model and the stochastic and friction
effects of surrounding water molecules and ions are introduced by additional terms
in the motion equation. The flexibility of the interacting molecules can be simulated
using a coarse grained force field or by switching between conformations on the fly.
Since, the internal flexibility of the proteins is generally ignored, the conformational
changes upon binding of the ligand cannot be captured in BD. However, having
fewer degrees of freedom due to the rigid-body representation in implicit solvent,
allows longer time scales (µs-ms range) of diffusional processes to be simulated and
large systems (several µm) can also be studied using BD. With BD simulations, it is
also possible to compute kinetic parameters of binding processes which is otherwise
not possible with MD simulations. But, the computation of binding kinetics is
generally limited to diffusional encounter complexes rather than bound complexes,
as short-range effects are not modelled in BD.
2.2.1 The concept of Brownian motion
Brownian dynamics is named after Robert Brown who observed the random motions
of pollen particles in water and he suggested that the stochastic collisions of particles
with the solvent (water) resulted in their random motions. The diffusive displace-
ment (∆r) of a particle in 3D in BD for a given time-step (∆t) can be determined
from the following equation given by Einstein[50] and Smoluchowski[51].
∆r2 = 6D∆t (2.10)
Here, D is the translational diffusion coefficient of the particle and for spherical
objects, it can be calculated using the following formula:
D =
kBT
6πηa
(2.11)
Here, kB is the Boltzmann constant, T is the temperature in Kelvin, η is the
viscosity of the solvent and a is the hydrodynamic radius of the particle.
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Simulating diffusional encounter
Ermak and McCammon developed an algorithm to model Brownian motion for dif-
fusional encounter of proteins by considering both translational (∆r) and rotational
(∆w) motions[52].
The translational (∆r) displacement is given by:
∆r = (kBT )
−1DTF∆t+R (2.12)
And, the rotational (∆w) displacement is given by:
∆w = (kBT )
−1DRT ∆t+ Θ (2.13)
Here, DT and DR are translational and rotational diffusion coefficients of the
molecule respectively, F and T are the position-dependent interaction force and
torque acting on the molecule and they are computed prior to taking the step ∆t.
R is the random displacement and it should satisfy the following conditions.
〈R〉 = 0 (2.14)
〈R2〉 = 6D∆t (2.15)
Similarly, Θ is the random rotational angle and it should also satisfy:
〈Θ〉 = 0 (2.16)
〈Θ2〉 = 6D∆t (2.17)
For simulating diffusional protein-ligand association in any BD software such as
SDA, one of the molecules (usually a protein) is kept fixed and the movement of the
ligand is simulated. Therefore, to account for the diffusive motion of both of the
interacting molecules, the relative translational diffusion coefficient is used in the
calculations.
2.2.2 Simulation of Diffusional Association (SDA) software
SDA (https://mcm.h-its.org/sda/) is a software package that can be used to run
Brownian dynamics simulations of the diffusional association of solute molecules
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in a continuum implicit solvent[53, 54]. Using rigid-body structures and a suitable
force field, SDA can be used to apply BD simulations to calculate binding kinetics for
protein-protein or protein-ligand association. It can also be used to perform rigid-
body docking to record diffusional encounter complexes and to calculate bimolecular
electron transfer rate constants. In addition, protein flexibility and hydrodynamic
interactions can be introduced in SDA to account for protein’s internal motion and
induced solvent effects. The theoretical background on how different interaction
forces are computed in SDA, is outlined in the following sections.
Calculation of interaction forces
The diffusional association of interacting molecules is modelled as mainly driven by
the Poisson-Boltzmann (PB) equation-derived electrostatic interaction and limited
by the presence of exclusion forces. In SDA, electrostatic interaction, electrostatic
desolvation and hydrophobic (non-polar) desolvation energies are used to simulate
diffusional association of two solute molecules[54]. The total interaction energy
(∆G1−2) between these solutes is calculated using the following equation in SDA:
∆G1−2 = ∆G1−2el + ∆G
1−2
edesolv + ∆G
1−2
DH (r) + ∆G
1−2
np + ∆G
1−2
rep (2.18)
Here, the first 3 terms approximate the Poisson-Boltzmann equation derived
electrostatic energy between a pair of solutes and the last 2 terms account for the
non-polar interactions between solutes and exclusion forces. ∆G1−2el is the long-range
electrostatic interaction energy, ∆G1−2edesolv is the short-range electrostatic desolvation
energy and ∆G1−2DH is the distance-dependent Debye-Hückel correction to the long-
range energy term, accounting for the use of finite-sized grids in the calculations.
∆G1−2np is the non-polar desolvation energy which account for the change in the
total solute-solvent interface area upon binding of solutes[55]. ∆G1−2rep is soft-core
repulsion term that describes exclusion forces by applying a continuous, repulsive
potential which prevents solutes from overlapping[56]. The exclusion forces can also
be modelled as hard-core repulsion by defining an exclusion grid.
Electrostatic interactions and effective charges
The electrostatic potential (Φ) of a solute can be computed by solving the non-linear
second-order PB equation which describes the distribution of electric potential in a
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non-uniform dielectric. This equation (2.19) can be linearized and solved numerically
for discrete grid points in the system r.
−∇.(~ε(r)∇Φ(r)) = ρ(r) +
∑
i
ciqie
− qiΦ
kBT (2.19)
Here ~ε(r) is position-dependent dielectric constant, Φ(r) is the electrostatic po-
tential, ρ(r) is molecular charge density, ci is the concentration and qi is the charge
of ions in the solvent. kB is the Boltzmann constant and T is the temperature
in Kelvin. The Adaptive Poisson-Boltzmann Solver (APBS)[57] and University of
Houston Brownian Dynamics (UHBD)[58] are two of the most commonly used pro-
grams to calculate electrostatic potentials of biomolecules by numerically solving
the Poisson-Boltzmann equation. We have used APBS for generating electrostatic
potentials of different protein and ligand systems used in this thesis.
Since it is computationally very expensive to calculate electrostatic interaction
free energy between a pair of solutes at each time-step of the BD simulation, SDA
uses the Effective Charge Model (ECM)[59] to approximate the PB theory derived
electrostatic interaction. In this model, the electrostatic interaction energy between a
solute pair (∆G1−2el ) is calculated as the interaction between PB derived electrostatic
potential (Φel) of one solute and a set of effective charges (qi) on the other solute, and
vice-versa. The total interaction energy is multiplied by a factor of 1/2 to prevent
double counting of the interaction. These effective charges are fitted in such a way
that, they reproduce the electrostatic potential derived with PB in a heterogeneous
dielectric medium, when they are placed in an uniform dielectric medium. For
proteins, these effective charges are assigned on Lys, Arg, Glu, Asp residues, and
C and N-termini of proteins. For small molecules, these charges are assigned on
hydrogen bond donor-acceptor atoms (N,O,F,S), halogen atoms (Cl,Br,I) and on P
and Fe atoms in case of co-factors.
∆G1−2el =
1
2
∑
i1
qi1Φel2(ri1) +
1
2
∑
i2
qi2Φel1(ri2) (2.20)
Here, qin is an effective charge on solute n and Φelm(rin) is the electrostatic
potential of solute m, at the position of effective charge qin on solute n.
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Electrostatic desolvation interaction
Binding of two solutes results in the exclusion of high dielectric solvent from the
binding interface, which results in desolvation of the surface-lying charges. This
creates an unfavorable contribution to the binding interaction between two solutes.
This unfavorable penalty is corrected in SDA by an extended ECM model which
includes an electrostatic desolvation correction term (∆G1−2edesolv), which is calculated
as:
∆G1−2edesolv =
1
2
∑
i1
q2i1Φedesolv2(ri1) +
1
2
∑
i2
q2i2Φedesolv1(ri2) (2.21)
Here, Φedesolvm is the the electrostatic desolvation potential of solute m and it
accounts for the effect of reduction in the dielectric constant at the interface. The
electrostatic desolvation potential of a solute at point r is calculated by using the
following formula.
Φedesolv(r) = α
εs − εp
εs(2εs + εp)
∑
j
a3j
(1 + κrj)
2
r4j
e−2κrj (2.22)
Here, α is an emperical scaling parameter, εs and εp are the dielectric constants
of solvent and solute respectively, aj is the radius of atom j and κ is the inverse of
Debye length and it depends on ionic strength of the solvent.
Nonpolar desolvation interaction
The binding of two solutes at the interface leads to the reduction of total solute-
solvent interface area which results in increased binding affinity. This interaction
is modelled in SDA by nonpolar desolvation interaction energy[55] which is propor-
tional to the solvent accessible surface area (SASA) of a solute that is obstructed by
the interacting solute.
∆G1−2np =
∑
i1
SASAi1Φnp2(ri1) +
∑
i2
SASAi2Φnp1(ri2) (2.23)
Here, Φnpm(rin) is the non-polar burial potential of solute m at the position of
atom in of interacting solute n and SASAin is solvent-accessible surface area of
surface atom in.
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2.2.3 Calculation of protein-ligand association rates in SDA
Figure 2.1: Schematic representation of the geometric setup for the diffusional association of
protein and ligand molecules in BD simulations.
Association rate constants of two interacting molecules can be computed from
BD simulations when the encounter is diffusion-controlled. The steady state rate
constant kD(b) of two spherical molecules approaching each other at a separation
distance r = b, can be given by the analytical Smoluchowski expression[60].
kD(b) =
4πD∫∞
b
e
E(r)
kBT
r2
dr
(2.24)
Here D is the relative diffusion constant, E(r) is the interaction potential acting
between two spherical molecules. To obtain the association rate constant kon of
protein-ligand association in BD simulations, the steady-state rate constant from
the previous equation is multiplied with the probability of formation of protein-
ligand encounter complex β∞. BD trajectories are run starting at a relatively large
protein-ligand separation b, where the centrosymmetric forces between protein and
ligand are negligible. Each trajectory is stopped when either reaction criteria are
satisfied or the molecules reach a much larger separation c (Figure 5.11). In case,
the reaction conditions are satisfied, the trajectory is considered as reactive. In
BD simulations, thousands of trajectories are run and β, the fraction of reactive
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trajectories is calculated. To account for the possibility that in case of non-reactive
trajectories, ligand may come back from c surface and form an encounter complex
with protein, β is corrected by a multiplying factor Ω to get β∞[61].
kon = kD(b)β
∞ (2.25)
β∞ =
β
1− (1− β)Ω
(2.26)
Here, Ω describes the probability that the ligand at separation distance c > b
returns to b. It is given by:
Ω =
kD(b)
kD(c)
(2.27)
By substituting the values of β∞ and Ω, the equation 2.28 can be written as:
kon = kD(b)
β
1− (1− β)kD(b)
kD(c)
(2.28)
2.3 Molecular Dynamics (MD) technique
Molecular Dynamics (MD) simulation is one of the most common computer simu-
lation techniques to monitor time-dependent processes of biological molecules. MD
is widely used to gain insights into the molecular mechanisms of dynamic processes
such as protein-folding, membrane transport, self-assembly and for studying ther-
modynamic properties and kinetics of bimolecular association. In MD simulation,
movements for set of atoms and molecules are computed by numerically solving
Newton’s equations of motion as a function of time:
mi
∂2
∂t2
~ri = −∇E(~ri) (2.29)
where mi and ~ri are the mass and position of the particle i, E is the total potential
energy which depends on the positions of all particles in the system.
In order to run MD simulation, initial position ~ri and velocity ~vi of particles is
determined for t = 0 and a short time step ∆t is chosen. The force ~F acting on
each particle can be calculated from the total potential energy E as:
~Fi = −
∂E
∂~ri
(2.30)
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And, the acceleration ~ai of each particle can be calculated from the force ~Fi as:
~ai =
~Fi
mi
(2.31)
The particles are moved for time ∆t and a new set of positions is computed for
the next time step (t + ∆t):
~ri(t+∆t) = ~ri + ~vi∆t+
1
2
~ai∆t
2 (2.32)
Therefore, for each MD time step, forces and velocities of particles are calculated
and integrated for next time step. The iteration of the above process for subsequent
time-steps gives the spatio-temporal evolution of the system. Since, small scale
motions such as vibration of bonds or hydrogen atoms occur very fast, the time step
of the integration chosen is usually very small (1 fs). For study of large scale motions,
dynamics of bonds with hydrogen atoms becomes no longer important. Therefore,
algorithms such as SHAKE[62] are used to constrain bonds with hydrogens which
allow a bigger time step (2 fs) to be used for MD simulation, thereby resulting in
increased computational efficiency.
Integration of Newton’s equation of motion
To integrate Newton’s equation of motion at finite time steps, a numerical integrator
is required. Verlet[63] is one of the most commonly used integrators in MD simula-
tions. The Verlet algorithm uses the Taylor expansion to approximate the particle’s
position and dynamic properties, where new positions ~rt+∆t and acceleration at time
t + ∆t are determined from the positions and acceleration at time t and from the
positions of the previous step ~rt−∆t:
~rt+∆t = ~rt + ~vi∆t+
1
2
~at∆t
2 + ... (2.33)
~rt−∆t = ~rt − ~vi∆t+
1
2
~at∆t
2 − ... (2.34)
Summing both equations:
~rt+∆t = 2~rt − ~rt−∆t + ~at∆t2 (2.35)
And, the velocity is calculated as:
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~vt+∆t =
[~rt+∆t − ~rt−∆t]
2∆t
(2.36)
The Verlet algorithm is time-reversible which means that if the direction of ve-
locities of particles is reverse, the simulation will run in the reverse direction.
Molecular Mechanics force fields
A molecular mechanics force field is a set of energy functions or equations and the
associated constants to define the potential energy of a molecular system as a func-
tion of its three-dimensional structure in molecular mechanics or molecular dynamics
simulations. A force field is required in MD simulations to describe the time evolu-
tion of both bonding terms (such as bond lengths, bond angles, torsions) and the
non-bonding electrostatic and van der Waals interactions between atoms. During
MD simulations, pairwise potentials between atoms are calculated from this com-
mon potential energy function that describes both intramolecular and intermolecular
interactions. Force fields are always optimized for specific classes of molecules, for
example, AMBER ff14SB[64] was optimized for proteins and nucleic acids and
MMFF94[65] was optimized for small organic molecules.
A force field typically includes set of following energy functions:
Etotal =
∑
bonds
Kr(r − req)2 +
∑
angles
Kθ(θ − θeq)2 +
∑
dihedrals
Vn
2
[1 + cos(nφ− γ)]
+
∑
i<j
[
Aij
R12ij
− Bij
R6ij
+
qiqj
εRij
]
+
∑
H−bonds
[
Cij
R12ij
− Dij
R10ij
] (2.37)
Temperature and pressure control in MD simulations
Like experiments, it is also important to describe the thermodynamic state of the
system in MD simulations. Macroscopic properties that represent the thermody-
namic state of a system include number of particles (N), pressure (P), temperature
(T) and volume (V). An ensemble that describes a macroscopic or thermodynamic
state is a collection of different microscopic properties. MD simulations can be
run using different ensembles such as canonical (NVT), isothermal-isobaric (NPT),
and microcanonical (NVE) emsembles. In MD simulations, integration of Newton’s
equation of motion results in a microcanonical NVE emsemble with constant number
of particles, constant volume and constant energy. However, biological experiments
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are usually performed at constant temperature and constant volume (NVT) and/or
constant temperature and constant pressure (NPT). MD simulations therefore need
to be performed with any of these ensembles to compare the simulation results with
experiments.
For NVT ensemble, temperature need to be maintained constant using external
thermal bath and for this there are several thermostat algorithms available that can
be used to keep the temperature constant to any desired value. Berendsen weak-
coupling method[66], Nosé–Hoover and Langevin piston are some of the commonly
used thermostats in MD simulations. In the case of NPT ensemble, the constant
pressure is maintained by allowing the volume of the simulation box to change using
external barostats. The Nosé–Hoover Langewin piston[67] method, Berendsen weak-
coupling[66] and Parinello-Rahman[68] methods are some of the common barostats
used to maintain NPT conditions in MD simulations.
Implicit and Explicit Solvent Models
In order to model a realistic system, it is crucial to define the solvent environment
of a biological system appropriately. For MD simulations of biomolecules, solvent
effects can be treated using either explicit water model or implicit water model. In
explicit solvent model, large number of water molecules are explicitly included in
the simulation. This leads to enormous increase in the computational requirement,
especially if longer time scales need to be simulated. Transferable intermolecular
potential n point models (TIPnP)[69] from Jorgensen group and extended simple
point charge model (SPC/E)[70] from Berendsen group are the most commonly used
explicit water models. These models are based on standard non-polarizable force
fields and they have been parameterized to reproduce the characteristic properties of
real liquid water, such as density, diffusivity, energy and dielectricity. In this work,
the TIP3P water model has been used to model the explicit water in MD.
Implicit solvent models tend to greatly reduce the number of degrees of freedom
by using the continuum approximation of the discrete solvent, where the effect of
solvent on solute molecules is described by a set of polar and non-polar terms in-
cluded in the equation of energy. Using implicit solvent model has several advantages
over explicit model such as reduced computational cost, instantaneous thermody-
namic equilibrium with the solute, and enhanced conformational sampling. Poisson-
Boltzmann (PB) and Generalized Born (GB)[71] are the most widely used implicit
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solvent models in MD simulations of biomolecules. The GB model is an empiri-
cal approximation to the linear Poisson- Boltzmann equation. The GB model also
includes the charge screening effects caused by ions and salt and can describe the
solvent effects in MD fairly well but with very low computational cost. In order to
choose the optimal water model for the simulations, one must consider several factors
such as the molecular structure of biomolecules, available computational resources
and the specific questions related to the calculation, that are being addressed.
Periodic boundary conditions (PBC)
MD simulations are used to simulate finite systems with a finite number of molecules.
However, to predict properties at the bulk level, a relatively smaller system is used
and periodic boundary conditions (PBC) are applied in MD to make the system look
like an infinite one. By applying PBCs, a simulation box of unit size is replicated
in all directions and it is assumed that all the molecular properties are identical in
each of the unit cells. Existence of PBCs means that, if a particle exits from one
side of the simulation box, then it is replaced by an image particle entering from
the opposite side of box, thereby keeping the total number of particles constant
in the simulation. Therefore, PBC helps to avoid any boundary effects caused by
the box-edges and provides a homogeneous system to simulate bulk effects. The
most common box shapes used in MD with PBCs are cubic, hexagonal, octahedron
and rhombic dodecahedron. Using PBCs also has some limitations, for example, any
fluctuations in the system with wavelength greater than the unit cell are not possible
to observe. Moreover, the size of the simulation box chosen should be large enough
to avoid any periodic artifacts caused by the artificial long-range interactions with
the image molecule.
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2.3.1 τ Random Acceleration Molecular Dynamics
(τRAMD)
τRAMD is an enhanced sampling procedure based on MD simulations developed
to compute relative residence times of drug-like compounds and to explore ligand
exit pathways from the buried binding sites in proteins[29]. RAMD[28] simulations
are performed in an explicit solvent with parameters similar to the standard MD
simulations. In RAMD, during MD simulations of the bound protein-ligand com-
plex, a small additional randomly oriented force is applied to the centre of mass of
the ligand to accelerate its unbinding from the binding site. The movement of the
ligand is assessed at regular time intervals and the direction of the force is reas-
signed randomly if the ligand’s movement is smaller than the specified threshhold
distance. In RAMD simulations, ligands that have higher residence times take longer
to egress from the binding pocket or require application of a stronger force to exit
within a specified simulation time. By applying this artificial force, the unbinding
of the ligands from the binding site can be observed in short simulations of few
nanoseconds. Therefore, RAMD may be very useful and computationally efficient
approach to obtain relative estimates of residence times. The main advantage of
RAMD over other enhanced sampling methods such as Smoothed potential MD[26]
or Metadynamics[25], is that it does not require extensive parametrization or any
prior knowledge of the dissociation pathway. The magnitude of the random force is
the only parameter that needs to be set by the user in RAMD simulations and it
should be carefully chosen within a reasonable range, so that it does not affect the
computed relative residence times.
2.3.2 MM/GBSA free-energy calculations
In the molecular mechanics generalized Born surface area (MM/GBSA) method[72,
73], the binding free energy of a ligand to a protein to form a complex is obtained
as the difference:
∆Gbind = Gcomplex −Greceptor −Gligand (2.38)
The free energy of each of the molecular systems is given by the expression:
G = Ebnd + Eel + EvdW +Gpol +Gnp − TS (2.39)
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where Ebnd, Eel and EvdW are the standard molecular mechanics energy terms
accounting for bonded, electrostatic and van der Waals interactions, respectively, in
the gas phase. Gpol and Gnp are polar and non-polar contributions to the solvation
free energies, and S is the entropy contribution arising from changes in the dynamics
upon ligand binding and it is calculated by a normal-mode analysis of the vibrational
frequencies. In MM/GBSA, the generalized Born (GB) model is used to estimate
Gpol, whereas Gnp is obtained from a linear relation to the solvent accessible surface
area (SASA).
2.3.3 Møller–Plesset energy calculations
In quantum chemistry, Moeller-Plesset perturbation theory (MP)[74] is one of the
post-Hartree-Fock ab initio methods commonly implemented in many computational
chemistry software packages. The Moeller-Plesset perturbation theory[74] improves
on the Hartree-Fock method by adding electron-correlation effects using Rayleigh-
Schrödinger perturbation theory to different orders (MP2, MP3, MP4 etc.) However,
MP theory is not variational which means that the energy calculated by MP the-
ory may be lower than the true ground state energy. Ab initio interaction energies
using Møller-Plesset perturbation theory to second order (MP2)[75] were calculated
using the GAMESS software[76], and partitioned into their constituent interaction
energy terms using the many body interaction energy decomposition scheme (EDS)
described by Góra et al.[77, 78]. In this scheme, the total interaction energy is cal-
culated in a super-molecular approach as the difference between the total energy of
a complex and the sum of the energies of its isolated constituents. In all calcula-
tions, the complex centered basis set (CCBS) was used consistently and the results
are therefore basis set superposition error (BSSE) free due to the full counterpoise
correction.
The total MP2 interaction energy (EMP2) includes the components of the Hartree-
Fock interaction energy (ESCF ) and the second order Coulomb correlation correc-
tion term (ECORR). This correlation energy term (ECORR) includes the second order
intermolecular dispersion energy and the correlation corrections to the SCF compo-
nents.
EMP2 = ESCF + ECORR (2.40)
The Hartree-Fock interaction energy (ESCF ) was partitioned into a first order
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Heitler-London component (EHL) and a higher order Hartree-Fock delocalization
interaction energy component (ESDEL), which encompasses the induction and the
associated exchange effects. Because their separation could lead to a non-physical
charge transfer, this component was not partitioned any further.
ESCF = EHL + EDEL (2.41)
The Heitler-London interaction energy component (EHL) can be separated into
the first-order electrostatic interactions (EEL) of monomers and the associated Heitler-
London exchange repulsion energy (EEX) due to the Fermi electron correlation ef-
fects. The electrostatic interaction energy (EEL) was obtained as a first-order term in
the polarization perturbation theory and the exchange repulsion term (EEX) was cal-
culated by subtracting the electrostatic interaction energy from the Heitler-London
energy (EEX = EHL − EEL).
EHL = EEL + EEX (2.42)
EEL,MTP refers to the electrostatic multipole component estimated from an
atomic multipole expansion, EEL,PEN is the electrostatic penetration energy cal-
culated by subtracting the electrostatic multipole component from the electrostatic
interaction energy (EEL,PEN = EEL − EEL,MTP )
EEL = EEL,MTP + EEL,PEN (2.43)
2.4 Software and Tools
In this project, a number of software packages and visualization and modelling tools
was employed for a range of different applications such as running MD and BD
simulations, modelling of ligands and protein-ligand complexes, visualization and
analysis of 3D structures and trajectories from MD and BD simulations. For doing
data analysis and to automate some of the tasks, several scripts were written using
the Python programming language and bash scripting. Some tcl scripts, previously
developed in the group, were also used for the running and analysis of RAMD
simulations. All the plots used in this thesis were generated either using the Gnuplot
program or with Microsoft Excel 2016. All the major tools/software employed and
their application areas are briefly discussed below.
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2.4.1 Simulation software
AMBER (Assisted Model Building with Energy Refinement)
AMBER refers to a suite of programs (http://ambermd.org/) used for running
molecular dynamics simulations of proteins and nucleic acids[79]. It has a number of
tools and program for the preparation of necessary input files, to setup and perform
molecular dynamics simulations and to analyze the simulation results. AMBER has
an efficient parallel scaling implementation making it one of the most widely used
programs for biomolecular studies. The name Amber also refers to a set of molec-
ular mechanics force fields used for the simulation of biomolecules. In this thesis,
Amber was used for the preparation of topology files and the energy minimization
of protein-ligand complexes for COMBINE analysis, for running MM/GBSA sim-
ulations, energy-minimization and equilibration of protein-ligand complexes before
running RAMD simulations.
Version used: AMBER 14
NAMD (NAnoscale Molecular Dynamics program)
NAMD is a molecular dynamics simulation package (http://www.ks.uiuc.edu/Research/
namd/) designed for high-performance simulation of large biomolecular systems[80].
NAMD includes a rich set of MD features such as multiple time stepping, constraints,
and dissipative dynamics and can be used with the AMBER and CHARMM poten-
tial functions, parameters, and file formats. The code is highly parallelized as it
can scale to thousands of processors on high-end parallel platforms. It can also be
run on individual desktops and laptops. In addition, NAMD can be connected to
the molecular graphics software VMD in order to provide an interactive simulation
tool for modifying and viewing the running MD simulations. The τRAMD[29] pro-
cedure has been implemented in the NAMD software using tcl scripts and, in this
thesis, NAMD was used to run RAMD simulations of protein-ligand dissociation for
inhibitors of haspin kinase.
Version used: NAMD 2.9
SDA (Simulation of Diffusional Association)
SDA[54, 53] is a software package (http://mcm.h-its.org/sda7/) to carry out Brow-
nian dynamics simulations of the diffusional association of solute molecules (e.g.
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proteins) in a continuum aqueous solvent. It can also be used to perform rigid-body
docking to record Brownian dynamics trajectories or encounter complexes and to
calculate bimolecular rate constants. In SDA, the interaction between the solutes is
given by an approximation to the Poisson-Boltzmann equation-derived electrostatic
interaction[59]. In addition, short-ranged hydrophobic desolvation and electrostatic
desolvation forces can also be considered. In SDA, simulation of the diffusion of
multiple proteins, in dilute or concentrated solutions can also be performed to study
macromolecular crowding effects. In this work, SDA was used to perform Brownian
dynamics simulations of protein and ligand association for calculation of diffusional
association rate constants.
Version used: SDA7.1
2.4.2 Structure preparation and general molecular modeling
tools
Schrödinger suite
Schrödinger (https://www.schrodinger.com/) is a suite of tools used for molecular
modeling, drug-discovery and materials science research. In this thesis, Schrödinger
was used to pre-process the structures of the protein-ligand complexes, to add miss-
ing side chains, to add disulphide bonds, and for optimizing the H-bond network to
assign hydrogen atom positions.
Version used: Release 2015-4
MOE (Molecular Operating Environment)
MOE is an interactive integrated suite of applications (https://www.chemcomp.
com/) that provides a wide range of functionality to support Molecular Modelling,
Chemoinformatics, Structure- based Design, Virtual Screening and a broad range
of life science applications. In this thesis, MOE was used to aid in preparation of
protein structures, modeling of ligands and deciding correct protonation states for
ligands and titratable residues.
Version used: MOE 11
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AmberTools
AmberTools consists of several tools/packages that are either used independently
or with the Amber program[79]. AmberTools include programs/tools to generate
force fields for general organic molecules and metal centers, preparation programs
for Amber simulations, programs for semi-empirical and DFTB quantum chemistry
calculations, tools to compute numerical solutions to Poisson-Boltzmann models,
programs for structure and dynamics analysis of trajectories. In this thesis, several
programs from AmberTools, such as antechamber, sqm, parmchk, RESP and LEaP,
were used to generate partial atomic charges for small molecules and to generate force
field parameters for protein-ligand complexes, ambpdb was used for interconversion
between different file formats, MMPBSA.py was used for free-energy calculations
of haspin-inhibitor complexes, cpptraj was used for analysis of MD and RAMD
trajectories from Amber and NAMD simulations.
Version used: AmberTools14
APBS (The Adaptive Poisson-Boltzmann Solver)
APBS (http://www.poissonboltzmann.org/) is a macromolecular electrostatics cal-
culation program used for solving the equations of continuum electrostatics for large
biomolecular systems[81]. The results of APBS calculations can be displayed as an
electrostatic potential molecular surface using PyMOL. Most of the APBS function-
ality is available through the online PDB2PQR web server (http://nbcr-222.ucsd.
edu/pdb2pqr_2.1.1/). In this thesis, APBS was used to generate electrostatic po-
tential grids of protein and ligand molecules for BD simulations and the PDB2PQR
webserver was used to generate PQR files for protein molecules.
Version used: APBS 1.4.1
HYDROPRO
HYDROPRO ( http://leonardo.inf.um.es/macromol/programs/hydropro/hydropro.
htm) is a computer program used to compute the hydrodynamic properties of rigid
molecules (proteins, small nucleic acids, macromolecular complexes, etc.) from their
atomic-level structure[82]. The HYDROPRO output comprises the basic hydrody-
namic properties: translational diffusion coefficient, sedimentation coefficient, intrin-
sic viscosity, and relaxation times, along with the radius of gyration. In this thesis,
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HYDROPRO was used to compute translational and rotational diffusion coefficients
of protein and ligand molecules required for simulating diffusional association with
SDA.
Version used: HYDROPRO10
2.4.3 Structure Visualization tools
PyMOL
PyMOL (https://www.pymol.org/) is a molecular visualization software used for
the manipulation of structures and generating high quality 3D images of biological
macromolecules, such as proteins. It also provides some basic functions that can
used to analyze molecular and chemical properties of biomolecules. In this thesis,
we have used PyMOL for visual inspection of the protein-ligand complexes and PDB
structures, and the creation and labelling of the crystallographic images.
Version used: PyMOL 1.7
VMD (Visual molecular dynamics)
VMD (http://www.ks.uiuc.edu/Research/vmd/) is another very commonly used vi-
sualization program designed for modelling, visualization and analysis of biological
systems, such as proteins, nucleic acids, lipid bilayer assemblies[83]. Most impor-
tantly, VMD can be used to view and analyze the results of MD simulations and to
visualize potential grids of the molecules. In this thesis, VMD was used to analyze
the trajectories from RAMD and MD simulations and to visualize potential grids of
proteins and ligands generated for running BD simulations in SDA.
Version used: VMD 1.9.3
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Chapter 3
Quantitative structure-kinetics
relationships (QSKRs) for koff
values of HSP90 and HIV-1 protease
inhibitors
This Chapter is based on the following publication:
Prediction of Drug–Target Binding Kinetics by Comparative Binding En-
ergy Analysis.
Gaurav K. Ganotra and Rebecca C. Wade, ACS Medicinal Chemistry Letters 2018
9 (11), 1134-1139
DOI: 10.1021/acsmedchemlett.8b00397
Quantitative structure activity relationships (QSARs) allow correlation of the
physio-chemical and structural descriptors/properties of a class of molecules with
their biological activities by applying regression-based machine learning techniques.
Over the time, a number of classical regression techniques have been developed
and successfully applied to derive QSARs for series of molecules[84, 85]. As more
number of three-dimensional (3D) structures of ligand-protein complexes is becom-
ing available, these QSAR approaches have been extended in three dimensions to
derive 3D-QSARs by incorporating information on ligand and protein interactions
into the models[86, 87, 88, 89]. COMparative BINding Energy (COMBINE) anal-
ysis is one of such medium-throughput approaches that has been successfully ap-
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plied to a number of protein targets to derive target specific scoring functions for
the prediction of binding affinity and target selectivity[46, 90, 91, 92, 93, 94, 95].
In COMBINE analysis, ligand-receptor interaction energies are computed using a
molecular mechanics model. These energies are then partitioned and subjected to
regression-based methods, such as Partial Least Squares (PLS) regression, to de-
rive a statistical model which relates the property of interest to weighted selected
components of the ligand-receptor interaction energy. COMBINE analysis seeks to
make complete and systematic use of the available information from 3D structures
of receptor–ligand complexes and the measured bioactivities of compounds, by ex-
plicitly including information about the receptor–ligand interaction energies. This
is in contrast to other 3D-QSAR approaches such as Comparative molecular field
analysis (CoMFA)[86] or Molecular Similarity Indices in a Comparative Analysis
(CoMSIA)[96] that only include information about the interaction properties of the
ligands based on their 3D structures.
Over the past few years, the interest in the evaluation of drug-binding kinetics
(kon and koff ) during lead optimization has increased considerably due to their in-
fluence on the time course of a drug’s effect. Since experimental assays used to
determine kinetic parameters for drug binding/unbinding are usually time consum-
ing and labor-intensive, robust, efficient and high-throughput in silico methods are
much in demand to predict kinetic parameters accurately and provide insights into
the mechanistic determinants of drug-protein binding. These insights can help in the
rational modulation of the binding kinetics during lead optimization. In this work,
we have applied COMBINE analysis to derive quantitative structure-kinetics rela-
tionships (QSKRs) for the dissociation rate constants (koff ) by studying two large
and chemically diverse sets of inhibitors of the well-characterized drug targets, heat-
shock protein 90 (HSP90) and HIV-1 protease. COMBINE analysis was originally
developed to derive QSARs for binding affinity; here, we provide its first applica-
tion to derive QSKRs for binding kinetic parameters. By performing COMBINE
analysis, we obtained QSKRs for dissociation rate constants (koff ) of HSP90 and
HIV-1 protease inhibitors with very good predictive ability. 70 structurally diverse
inhibitors of HSP90 and 36 inhibitors of HIV-1 protease with available experimental
kinetics data and co-crystallized or modelled protein-inhibitor complexes were used
to derive target-specific predictive models for koff rates. We have also identified key
protein-inhibitor interactions that distinguish inhibitors with slow and fast off-rates.
40
3.1 Systems studied
For demonstrating the first application of COMBINE analysis for deriving QSKRs,
we studied two established and well-studied drug targets: HSP90 and HIV-1 pro-
tease. Both proteins have been well characterized experimentally and have been the
subject of extensive structure-based drug discovery efforts. However, these two tar-
gets present different challenges for the prediction of drug-binding kinetics as they
show high binding site flexibility and inhibitors with both slow and fast binding
kinetics are known[97, 40].
3.1.1 Heat-shock protein 90 (HSP90)
HSP90 is one of the common chaperone proteins that assists in the proper folding
of other proteins and stabilizes proteins against elevated temperatures. It is known
for its role in stabilizing a number of proteins essential for tumor growth, and it
is therefore an anti-cancer target[98]. The name HSP90 comes from the fact that
it weighs approximately 90 kiloDaltons (kDa). The N-terminal domain (NTD) of
HSP90 is a highly conserved domain and with a mass of approximately 25 kDa. The
binding pocket for ATP is situated in the NTD and therefore the ATPase function of
the NTD can be blocked by designing small molecule inhibitors that bind to the ATP
binding pocket. Blocking of the ATPase function disrupts the chaperone activity of
HSP90 which leads to degradation of client proteins and hence suppressed tumor
growth[99].
The structures of the NTD of HSP90 (N-HSP90) in complex with inhibitors are
known to have high plasticity and exist in "loop-in", "helical" or "loop-out" confor-
mations which differ at the side of the ATP-binding site where α-helix3 is located
(see Figure 3.1). Both loop conformations (loop-in and loop-out) have been ob-
served in the crystallographic structures of unbound apo-protein as well as in the
holo-structures with different small inhibitors bound to the ATP-binding pocket[97].
In contrast, the helix conformation, with a complete α-helix3, has been observed
only in holo-structures and only when the bound inhibitor occupies a transient hy-
drophobic subpocket between α-helix3 and the beta-strands, in addition to the ATP
binding site (see Figure 3.1 A).
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Figure 3.1: A) Helix conformation of the N-HSP90 in complex with the inhibitor bound to the
ATP binding-site (PDB ID: 5J20[97]). B) Loop-in conformation of the N-HSP90 in complex with
the inhibitor bound to the ATP binding-site (PDB ID: 5NYI[97]). The structures of N-HSP90 are
shown in ribbon representation where helices, β-sheets and loops are colored in red, yellow and
green, respectively, and inhibitors are shown with cyan stick representation.
3.1.2 HIV-1 protease
HIV-1 protease is a homodimeric aspartyl protease and it specifically cleaves the pre-
cursor Gag and Gag-Pol polyproteins into various viral capsid and other structural
proteins. As HIV-1 protease plays a critical role in viral maturation for producing
infectious virus particles, it is an attractive target for AIDS therapy[100].
Figure 3.2: A) The HIV-1 protease homodimer with DMP323 bound (PDB ID: 1QBS[101]). HIV-
protease has two β-hairpin loops (flaps) that exist in a closed state on ligand binding. B) semi-open
and C) open conformations of the flaps in unbound HIV-1 protease (conformations shown were
obtained from the MD simulation run of unliganded HIV-1 protease with PDB ID: 1HXW[102]).
The structures of HIV-1 protease are shown in ribbon representation where helices, β-sheets and
loops are colored in red, yellow and green, respectively and the DMP323 is shown with cyan stick
representation.
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Each subunit of HIV-1 protease is a polypeptide chain consisting of 99 residues.
The active site is located at the interface between both subunits and is composed of
the two conserved catalytic triplets (Asp25-Thr26-Gly27)[103]. Specific inhibitors of
HIV-1 protease, including clinically approved drug molecules, bind to the substrate
binding pocket[41] which is mainly formed by the side chains of Arg8, Leu23, Asp25,
Gly27, Ala28, Asp29, Asp30, Val32, Ile47, Gly48, Gly49, Ile50, Phe53, Leu76, Thr80,
Pro81, Val82, and Ile84 residues of both subunits. Each monomer contains an
extended β-sheet region (a glycine-rich loop), also known as the flap. These flaps
exist in a closed state in the liganded form, and can exist in either semi-open or
open conformations in the unbound form (see Figure 3.2).
3.2 Dataset used for the COMBINE analysis
3.2.1 Heat-shock protein 90
For generating the COMBINE analysis model of HSP90, 70 inhibitors with avail-
able experimental kinetics measurements, were used (see Table 3.1 for SMILES
strings and Figure 3.3 for their chemical structures). These inhibitors are struc-
turally very diverse and they belong to 11 different chemical classes: resorcinol,
indazole, hydroxylindazole, aminoquinazoline, benzamide, aminopyrrolopyrimidine,
7-imidazopyridine, 7-azaindole, aminothienopyridine, 6-hydroxyindole, adenine and
2-aminopyridine (see Figure 3.3). All of these inhibitors block the ATPase function
of HSP90 by binding to its ATP binding pocket located in the N-terminal domain
of HSP90 (N-HSP90). 57 of these inhibitors bind to the helical conformation of N-
HSP90 and hence will be referred to as "helix-binders" in the following sections. The
remaining 13 inhibitors bind to the N-HSP90 in the loop conformation and will be
termed "loop-binders". The experimental koff , kon andKd values for these inhibitors
were available from Kokh et al.[29]. The range of experimental koff rate constants
for these inhibitors spans over 4 orders of magnitude with the fastest and slowest
dissociating inhibitors having koff values of 0.83 s−1 and 0.0001 s−1, respectively,
and therefore ideal for deriving QSKRs using COMBINE analysis. In addition, 3D
crystallographic structures of protein-inhibitor complexes for 37 of these inhibitors
are available in the PDB database. For the remaining 33 inhibitors, it was possible
to model their bound complex with the protein by introducing small substitutions
43
into similar compounds complexed with N-HSP90.
Compound
Id
SMILES
1 CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(C[NH+]2CCOCC2)cc1
2 CCNC(=O)c1noc(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1
3 CCNC(=O)c1[nH]nc(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1
4 CCNC(=O)c1noc(c2cc(Cl)c(O)cc2O)c1c3ccc(C[NH+]4CCOCC4)cc3
5 O=c1[nH]nc(-c2cc(Br)c(O)cc2O)n1-c1ccccc1F
6 COc1ccc(-c2c(C#N)c(N)nc3sc(C(N)=O)c(N)c23)cc1OCCCC(=O)O
7 CCc1cc(-c2n[nH]c(C)c2-c2ccccc2F)c(O)cc1O
8 O=c1[nH]nc(-c2ccc(O)cc2O)n1-c1ccccc1F
9 Cc1n[nH]c2cc(O)c(-c3ccnn3-c3ccccc3)cc12
10 COc1ccc(-c2c(-c3ccc(O)cc3O)n[nH]c2C)cc1
11 CN(Cc1ccco1)C(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2F)c(O)cc1O
12 Cc1ccccc1-n1c(-c2cc(C(=O)N(C)Cc3cccs3)c(O)cc2O)n[nH]c1=O
13 CCCCN(C)C(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2F)c(O)cc1O
14 Oc1cc(O)c(-c2ccnn2-c2ccccc2Cl)cc1CCc1ccccn1
15 CCCN(C)S(=O)(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2F)c(O)cc1O
16 CC(C)N(C)S(=O)(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2F)c(O)cc1O
17 Brc1cnc2[nH]cnc2c1C(=O)NC1c2ccccc2-c2c(-c3cnc4ccccc4c3)cccc21
19 O=C(NC1c2ccccc2-c2c(-c3nc4ccncc4[nH]3)cccc21)c1ccnc2[nH]ccc12
20 Cc1nn(-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)c2cccc(-c3cnc4ccccc4c3)c12
21 Cc1cn(-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)c2c1C(=O)CC(C)(C)C2
22 Cc1cn(-c2ccc(C(N)=O)c(NC3CCC(=O)CC3)c2)c2c1C(=O)CC(C)(C)C2
23 CC(C)N(C)S(=O)(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2Cl)c(O)cc1O
24 CCCN(C)C(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2C)c(O)cc1O
25 Cc1ccccc1-n1c(-c2cc(C(=O)N(C)Cc3ccccc3)c(O)cc2O)n[nH]c1=O
26 CCCCCCN(C)C(=O)c1cc(-c2ccnn2-c2ccccc2C)c(O)cc1O
27 Cc1cccc(CN(C)C(=O)c2cc(-c3n[nH]c(=O)n3-c3ccccc3C)c(O)cc2O)c1
28 Cc1ccccc1-n1c(-c2cc(C(=O)N(C)CC3CCCO3)c(O)cc2O)n[nH]c1=O
29 CCCCN(C)C(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2)c(O)cc1O
30 Cc1ccccc1-n1nccc1-c1cc(C(=O)N(C)Cc2ccco2)c(O)cc1O
31 Cc1ccccc1-n1c(-c2ccc(O)cc2O)n[nH]c1=O
32 O=c1[nH]nc(-c2ccc(O)cc2O)n1-c1ccccc1Cl
33 CCc1ccccc1-n1c(-c2ccc(O)cc2O)n[nH]c1=O
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Table 3.1 continued from previous page
Compound
Id
SMILES
34 CCCN(C)C(=O)c1cc(-c2n[nH]c(=O)n2-c2ccccc2F)c(O)cc1O
35 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc5c(c4)OCO5)cc23)c1
36 C[NH+]1CCC(c2ccc(N(C)C(=O)c3cc4c(CCC(C)(C)C)n[nH]c4cc3O)cc2)CC1
37 CCCCN(C)C(=O)c1n[nH]c2cc(O)c(C(=O)N(C)c3ccc(N4CCOCC4)cc3)cc12
38 CN(Cc1ccc(Cl)cc1)C(=O)c2cc3c(Cc4ccccc4)n[nH]c3cc2O
39 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)Cc4ccccc4)cc23)c1
40 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)Cc4ccc(Cl)cc4)cc23)c1
41 Oc1cc2[nH]nc(Cc3ccccc3)c2cc1-c1ccnn1-c1ccccc1
42 Cc1ccc(N(C)C(=O)c2cc3c(Cc4cccc(C)c4)n[nH]c3cc2O)cc1
43 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CCOCC5)cc4)cc23)c1
44 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccccc4)cc23)c1
45 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CCCCC5)cc4)cc23)c1
46 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N(C)C)cc4)cc23)c1
47 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CC[NH2+]CC5)cc4)cc23)c1
48 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CCN(C)CC5)cc4)cc23)c1
49 CO[C@H]1CCN(C(=O)c2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CCOCC5)cc4)cc23)C1
50 CO[C@H]1CCCN(C(=O)c2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CCOCC5)cc4)cc23)C1
51 CN(C(=O)c1cc2c(C(=O)N3CCCC3)n[nH]c2cc1O)c1ccc(N2CCOCC2)cc1
52 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(N5CCOCC5=O)cc4)cc23)c1
53 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4ccc(F)cc4)cc23)c1
54 COc1cccc(N(C)C(=O)c2cc3c(Cc4cccc(C)c4)n[nH]c3cc2O)c1
55 Cc1cccc(Cc2n[nH]c3cc(O)c(C(=O)N(C)c4cccc(C)c4)cc23)c1
56 CN(C(=O)c1cc2c(cc1O)[nH]nc2C(=O)N1CCOCC1)c1ccc(N2CCOCC2)cc1
57 CN(C(=O)c1cc2c(C(=O)N3CCCCC3)n[nH]c2cc1O)c1ccc(N2CCOCC2)cc1
58 Nc1nc(C(=O)N2Cc3ccc(O)cc3C2)c2ccccc2n1
59 Nc1nc(C(=O)N2Cc3ccccc3C2)c2cc(O)ccc2n1
60 C[NH+]1CCN(S(=O)(=O)c2ccccc2-c2ccc3nc(N)nc(C(=O)N4Cc5ccccc5C4)c3c2)CC1
61 Cc1ccc2nc(N)nc(C(=O)N3Cc4ccccc4C3)c2c1
62 CNCc1ccccc1-c1ccc2nc(N)nc(C(=O)N3Cc4ccccc4C3)c2c1
63 Nc1nc(C(=O)N2Cc3ccccc3C2)c2cc(-c3cc(F)c(F)cc3CCc3nnn[nH]3)ccc2n1
64 Nc1nc(C(=O)N2Cc3ccccc3C2)c2ccccc2n1
65 Nc1nc(C(=O)N2Cc3ccccc3C2)c2cc(-c3ccccc3O)ccc2n1
66 COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc32)c1C
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Table 3.1 continued from previous page
Compound
Id
SMILES
67 Cc1cnc(Cn2ccc3c(Cl)nc(N)nc32)c(C)c1Cl
68 C#CCCCn1c(Cc2cc(OC)c(OC)c(OC)c2Cl)nc2c(N)nc(F)nc21
69 N#Cc1ccc(N2CCN(CCCc3c[nH]c4cc(O)c(C#N)cc34)CC2)cc1
70 Nc1cc(C(=O)NC2c3ccccc3-c3c(-c4nc5ccncc5[nH]4)cccc32)ccn1
Table 3.1: List of the SMILES strings for the 70 HSP90 inhibitors used for the COMBINE
analysis.
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Figure 3.3: 2D chemical structures of inhibitors of HSP90 used for the COMBINE analysis. These
70 inhibitors belong to 11 different chemical classes: resorcinol, hydroxyl-indazole, aminoquina-
zoline, benzamide, aminopyrrolopyrimidine, 7-imidazopyridine, 7-azaindole, aminothienopyridine,
6-hydroxyindole, adenine and 2-aminopyridine.
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3.2.2 HIV-1 protease
For the COMBINE analysis of HIV-1 protease, we decided to consider 36 inhibitors
in our analysis as it was possible to either model their bound structure with HIV-1
protease based on analogy or their co-crystallized structure was available in the PDB
database (see Table 3.2 for SMILES strings and Figure 6.1 for their chemical sruc-
tures). For 12 of these inhibitors, their co-crystallized structures with HIV-1 protease
were available in the PDB database and the remaining 24 protease-inhibitor com-
plexes were modelled by introducing small substitutions into co-crystallized struc-
tures of similar compounds complexed with HIV-1 protease. The experimental mea-
surements of koff rates for these compounds were available from Markgren et al.[? ].
The koff values of these inhibitors span over 5 orders of magnitude with the fastest
and slowest dissociating inhibitors having koff rate constants of 0.00022 s−1 and 83.3
s−1, respectively. These inhibitors are also structurally very diverse with their scaf-
folds belonging to different chemical classes such as cyclic ureas, cyclic sulfamides,
linear analogues of compound B268, and non-analogues of B268 (see Figure 6.1).
Compound
Id
SMILES
B435 O[C@H]([C@@H](O)[C@@H](OCc1ccccc1)C(=O)NC2[C@H](O)Cc3ccccc23)
[C@@H](OCc4ccccc4)C(=O)NCc5ccccc5
A047 CNC(=O)c1cccc(CN2[C@H](COc3ccccc3)[C@H](O)[C@@H](O)[C@@H](COc
4ccccc4)N(Cc5ccccc5)S2(=O)=O)c1
A023 OCCc1cccc(CN2[C@H](COc3ccccc3)[C@H](O)[C@@H](O)[C@@H](COc4ccc
cc4)N(Cc5cccc(CCO)c5)S2(=O)=O)c1
A024 COC(=O)c1ccc(CN2[C@H](COc3ccccc3)[C@H](O)[C@@H](O)[C@@H](COc4
ccccc4)N(Cc5ccc(CO)cc5)S2(=O)=O)cc1
B429 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(cc1)c2ccccn2)[C@H](O)[C@@H]
(O)[C@@H](OCc3ccc(cc3)c4ccccn4)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
B409 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(cc1)c2ccsc2)[C@H](O)[C@@H](
O)[C@@H](OCc3ccc(cc3)c4ccsc4)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
B268 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H
](OCc2ccccc2)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
A045 CNC(=O)c1cccc(CN2[C@H](COc3ccccc3)[C@H](O)[C@@H](O)[C@@H](COc
4ccccc4)N(Cc5cccc(c5)C(=O)NC)S2(=O)=O)c1
B425 O[C@H](C[C@@H](OCc1ccccc1)C(=O)NC2[C@H](O)Cc3ccccc23)[C@@H](O
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Compound
Id
SMILES
Cc4ccccc4)C(=O)NC5[C@@H](O)Cc6ccccc56
A021 OCc1ccc(CN2[C@H](COc3ccccc3)[C@H](O)[C@@H](O)[C@@H](COc4ccccc
4)N(Cc5ccc(CO)cc5)S2(=O)=O)cc1
saquinavir CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H]
(Cc3ccccc3)NC(=O)[C@H](CC(=O)N)NC(=O)c4ccc5ccccc5n4
indinavir CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc3ccccc3
)C(=O)N[C@@H]4[C@H](O)Cc5ccccc45
ritonavir CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H]
(Cc2ccccc2)NC(=O)OCc3cncs3)Cc4ccccc4
DMP323 OCc1ccc(CN2[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@@H](Cc3ccccc3)
N(Cc3ccc(CO)cc3)C2=O)cc1
nelfinavir Cc1c(O)cccc1C(=O)N[C@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2
C[C@H]1C(=O)NC(C)(C)C
B369 O[C@H]([C@@H](O)[C@@H](OCc1ccccc1)C(=O)NC2[C@@H](O)Cc3ccccc23
)[C@@H](OCc4ccccc4)C(=O)NC5[C@H](O)Cc6ccccc56
B388 CC(C)C(N(C)C(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc2
ccccc2)C(=O)NC3[C@@H](O)Cc4ccccc34)C(=O)O
A038 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(cc1)C2=C(O)C(=O)CCC2)[C@H](O)[
C@@H](O)[C@@H](OCc3ccc(cc3)C4=C(O)C(=O)CCC4)C(=O)N[C@@H](C(C)C)
C(=O)NC)C(C)C
A037 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(\C=C\C(=O)OC)cc1)[C@H](O)[C@@H]
(O)[C@@H](OCc2ccc(\C=C\C(=O)OC)cc2)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
B440 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(cc1)c2nccs2)[C@H](O)[C@@H](
O)[C@@H](OCc3ccc(cc3)c4nccs4)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
B439 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(CCc2ccccc2)cc1)[C@H](O)[C@@H]
(O)[C@@H](OCc3ccc(CCc4ccccc4)cc3)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
B408 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(Br)cc1)[C@H](O)[C@@H](O)[
C@@H](OCc2ccc(Br)cc2)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C
B412 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccc(cc1)c2cccc(c2)[N+](=O)[O-])[C@H](O)
[C@@H](O)[C@@H](OCc3ccc(cc3)c4cccc(c4)[N+](=O)[O-])C(=O)N[C@@H](C(C)C)
C(=O)NC)C(C)C
U75875 CC[C@@H](C)[C@H](NC(=O)[C@H](C(C)C)[C@@H](O)[C@H](O)[C@H]
(CC1CCCCC1)NC(=O)[C@H](Cc2c[nH+]c[nH]2)NC(=O)COc3cccc4ccccc34)
C(=O)NCc5ccccn5
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Compound
Id
SMILES
A008 OCc1ccc(CN2C(COc3ccccc3)[C@H](O)[C@@H](O)C(COc4ccccc4)N(Cc5ccc
(CO)cc5)C2=O)cc1
B277 CCCO[C@H]([C@H](O)[C@@H](O)[C@@H](OCCC)C(=O)N[C@@H](C(C)C
)C(=O)NC)C(=O)N[C@@H](C(C)C)C(=O)NC
A030 C\C(=N/O)\c1cccc(CN2[C@H](COc3ccccc3)[C@H](O)[C@@H](O)[C@@H](CO
c4ccccc4)N(Cc5cccc(c5)\C(=N\O)\C)S2(=O)=O)c1
A015 CN(C(Cc1ccccc1)C(=O)O)C(=O)[C@H](OCc2ccccc2)[C@H](O)[C@@H](O)[C
@@H](OCc3ccccc3)C(=O)N(C)C(Cc4ccccc4)C(=O)O
A016 CN(C(Cc1ccc(O)cc1)C(=O)O)C(=O)[C@H](OCc2ccccc2)[C@H](O)[C@@H](O)[
C@@H](OCc3ccccc3)C(=O)N(C)C(Cc4ccc(O)cc4)C(=O)O
A017 CC(O)C(N(C)C(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc2
ccccc2)C(=O)N(C)C(C(C)O)C(=O)O)C(=O)O
B322 CCC(C)C(N(C)C(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc
2ccccc2)C(=O)N(C)C(C(C)CC)C(=O)O)C(=O)O
B365 CC(C)C(N(C)C(=O)[C@@H](C[C@@H](O)[C@@H](OCc1ccccc1)C(=O)N(C)
C(C(C)C)C(=O)O)OCc2ccccc2)C(=O)O
B347 CC(C)C(N(C)C(=O)[C@H](OCc1ccccc1)[C@@H](O)[C@H](O)[C@@H](OCc2
ccccc2)C(=O)N(C)C(C(C)C)C(=O)O)C(=O)O
A018 CSCCC(N(C)C(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc2c
cccc2)C(=O)N(C)C(CCSC)C(=O)O)C(=O)O
B249 COC(=O)C(NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc2c
cccc2)C(=O)NC(C(C)C)C(=O)OC)C(C)C
B376 CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H
](OCc2ccccc2)C(=O)N[C@H](C(=O)NC)c3ccccc3)c4ccccc4
Table 3.2: List of the SMILES strings for the 36 HIV-1 protease inhibitors used for COMBINE
analysis.
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Figure 3.4: 2D chemical structures of inhibitors of HIV-1 protease used for COMBINE analysis.
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3.3 Methods
3.3.1 Preparation of protein and ligand structures
Coordinates of the 37 crystallographic structures of protein-inhibitor complexes
for N-HSP90 and 12 structures of HIV-1 protease-inhibitor complexes were down-
loaded from the PDB database (https://www.rcsb.org/). The remaining 33 protein-
inhibitor complexes for N-HSP90 and 24 complexes for HIV-1 protease were modeled
based on analogy by introducing small substitutions into similar compounds com-
plexed with the proteins, using the Schrödinger software (release 2015-4, Schrödinger,
LLC, New York). The Protein Preparation Wizard [104] of the Schrodinger suite was
used to prepare and pre-process the structures of the bound complexes. The prepa-
ration of complexes involved addition of missing side chains and disulphide bonds,
deletion of crystallographic waters present, and the optimization of the hydrogen
bonding network to assign hydrogen atom positions. The protonation states of
titratable residues were assigned at pH 7.0 using the PROPKA[105] program avail-
able through the Protein Preparation Wizard of Schrodinger. To get rid of bad
contacts and steric clashes, all of the prepared complex structures were subjected to
initial energy minimization using the Impref module [104] of the Schrodinger suite
with default parameters and the OPLS3 force field. The Impref minimization is a
two-step relaxation procedure in which first the rotatable hydrogen atoms are mini-
mized with all the torsional potentials removed, and then an all-atom minimization
is performed that is terminated either when the system is fully converged or when
it reaches a heavy-atom RMSD from the initial structure of 0.30 Å.
3.3.2 Generation of force field parameters and energy
minimization
The partial atomic charges of the inhibitors were calculated using the RESP ap-
proach, where the RESP [106] program was used to fit the atom-centered charges
to the molecular electrostatic potential (MEP) grid computed by the GAMESS
program[76]. The LEap program of the Amber14 software[79] was used to prepare
the force field parameters and topology files for all the protein-inhibitor complexes.
The ff14SB [107] and the General Amber Force Field (GAFF ) were used for the pro-
teins and inhibitors, respectively. For energy minimization, the PMEMD module of
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Amber14 software was used. The Amber minimization protocol involved 4 different
minimization procedures with gradually decreasing restraints on heavy atoms (100
kcal/mol.2, 100 kcal/mol.2 and 5 kcal/mol.2) to no positional restraints in the final
minimization procedure. For each minimization procedure, 500 steps of steepest-
descent minimization followed by 500 steps of conjugate-gradient minimization were
applied. Minimization was performed using implicit solvent and a distance depen-
dent dielectric constant (4r) was used.
Figure 3.5: Schematic outline of the different steps involved in applying COMBINE analysis to
derive a QSKR to predict drug-binding kinetics.
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3.3.3 Selection of the training and the test datasets
Four (compounds 6, 30, 65 and 69) of the 70 inhibitors of HSP90 were detected
as outliers during the chemometric analysis as they diminished the quality of the
model significantly. Interestingly, three of these compounds (30, 65 and 69) were
also identified as outliers in the recent work by Kokh et al.[29] where the authors
used τRAMD, an enhanced sampling procedure based on molecular dynamics simu-
lations, to calculate the relative residence times of HSP90 inhibitors. Therefore, we
decided to exclude these 4 outliers from our dataset and the remaining 66 inhibitors
were considered for further analysis. For generating training and test datasets for
COMBINE analysis for HSP90, all the inhibitors were ranked from high to low koff
values and every fifth inhibitor (≈ 20 %) in the ranked list was selected for the
test set, while the remaining (≈ 80 %) inhibitors were selected for the training set.
Therefore the training set and test set consisted of 53 and 13 inhibitors, respectively.
Out of the 36 inhibitors in the HIV-1 protease dataset, 3 inhibitors (U75875,
B249 and B376) were identified as outliers and hence not considered further. Two
of these outliers: B249 and B376, which are dihydroxy analogues of compound
B268, have a variety of substituents at the valine side chains of B268 and no crystal
structures were available for them. These small substitutions in B268 resulted in
large increases of koff rates by almost 1000-fold, and this effect was not captured
by the COMBINE analysis as the modeled complexes of these compounds were very
similar to the reference structure. Due to the smaller size of the dataset, we decided
to train our COMBINE analysis model with all of the 33 inhibitors and therefore
no separate test-set was chosen. The model was only validated with different cross-
validation methods such as leave-one-out, leave-two-out and leave-three-out cross-
validation.
3.3.4 Calculation of the interaction energy terms and
generation of energy matrix for PLS analysis
The gCOMBINE program[108] was used for the calculations of LJ and Coulombic in-
teraction energies between protein and inhibitors using Amber force field parameters
generated by the LEap program of the Amber14 software. gCOMBINE decomposes
the total LJ and Coulombic interaction energy between protein and the bound in-
hibitor on a per-residue basis, thereby resulting in a matrix of interaction energy
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terms where each energy term corresponds to Coulombic or LJ interaction energy
between one of the amino acid residues of the protein and the bound inhibitor.
Since there are 207 amino acid residues in the N-HSP90, gCOMBINE generated 207
Coulombic and 207 LJ energy terms for all HSP90 inhibitors. Similarly, 198 Coulom-
bic and 198 LJ energy terms were calculated for all HIV-1 protease inhibitors cor-
responding to 198 amino acid residues in the HIV-1 protease dimer (each monomer
of protease has 99 amino acids).
3.3.5 PLS analysis
PLS analysis was also performed using the gCOMBINE program. Only those inter-
action energy terms that showed variance across the entire training dataset, and have
a standard deviation greater than the specified cutoff value, were selected for PLS
analysis. Different cutoff values in the range of 0.2–1.0 kcal/mol were tested for both
datasets. For HSP90, choosing a standard deviation cut-off of 0.25 kcal/mol resulted
in the most robust model with the least sensitivity and best predictive performance
(Q2) observed in different cross-validation methods used. The best model for HIV-1
protease was obtained when a cutoff of 0.65 kcal/mol was chosen. Then the weights
(or the contributions) of these interaction energy terms and their projection over
different numbers of latent variables were determined from PLS regression by corre-
lating the interaction energies with the experimental log10(koff ) values. Projections
were made for up to 10 latent variables for both datasets. Regression coefficients
(R2), average absolute errors (AAE) and root-mean squared errors (RME) for differ-
ent models obtained with projection over different numbers of latent variables were
calculated by gCOMBINE.
3.3.6 Model validation
In order to access the sensitivity of the different models obtained, the models ob-
tained from PLS regression were subjected to different validation techniques such
as: leave-one-out (LOO), leave-two-out (L2O), leave-three-out (L3O) and random
groups of 7. The model with the best predictive power and least sensitivity was
selected as the best model.
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3.4 Results
3.4.1 COMBINE analysis model for HSP90 inhibitors
Lennard-Jones and Coulombic interaction energies were computed between inhibitors
and 207 residues in the N-terminal domain of HSP90 for all 66 N-HSP90-inhibitor
complexes in the training and test datasets (see Figure 3.6). As seen in Figure 3.6,
the interaction energies between bound inhibitors and amino acid residues close to
the active site (labelled residues) show high variation across the entire dataset and
should therefore be considered further for PLS regression. On the other hand, the
interaction energies between inhibitors and residues located far from the active site
are almost negligible.
Figure 3.6: Interaction energies between N-HSP90 amino acid residues and inhibitors. The first
207 columns on the x-axis correspond to Lennard-Jones energies (kcal/mol) for each residue and
the last 207 columns correspond to Coulombic energies (kcal/mol) between each inhibitor and
different residues. Each column has 66 data points corresponding to the 66 inhibitors used for the
COMBINE analysis.
The best QSKR model having least sensitivity and the best predictive power (Q2)
for koff rates constants of HSP90 inhibitors was obtained when a standard deviation
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cutoff of 0.25 kcal/mol was used to select a subset of interaction energy terms for PLS
analysis. A total of 42 inhibitor–residue interaction energy terms (12 coulombic and
30 LJ terms) that have standard deviation higher than 0.25 kcal/mol in the training
dataset were used in the PLS regression (see Figure 3.7). Nine amino acid residues:
N51, D54, K58, D93, G97, D102, L103, Y139, and T184, make contributions of both
coulombic and LJ interaction energies to the QSKR model.
Figure 3.7: Key protein-inhibitor interactions identified from the COMBINE analysis of HSP90
inhibitors. 30 LJ and 12 coulombic protein residue–inhibitor interaction energy terms were selected
based on variance over the inhibitors for deriving the PLS model. On the crystal structure (PDB
ID: 5J20) of compound 11 (cyan sticks) complexed with N-HSP90 (ribbon representation), the
residues are colored according to whether their coulombic (blue), LJ (red), or both coulombic and
LJ (magenta) interaction energies with the bound inhibitor contribute to the model. The figure is
taken from Ganotra and Wade, 2018[109].
Then the predictor variables (interaction energies) and the response variable (ex-
perimental log10(koff ) values) were projected over different numbers of latent vari-
ables in PLS analysis and the weights (or the contributions) of the 42 interaction
energy terms were determined from PLS regression (see Figure 3.9). The regres-
sion coefficients and standard mean errors were determined for different numbers of
latent variables (see Table 3.3). The models were then subjected to different cross-
validation techniques to access their sensitivity and predictive ability (see Table 3.5).
The model with three latent variables was found to have the best predictive power
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and least sensitivity with a R2 of 0.80 and a leave-one-out (LOO) cross-validated
correlation coefficient (Q2) of 0.69 (see Table 3.4 and Figure 3.8). The average ab-
solute error (AAET ) and the root mean squared error (RMET ) for the training set
were calculated to be 0.37 (log10(s−1) units) and 0.46 (log10(s−1) units), respectively
(Table 3.3). The model obtained has good predictive power as the correlation coeffi-
cient for the test-set (R2PRED) with 13 compounds was calculated to be 0.86 with an
AAETP of 0.33 and RMEP of 0.37 (see Figure 3.8 and Table 3.6). The values of the
average absolute error (AAEV ) and the root mean squared error (RMEV ) for differ-
ent cross-validation sets were found to be consistent for the different cross-validation
methods used (Table 3.5).
LV R2 Q2LOO AAET AAEV RMET RMEV R
2
PRED AAEP RMEP
1 0.43 0.31 0.61 0.67 0.78 0.85 0.33 0.60 0.79
2 0.75 0.66 0.39 0.45 0.51 0.60 0.71 0.44 0.52
3 0.80 0.69 0.37 0.45 0.46 0.57 0.86 0.33 0.37
4 0.82 0.72 0.35 0.44 0.44 0.55 0.87 0.32 0.35
5 0.85 0.71 0.32 0.45 0.40 0.55 0.86 0.31 0.36
6 0.87 0.71 0.30 0.45 0.38 0.56 0.89 0.26 0.33
7 0.88 0.69 0.27 0.45 0.36 0.58 0.89 0.27 0.33
8 0.89 0.66 0.26 0.47 0.34 0.60 0.86 0.32 0.36
9 0.90 0.64 0.25 0.46 0.33 0.62 0.85 0.33 0.37
10 0.91 0.55 0.23 0.51 0.31 0.70 0.69 0.48 0.54
Table 3.3: Summary of the models derived for different numbers of latent variables (LVs) for
the COMBINE analysis for koff rate constants of N-HSP90 inhibitors. The models were derived
using the log10(koff ) value (unit of koff rates in s−1) as the response variable in the PLS analysis.
The table lists the regression coefficient (R2) for the training set, the correlation coefficient for
leave-one-out cross validation sets (Q2LOO), average absolute errors (AAET and AAEV ) and root
mean squared errors (RMET and RMEV ) for the training set and leave-one-out validation sets,
respectively, the correlation coefficient (R2PRED) for the test-set (prediction set), average absolute
error (AAEP ) and root mean squared error (RMEP ) for the test-set.
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Compound
Id
N-HSP90
Binding site
conformation
PDB
Id
Experimental
log10(koff(s−1))
Fitted
log10(koff(s−1))
(PLS regression)
Predicted
log10(koff(s−1))
(LOO validation)
1 loop 2VCI -4.00 ± 0.00 -3.45 -2.57
3 loop 2BSM -2.00 ± 0.04 -2.54 -2.47
5 loop 5J2X -1.85 ± 0.07 -1.21 -1.16
7 loop 6ELO -1.20 ± 0.02 -0.77 -0.65
8 loop 5J64 -0.68 ± 0.07 -0.60 -0.65
9 loop n.a. -0.08 ± 0.03 -0.86 -1.13
10 loop 6ELN -0.60 ± 0.03 -1.12 -1.25
11 helix 5J20 -3.48 ± 0.03 -2.47 -2.37
12 helix 5J86 -2.75 ± 0.09 -2.80 -2.79
13 helix 5J9X -2.77 ± 0.12 -2.43 -2.41
14 helix 6ELP -0.76 ± 0.06 -1.91 -2.16
15 helix 5J27 -2.19 ± 0.03 -2.02 -2.00
16 helix 5J86 -1.85 ± 0.05 -2.09 -2.13
17 helix 5LRZ -3.56 ± 0.01 -3.99 -3.89
18 helix 5LR7 -3.72 ± 0.16 -3.18 -2.59
20 helix 5LQ9 -3.87 ± 0.01 -4.18 -4.11
21 helix 5LS1 -3.31 ± 0.12 -2.89 -2.80
22 helix 5T21 -3.12 ± 0.03 -2.61 -2.52
23 helix n.a. -2.02 ± 0.02 -1.80 -1.76
24 helix n.a. -2.33 ± 0.07 -2.06 -2.04
27 helix n.a. -2.92 ± 0.04 -2.53 -2.52
28 helix n.a. -2.34 ± 0.08 -2.59 -2.66
29 helix n.a. -2.52 ± 0.04 -2.43 -2.44
31 loop n.a. -0.96 ± 0.17 -1.26 -1.34
33 loop n.a. -1.15 ± 0.10 -0.64 -0.58
36 helix 5LO6 -2.86 ± 0.12 -3.21 -3.32
37 helix 5LNZ -2.70 ± 0.04 -3.13 -3.14
38 helix 6EY8 -1.54 ± 0.02 -2.09 -2.08
39 helix 6EFU -1.65 ± 0.02 -1.95 -1.93
40 helix 6EY9 -1.76 ± 0.01 -2.16 -2.13
41 helix 6EY8 -0.63 ± 0.04 -1.72 -1.87
42 helix n.a. -2.30 ± 0.08 -2.19 -2.17
43 helix 5OCI -3.17 ± 0.00 -2.81 -2.77
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Compound
Id
N-HSP90
Binding site
conformation
PDB
Id
Experimental
log10(koff(s−1))
Fitted
log10(koff(s−1))
(PLS regression)
Predicted
log10(koff(s−1))
(LOO validation)
44 helix n.a. -2.04 ± 0.05 -1.93 -1.91
46 helix n.a. -2.63 ± 0.07 -2.76 -2.78
47 helix n.a. -2.91 ± 0.03 -2.76 -2.75
48 helix n.a. -3.12 ± 0.07 -2.98 -2.94
50 helix 5ODX -3.53 ± 0.02 -3.34 -3.28
51 helix 5NYH -2.62 ± 0.01 -2.60 -2.56
52 helix n.a. -2.86 ± 0.14 -2.78 -2.73
55 helix n.a. -2.11 ± 0.27 -2.10 -2.08
56 helix n.a. -1.88 ± 0.02 -2.62 -2.67
57 helix n.a. -3.04 ± 0.12 -2.78 -2.72
58 helix n.a. -0.26 ± 0.12 -0.45 -0.63
59 helix n.a. -0.24 ± 0.02 -0.45 -0.57
60 helix 5OD7 -3.62 ± 0.11 -3.85 -3.64
62 helix 6EI5 -2.34 ± 0.04 -2.11 -2.06
63 helix n.a. -2.82 ± 0.05 -2.83 -3.25
64 helix n.a. -0.26 ± 0.04 -0.21 -0.29
66 helix n.a. -2.90 ± 0.08 -2.26 -2.17
67 helix 5LR1 -1.59 ± 0.02 -0.73 -0.68
68 helix 6EL5 -1.48 ± 0.02 -2.04 -2.19
70 helix 2YKJ -3.00 ± 0.06 -2.65 -2.27
Table 3.4: Comparison of log10(koff ) values calculated by the COMBINE analysis model in
PLS regression (column 5) and the experimental log10(koff ) values from Ref.[29] (column 4) for
different N-HSP90 inhibitors (53 compounds) used for training the COMBINE analysis model.
The log10(koff ) values predicted from leave-one-out (LOO) cross-validation for the training set of
inhibitors are given in the last column.
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Validation Q2 AAEV RMEV
Leave-one-out (LOO) 0.69 0.45 0.57
Leave-two-out (L2O) 0.69 0.45 0.58
Leave-three-out (L3O) 0.68 0.46 0.59
Random groups of 7 0.68 0.46 0.59
(10 iterations)
Table 3.5: Statistical measures of correlation for the COMBINE Analysis Models Derived for
log(koff ) of HSP90 inhibitors. Cross-validated correlation coefficient (Q2), average absolute errors
(AAEV ) and root mean squared errors (RMEV ) for different validation methods for the PLS model
derived with 3 latent variables for HSP90 inhibitors.
Compound
Id
N-HSP90
Binding site
conformation
PDB
Id
Experimental
log10(koff(s−1))
Predicted
log10(koff(s−1))
2 loop 2UWD -2.70 ± 0.03 -2.45
4 loop 5NYI -4.00 ± 0.00 -3.77
19 helix 2YKI -3.55 ± 0.07 -3.23
25 helix n.a. -2.96 ± 0.21 -2.45
26 helix n.a. -2.00 ± 0.07 -2.44
32 loop n.a. -0.92 ± 0.07 -1.32
34 helix n.a. -2.38 ± 0.05 -2.90
35 helix 6EYA -2.27 ± 0.03 -2.31
45 helix n.a. -3.13 ± 0.05 -2.67
49 helix n.a. -2.86 ± 0.06 -2.91
53 helix n.a. -1.50 ± 0.22 -1.96
54 helix n.a. -1.79 ± 0.10 -2.24
61 helix n.a. -0.58 ± 0.12 -0.42
Table 3.6: Comparison of log10(koff ) values predicted by the COMBINE analysis model and the
experimental log10(koff ) values from Ref.[29] (column 4) for different N-HSP90 inhibitors used in
the test set (13 compounds) for validation of the COMBINE analysis model.
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Figure 3.8: A) Plot of calculated vs experimental log(koff ) values for the training data set (R2
= 0.80) and LOO cross-validation (Q2 = 0.69). B) Plot of calculated vs experimental log(koff )
values for the test data set with 13 compounds (R2PRED = 0.86). The diagonal straight lines in
both plots corresponds to y = x (ideal case).
Figure 3.9: Weights for different LJ and coulombic interaction energy contributions derived from
the PLS analysis (projection to 3 latent variables). The figure is taken from Ganotra and Wade,
2018[109].
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The major contribution to the koff rate constants comes from the LJ energies
of the hydrophobic residues lining the binding pocket (see Figure 3.9). Therefore,
compounds with slow koff rates tend to have bulky hydrophobic groups mediating
strong LJ interactions with the nonpolar binding site residues. Most of the helix-
binders are relatively bulkier in size and have lower koff rate constants, as they have
additional hydrophobic moieties which occupy a transient hydrophobic cavity formed
between α-helix3 and the β-strands and mediate strong van der Waals interactions
with hydrophobic residues L103, I104, N106, L107, G108, T109, I110, and A111 (see
Figure 3.10). On the other hand, loop-binders are usually smaller in size and have
relatively higher koff rates. Loop-binders that have lower koff rates have additional
polar moieties mediating coulombic interactions with amino acid residues such as
N51, E47, and G97, thereby stabilizing the bound-state (see Figure 3.10).
Figure 3.10: Comparison of the binding modes and the key interactions for a helix-binder (com-
pound 11, crystal structure PDB ID: 5J20), a faster dissociating loop-binder (compound 9, model
based on PDB ID: 5OCI), and a slower dissociating loop-binder (compound 4, crystal structure
PDB ID: 5NYI), respectively. Hydrophobic moieties (shown with a black circle in the left panel) of
helix-binders occupy a transient hydrophobic cavity formed by the helix conformation of N-HSP90
and mediate strong LJ interactions with hydrophobic residues. Most of the loop binders are smaller
in size and dissociate faster (middle panel). Some of the slower dissociating loop-binders have addi-
tional polar moieties (marked with red and black circles in the right panel) that mediate additional
electrostatic interactions with the binding-site residues. The figure is taken from Ganotra and
Wade, 2018[109].
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3.4.2 Results: COMBINE analysis model for HIV-1
protease inhibitors
HIV-1 protease is a homodimer with each monomer consisting of 99 amino acid
residues. Therefore, for each of the 33 protease inhibitors in the training dataset,
198 coulombic and 198 LJ energies were calculated using gCOMBINE (see Figure
3.11).
Figure 3.11: Interaction energies between HIV-1 protease residues and inhibitors. Lennard-Jones
and Coulombic interaction energies were computed between the inhibitors and 198 amino acid
residues of the protease dimer using the gCOMBINE program. The first 198 columns on the x-
axis correspond to Lennard-Jones energies (kcal/mol) for each residue and the last 198 columns
correspond to Coulombic energies (kcal/mol) between each inhibitor and different residues. Each
column has 33 data points corresponding to the 33 inhibitors used for the COMBINE analysis.
To select a subset of interaction energy terms for PLS, a standard deviation
cutoff range (from 0.2 to 1.0 kcal/mol) was tested and the choice of a cutoff of 0.65
kcal/mol resulted in the best model. Seventeen coulombic and 17 LJ terms that
have standard deviations higher than the cutoff value were used for PLS analysis
(see Figure 3.12). The models were derived for different numbers of latent variables
and validated using several validation methods (see Tables 3.7 and 3.8). The model
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with the best predictive ability and least sensitivity was obtained when projection
was made to six latent variables. The R2, AAET , and RMET for the training set are
0.94, 0.26 (log10(s−1) units), and 0.34 (log10(s−1) units), respectively (see Table 3.9
and Figure 3.13). The Q2 value for different validation methods ranged from 0.51
to 0.70 (Table 3.8).
LV R2 Q2LOO AAET AAEV RMET RMEV
1 0.20 0.01 1.03 1.14 1.23 1.36
2 0.38 -0.01 0.86 1.09 1.09 1.38
3 0.56 0.06 0.70 1.02 0.91 1.33
4 0.74 0.34 0.55 0.89 0.70 1.11
5 0.83 0.38 0.46 0.83 0.57 1.08
6 0.94 0.70 0.26 0.58 0.34 0.75
7 0.96 0.77 0.23 0.52 0.27 0.66
8 0.97 0.83 0.20 0.47 0.23 0.57
9 0.98 0.83 0.18 0.47 0.20 0.56
10 0.98 0.83 0.16 0.48 0.19 0.57
Table 3.7: Summary of the models derived for different numbers of latent variables (LVs) for the
COMBINE analysis for koff rate constants of HIV-1 protease inhibitors. The models were derived
using the log10(koff ) value ( unit of koff rates in s−1) as the response variable in the PLS analysis.
The table lists the regression coefficient (R2) for the training set, the correlation coefficient for
leave-one-out cross validation sets (Q2LOO), average absolute errors (AAET and AAEV ) and root
mean squared errors (RMET and RMEV ) for the training set and leave-one-out validation sets,
respectively. The model with 6 LVs displayed the best predictive performance and least sensitivity
in different cross-validation methods used.
Validation Q2 AAEV RMEV
Leave-one-out (LOO) 0.70 0.58 0.75
Leave-two-out (L2O) 0.51 0.68 0.96
Leave-three-out (L3O) 0.52 0.68 0.95
Random groups of 7 0.60 0.63 0.86
(10 iterations)
Table 3.8: Cross-validated correlation coefficient (Q2), average absolute errors (AAEV ) and root
mean squared errors (RMEV ) for different validation methods for the PLS model derived with 6
latent variables for HIV-1 protease inhibitors.
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Figure 3.12: Key protein-inhibitor interactions identified from the COMBINE analysis of HIV-1
protease inhibitors. 17 LJ and 17 coulombic protein residue–inhibitor interactions were selected
based on variance over the inhibitors. Residues are shown on the crystal structure (PDB ID: 1OHR)
of nelfinavir (cyan sticks) bound to HIV-1 protease (ribbon representation) colored according to
whether their LJ (red), coulombic (blue), or both LJ and coulombic (magenta) interaction energy
terms, contribute to the PLS model. The figure is taken from Ganotra and Wade, 2018[109].
Figure 3.13: Correlation plot for experimental log(koff ) values vs log(koff ) values calculated by
COMBINE analysis of HIV-1 protease inhibitors for the training dataset (R2=0.94) and leave-one-
out (LOO) cross-validation (Q2=0.78). The straight line corresponds to y=x (ideal case).
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Compound
Id
PDB
Id
Experimental
log10(koff(s−1))
Fitted
log10(koff(s−1))
(PLS regression)
Predicted
log10(koff(s−1))
(LOO validation)
B435 1D4H -2.19 ± 0.09 -1.48 -1.36
A047 1G2K -1.16 ± 0.10 -0.81 -0.74
A023 n.a. -0.86 ± 0.11 -0.66 -0.05
A024 1G35 -1.16 ± 0.10 -1.30 -1.44
B429 n.a. -3.43 ± 0.09 -3.71 -3.69
B409 1EC1 -3.37 ± 0.13 -3.21 -3.16
B268 n.a. -2.44 ± 0.05 -2.43 -2.49
A045 n.a. -0.58 ± 0.09 -0.90 -1.00
B425 1D4I -0.63 ± 0.00 -1.62 -2.06
A021 n.a. -1.56 ± 0.04 -1.16 -0.94
saquinavir 3OXC -3.64 ± 0.06 -4.00 -3.72
indinavir 2BPX -2.80 ± 0.04 -2.35 -0.77
ritonavir 1HXW -2.67 ± 0.06 -2.39 -1.69
DMP323 1QBS 1.92 ± 0.12 1.91 1.41
nelfinavir 1OHR -3.18 ± 0.04 -3.07 -2.08
B369 1EBY -1.88 ± 0.19 -2.09 -2.38
B388 n.a. -1.64 ± 0.15 -1.66 -1.67
A038 n.a. -3.31 ± 0.02 -3.01 -1.89
A037 n.a. -3.44 ± 0.04 -3.57 -3.05
B440 n.a. -3.52 ± 0.02 -3.54 -3.51
B439 n.a. -2.79 ± 0.06 -2.87 -2.89
B408 n.a. -2.77 ± 0.02 -2.52 -2.37
B412 n.a. -3.09 ± 0.19 -3.28 -3.29
A008 n.a. 1.64 ± 0.15 1.45 0.51
B277 n.a. -2.31 ± 0.17 -2.07 -1.96
A030 n.a. -1.38 ± 0.13 -1.00 -0.71
A015 n.a. -0.03 ± 0.37 -0.78 -1.35
A016 n.a. -1.22 ± 0.22 -1.37 -1.50
A017 n.a. -0.75 ± 0.09 -0.61 -0.71
B322 n.a. -1.17 ± 0.29 -1.43 -1.60
B365 n.a. -1.51 ± 0.06 -1.52 -1.60
B347 n.a. -1.57 ± 0.05 -1.31 -0.88
A018 n.a. -0.32 ± 0.20 -0.43 -1.28
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Table 3.9 continued from previous page
Compound
Id
PDB
Id
Experimental
log10(koff(s−1))
Fitted
log10(koff(s−1))
(PLS regression)
Predicted
log10(koff(s−1))
(LOO validation)
Table 3.9: Comparison of log10(koff ) values calculated by the COMBINE analysis model in PLS
regression (column 4) and the experimental log10(koff ) values from Ref.[? ] (column 3) for different
HIV-1 protease inhibitors used for training the COMBINE analysis model. The log10(koff ) values
predicted from leave-one-out (LOO) cross-validation for the training set of inhibitors are given in
the last column.
Of the 17 coulombic and 17 LJ interactions considered in the PLS analysis, many
make an unfavorable contribution to the dissociation kinetics (see Figure 3.14). It
was observed that some of the interactions of the inhibitors, specifically with the
residues in the flap region of HIV-1 protease, favor fast unbinding. For example, the
cyclic urea and cyclic sulfamide inhibitors have direct polar contacts with the I50
residues located in the flap regions of the HIV-1 protease dimer and have fast dissoci-
ation rates. The flaps are very dynamic in nature and are known to exist in different
conformations ranging from open to semiclosed to closed. Their fast movements
could lead to these small cyclic compounds being driven out of the binding pocket.
The cyclic urea inhibitors A008 and DMP323 have the highest koff rate constants,
and they have hydroxyl groups that make hydrogen bonds with the amide backbone
atoms of both D30 residues in the bound complexes. The interaction with D30B
was identified as unfavorable by the COMBINE analysis (Figure 3.14, bottom inset).
The acyclic inhibitors, on the other hand, are peptidomimetic and have relatively
slow dissociation rates. They do not form direct contacts with the flap residues
and their aromatic groups mediate favorable LJ interactions with residues such as
P81 and R08 (Figure 3.14, top inset). In some of the crystal structures of acyclic
inhibitors complexed with HIV-1 protease, bridging waters mediate the interaction
between the inhibitors and binding site residues such as D30 and I50. While inter-
facial water molecules can be considered explicitly in COMBINE analysis[95], we
omitted them in this study. Thus, the effect of the water-mediated interactions that
tend to correlate with slow dissociation rates appears to be represented implicitly
by direct hydrogen-bonding to the corresponding residues in the complexes of fast
dissociating inhibitors having negative weights in the PLS model.
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Figure 3.14: Weights for different LJ and coulombic interaction energy terms derived from the
PLS analysis (projection to six latent variables, the value of constant C was 0.134). A negative
weight means that an energetically favorable (negative) interaction energy term tends to shorten
the residence time. The labels of some of the interaction energy terms that characterize slow and
fast dissociating inhibitors are boxed, and the corresponding residues are also shown in the inset
figures. The top inset shows a few of the interactions (yellow) contributing to the long residence
time of the slowly dissociating inhibitor saquinavir (koff = 0.00023 s−1) and the bottom inset shows
the interactions (magenta) contributing to the short residence time of a very fast dissociating cyclic
urea inhibitor DMP323 (koff = 83.3 s−1) in the crystal structures with PDB IDs 3OXC and 1QBS,
respectively. The figure is taken from Ganotra and Wade, 2018[109].
3.5 Concluding Discussions
Using COMBINE analysis, we have obtained QSKRs for koff rates with very good
predictive power (Q2LOO = 0.69, R2PRED = 0.86 for N-HSP90 and Q2LOO =0.70 for
HIV-1 protease) and identified the key ligand–receptor interactions that contribute
to the variance in binding kinetics. These specific interaction energy components
provide insights into the mechanisms of specific slow and fast dissociating classes of
compounds. Additionally, COMBINE analysis could be used to predict the effect
of specific mutations in the protein on the dissociation kinetics of its inhibitors.
COMBINE analysis was originally developed to derive QSARs for binding affinity
(or Kd, the equilibrium dissociation constant) for a congeneric series of compounds
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with a similar binding mode to a protein target. Here, we have not used congeneric
series, but rather diverse sets of compounds with very different scaffolds and binding
modes. We find that our COMBINE analysis models for Kd are not as predictive
as the COMBINE models for koff for these diverse sets of compounds (see Tables
3.10, 3.11, 3.12, 3.13). For deriving the model for Kd of the N-HSP90 inhibitors, the
full dataset of 66 compounds was initially used for training. 3 outliers (compounds
17, 50 and 67) were later removed from the PLS analysis to improve the quality
of the model. Therefore, the final model for Kd was trained with 63 compounds.
Inspite of training the model with the whole dataset, the model for Kd had only
weak predictive ability with R2 = 0.59 and Q2LOO = 0.41 for 3 latent variables (see
Tables 3.10 and 3.11). Similarly, for deriving the model for Kd of HIV-1 protease
inhibitors, the full dataset of 36 compounds was initially used for training. 3 outliers
(compounds B435, A037 and B249) were later removed from the PLS analysis to
improve the quality of the model. Therefore, the final model for Kd of protease
inhibitors was trained with 33 compounds.
LV R2 Q2LOO AAET AAEV RMET RMEV
1 0.33 0.13 0.66 0.74 0.90 1.02
2 0.55 0.34 0.58 0.68 0.73 0.89
3 0.59 0.41 0.57 0.67 0.70 0.84
4 0.64 0.39 0.52 0.67 0.66 0.85
5 0.69 0.40 0.49 0.67 0.61 0.85
6 0.70 0.32 0.48 0.68 0.60 0.90
7 0.72 0.16 0.47 0.74 0.58 1.00
8 0.74 0.09 0.45 0.76 0.56 1.04
9 0.74 -0.17 0.44 0.82 0.55 1.18
10 0.75 -0.75 0.44 0.91 0.54 1.44
Table 3.10: Summary of the models derived for different numbers of latent variables (LVs) for
the COMBINE analysis for Kd of the N-HSP90 inhibitors. The models were derived using the
log10(Kd) value (unit of Kd is M) as the response variable in the PLS analysis. The table lists
the regression coefficient (R2) for the training set, the correlation coefficient for leave-one-out cross
validation sets (Q2LOO), average absolute errors (AAET and AAEV ) and root mean squared errors
(RMET and RMEV ) for the training set and leave-one-out validation sets, respectively.
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Validation Q2 AAEV RMEV
Leave-one-out (LOO) 0.41 0.67 0.84
Leave-two-out (L2O) 0.41 0.68 0.84
Leave-three-out (L3O) 0.38 0.70 0.86
Random groups of 7 0.37 0.69 0.87
(10 iterations)
Table 3.11: Statistical measures of correlation for the COMBINE Analysis models Derived for
log(Kd) of N-HSP90 inhibitors. The table lists the cross-validated correlation coefficient (Q2),
average absolute errors (AAEV ) and root mean squared errors (RMEV ) for different validation
methods for the PLS model derived with 3 latent variables for N-HSP90 inhibitors.
LV R2 Q2LOO AAET AAEV RMET RMEV
1 0.30 0.08 1.04 1.22 1.23 1.42
2 0.39 0.16 0.95 1.13 1.15 1.35
3 0.55 0.27 0.78 1.05 0.99 1.26
4 0.64 0.37 0.68 0.96 0.88 1.17
5 0.69 0.45 0.63 0.85 0.82 1.09
6 0.78 0.53 0.50 0.79 0.69 1.02
7 0.80 0.53 0.47 0.78 0.65 1.01
8 0.83 0.53 0.45 0.76 0.60 1.01
9 0.86 0.43 0.41 0.89 0.54 1.11
10 0.89 0.24 0.39 1.01 0.50 1.28
Table 3.12: Summary of the models derived for different numbers of latent variables (LVs) for
the COMBINE analysis for Kd of the HIV-1 protease inhibitors. The models were derived using
the log10(Kd) value (unit of Kd is M) as the response variable in the PLS analysis. The table lists
the regression coefficient (R2) for the training set, the correlation coefficient for leave-one-out cross
validation sets (Q2LOO), average absolute errors (AAET and AAEV ) and root mean squared errors
(RMET and RMEV ) for the training set and leave-one-out validation sets, respectively.
The R2 and Q2LOO for the COMBINE analysis model derived with 6 latent vari-
ables are 0.78 and 0.53 respectively (see Tables 3.12 and 3.13). We do however,
obtain better statistics for a COMBINE model for Kd generated with a smaller data
set of resorcinol compounds that inhibit HSP90 and have a similar scaffold (Table
3.14). A possible explanation for the better predictions for koff than Kd may be
that dissociation rates are independent of the unbound state, and therefore differ-
ences in ligand and protein desolvation and conformational free energies are not so
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important.
Validation Q2 AAEV RMEV
Leave-one-out (LOO) 0.53 0.79 1.02
Leave-two-out (L2O) 0.46 0.81 1.08
Leave-three-out (L3O) 0.44 0.81 1.10
Random groups of 5 0.48 0.83 1.06
(10 iterations)
Table 3.13: Statistical measures of correlation for the COMBINE Analysis models Derived for
log(Kd) of HIV-1 protease inhibitors. The table lists the cross-validated correlation coefficient (Q2),
average absolute errors (AAEV ) and root mean squared errors (RMEV ) for different validation
methods for the PLS model derived with 6 latent variables for HIV-1 protease inhibitors.
Validation Q2 AAEV RMEV
Leave-one-out (LOO) 0.49 0.47 0.57
Leave-two-out (L2O) 0.45 0.47 0.59
Leave-three-out (L3O) 0.47 0.46 0.58
Random groups of 5 0.43 0.49 0.61
(10 iterations)
Table 3.14: Statistical measures of correlation for the COMBINE Analysis models Derived for
the log(Kd) of the resorcinol series of inhibitors of N-HSP90. For deriving the model for Kd, a
smaller dataset of 25 inhibitors belonging to the resorcinol series was used for training. 3 outliers
(compounds 23, 28, 30) were later removed from the PLS analysis to improve the quality of the
model. Therefore, the final model for Kd was trained with 22 compounds. The table lists the cross-
validated correlation coefficient (Q2), average absolute errors (AAEV ) and root mean squared errors
(RMEV ) for different validation methods used. These statistical measures correspond to a model
derived with 4 latent variables in PLS analysis.
The current applications to HSP90 and HIV-1 protease data sets with very di-
verse sets of inhibitors, using both crystal structures and modeled protein-inhibitor
complexes, demonstrates the potential of COMBINE analysis as a robust QSKR
approach with increasing scope for application as more data sets of measured ki-
netic parameters become available. COMBINE analysis complements a growing
number of methods based on biomolecular simulation and machine learning to pre-
dict drug–target binding kinetics[9]. Indeed, a possible extension of the COMBINE
analysis approach would be to the analysis of structures from molecular dynamics
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simulations, including intermediates along drug binding or unbinding pathways.
73

Chapter 4
Halogen-aromatic π interactions
modulate inhibitor residence time
This Chapter is based on the following publication:
Halogen–Aromatic π Interactions Modulate Inhibitor Residence Times.
Christina Heroven, Victoria Georgi, Gaurav K. Ganotra, Paul E Brennan, Finn
Wolfreys, Rebecca C. Wade, Amaury E. Fernández-Montalván, Apirat Chaikuad,
Stefan Knapp, Angew. Chemie Int. Ed. 2018, 57 (24), 7220–7224.
4.1 Background
Designing drug molecules with longer residence times may result in increased drug
efficacy and prolonged inhibition after the free drug concentration has dropped owing
to in vivo clearance. Having slow off-rates specific for the target may also result in
kinetic-selectivity over off-targets with high dissociation rates despite similar bind-
ing constants[110]. Kinases are particularly dynamic proteins and after G-protein-
coupled receptors (GPCRs), kinases are the second most important group of drug
targets[111] under study with more than 150 kinase inhibitors in preclinical trials
waiting FDA approval[112]. There has been several reasons attributed to the slow
off-rates of several kinase inhibitors already approved as clinical drugs. In most
cases, an induced fit binding mechanism results in slow dissociation rates, where the
dissociation of the drug will require the structural rearrangement of the target. For
example, slow binding kinetics of a type II inhibitor of p38 MAP kinase, BIRB-796,
was suggested to be the result of its binding to an inactive conformation in which
75
the DFG motif is displaced in a so-called “DFG-out” conformation[113]. However,
not all type II inhibitors that bind to “DFG-out” conformation show slow binding
kinetics[114]. Indeed, recent study by Schneider et al.[115] suggested that the slow
off-rates were the result of efficient hydrophobic contacts rather than the kinetic
dissociation barrier introduced by the DFG-out transition. In the case of the type I
CDK inhibitor roniciclib, the long residence time was considered to be the result of
changes in the arrangement of water molecules coupled to conformational adapta-
tion of the DFG motif[116]. In some cases, the presence of water-shielded hydrogen
bonds can also lead to slow off-rates[117].
Figure 4.1: The 5-iodotubercidin inhibitor (5-iTU) exhibits tight binding with slow dissociation
kinetics from haspin. A) Chemical structures of 5-iTU and adenosine. B) Superimposition of
haspin-5iTU and AMP (pdb id: 4ouc) reveals similar binding modes of the two compounds. C)
BLI sensorgram suggests slow kinetic behavior of the 5-iTU-haspin interaction. D) The iodide
and the benzene moieties of 5-iTU and F605, respectively, are located in close proximity with a
favorable geometry for a halogen-π bond. The figure is taken from Heroven et al.[118] with
permissions.
Herein, we present data that suggest that targeting the interactions between
halogen atoms, commonly found in drugs, and the aromatic residues, which are also
typically found in drug binding sites on proteins, can be utilized to design inhibitors
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with long residence times. We (Heroven et al.[118]) chose haspin, a serine/threonine
kinase with a known three-dimensional structure, as a model system and the close
analogue of ATP, 5-iodotubercidin (5-iTU) as a model inhibitor for an archetypal
active state (type I) kinase-inhibitor binding mode. From the analysis of 3D crys-
tallographic structures of haspin, it was observed that the binding modes of both
5-iTU and the nucleoside adenosine, are highly conserved (see Figure 4.1 A,B). Both
of these molecules are very similar except for the presence of the iodide moiety in
5-iTU, in close proximity to the F605 gatekeeper, which forms a halogen–aromatic
π interaction (see Figure 4.1 D). Compared to ATP or adenosine (Kd = 180 µM),
5-iTU showed a very high affinity (Kd = 0.78 nM) for haspin and an unexpectedly
long residence time. This tight binding of 5-iTU with slow binding kinetics was
further confirmed by isothermal titration calorimetry (ITC), biolayer interferometry
(BLI), and surface plasmon resonance (SPR) experiments (see Figure 4.1 C for BLI
results). We (Heroven et al.[118]) therefore hypothesized that this halogen-π inter-
action between iodide of 5-iTU and aromatic gatekeeper residue (phenylalanine) of
haspin contributes to most of the increase in the binding free energy (∆G) and could
be responsible for the long residence time of 5-iTU.
Figure 4.2: The σ-hole model and the polarization of the electrostatic surface potential. Electro-
static surface potentials of halogenated methane (top) and uridine nucleobase (bottom), adapted
from Auffinger et al.[119] and Scholfield et al.[120]. Potential energies are shown from red
(negative) to green (neutral) to blue (positive), viewing into the halogen atoms down the X-C
bond. The resulting polarization increases with the atomic size of the halogen, following the series
F < Cl < Br < I. For comparison, the potential surface of methane and methylated uridine is
shown on the right.
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Quantum mechanical calculations suggest that there is an anisotropic distribu-
tion of the electrostatic potential across the surface of the halogen[121]. According
to σ-hole model[122], this direction polarization is the result of the covalent σ-bond
(C-X) between a carbon atom and the halogen. Halogens have five electrons in
the p-atomic orbitals of their valence shell. While both px and py orbitals have
paired electrons, it is the single valence electron of the pZ orbital that is involved
in formation of the covalent C-X σ-bond. This depopulation of the pZ orbital di-
rectly opposite the C-X σ-bond creates a hole, also known as a σ-hole, that partially
exposes the positive nuclear charge of the halogen. The magnitude of the σ-hole
depends on the the polarizability of the halogen, which follows the series I > Br
> Cl > F (see Figure 4.2). This σ-hole magnitude also depends on the electron-
withdrawing ability of the molecule that the halogen is covalently bound to. As the
partial positive charge exposed along the C-X σ-bond diminishes with decreasing size
of the halogen atom, the iodide in 5-iTU was substituted by smaller halogen atoms
(Br, Cl and F) and the affinities and binding kinetics of these 5-iTU derivatives
were characterized using experimental assays. The affinities of 5-iTU derivatives
diminished with decreasing size of the substituted halogen atom, as confirmed by
ITC experiments (see Figure 4.3 A). In comparison to 5-iTU, removal of the halogen
atom in tubercidin (TU), resulted in a 42-fold decrease in the potency (see Figure
4.3 A). Similarly, substitution of iodide in 5-iTU with a smaller sized fluoride led to a
eightfold decrease of potency in 5-fluorotubercidin (5-fTU). Binding kinetics of these
five synthesized 5-tubercidin halogen derivatives with haspin were performed using
three independent techniques: kinetic probe competition assays (kPCAs), BLI, and
SPR. The Kd values determined by these three independent methods correlated well
with each other and also with the binding constants determined in solution by ITC
(see Figure 4.3 B). The off-rates (koff ) calculated from three different experimen-
tal showed the same behavior with the off-rates increasing with decreasing halogen
size from the 5-iodo- to the 5-fluoro-substituted tubercidin, and the unsubstituted
tubercidin showed the fastest off-rate (see Figure 4.3 C,D).
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Figure 4.3: Binding kinetics of haspin with five tubercidin derivatives harboring halogen sub-
stituents at the 5-position. A) ITC thermodynamic binding parameters. B) Comparison of dis-
sociation constants (KD) measured by ITC, BLI, SPR and kPCA shows good correlation of the
measured equilibrium data. C) SPR sensorgrams demonstrating increasingly slow dissociation rates
with increasing size of the halogens. D) Rate plot with Isoaffinity Diagonal (RaPID) of kon and
koff constants measured by BLI, SPR and kPCA. The red arrow indicates the trend to increasing
kon and decreasing koff upon increasing the atomic radii of the halogens. E) Crystal structures
reveal conserved binding modes of all five tubercidin derivatives, albeit with an additional water
molecule adjacent to the inhibitor and F605 gatekeeper in tubercidin. The figure is taken from
Heroven et al.[118] with permissions.
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4.2 Aim of the work
Based on the observations from kinetic, thermodynamic, and structural measure-
ments performed for characterization of the halogen-aromatic π interactions in the
haspin-inhibitor complexes, we wanted to answer few important questions such as:
1) How is the polarization-mediated anisotropic charge distribution on halogen atoms
involved in mediating such a strong electrostatic interaction in the binding pocket
of kinase?,
2) What are the different energetic components that contribute to this electrostatic
interaction?,
3) Can the mechanism of prolonging drug-target residence times by introducing
aromatic-halogen interactions be applied to other kinases having aromatic residues
at the gatekeeper position?
To answer these questions, we decided to perform quantum mechanical calcula-
tions as it was important to consider polarization and electronic effects for explaining
such polarization mediated interactions. Therefore, to analyze the nature of the in-
teractions of the core inhibitor scaffold with the gatekeeper aromatic residues, we
calculated post-Hartree-Fock ab initio interaction energies using the Møller–Plesset
perturbation theory (MP) to second order (MP2). Then, we evaluated how different
contributions to the interaction energy, derived from Energy Decomposition Scheme
based on Hybrid Variation-Perturbation Theory, perform in scoring the residence
times and affinities. To account for the complete protein structure in the com-
putation of the binding free energies of the haspin–ligand complexes, we used the
classical MM/GBSA approach with an implicit solvent model. We also applied a new
computational approach based on Molecular dynamics Simulations: τ -Random Ac-
celeration Molecular Dynamics (τ -RAMD)[29] for prediction of relative dissociation
rates.
4.3 Methods
4.3.1 Quantum mechanical interaction energy calculations
The energy contributions of the inhibitor-aromatic gatekeeper interaction in haspin-
inhibitor complexes were calculated using ab initio Møller–Plesset perturbation the-
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ory to second order (MP2). The Protein Preparation Wizard [104] of the Schrodinger
suite (release 2015-4, Schrödinger, LLC, New York) was used to pre-process the X-
ray crystallographic structures of the haspin-inhibitor complexes, to add missing
side chains and to optimize the H-bond network. The impref [104] program of the
Schrödinger suite was used for energy minimization using the OPLS3 [123] force field.
The default minimization protocol using impref involves optimization of the position
of hydrogen atoms followed by all-atom minimization where non-hydrogen atoms are
restrained with a harmonic potential using a force constant of 25 kcal/mol.Å2. The
coordinates of the inhibitor and the gatekeeper phenylalanine residue were extracted
from energy-minimized structures of haspin-inhibitor complexes. The termini of the
phenylalanine residue were capped with hydrogen atoms and their positions were
optimized using the OPLS3 force field in the Maestro program of the Schrödinger
suite (release 2015-4, Schrödinger, LLC, New York). In the case of the gatekeeper
mutants, the corresponding gatekeeper residues (tyrosine and threonine) were pre-
pared in the same way. The def2TZVP basis set was used for all calculations and
effective core potentials (ECPs) were used for the iodine atom. Ab initio inter-
action energies at the MP2 level were calculated using the GAMESS[76] software,
and partitioned into their constituent interaction energy terms using the many body
interaction energy decomposition scheme (EDS) described by Góra et al.[78, 77].
4.3.2 Binding free energy calculations using MM/GBSA
The molecular mechanics-generalized Born surface area (MM/GBSA) method was
used to estimate the binding free energy of the inhibitors to haspin kinase. The initial
coordinates of the haspin-inhibitor complexes were obtained from the co-crystallized
structures. The Protein Preparation wizard [104] of the Schrödinger suite (release
2015-4, Schrödinger, LLC, New York) was used for pre-processing of the structures,
formation of disulfide bonds, addition of hydrogen atoms and assigning protonation
states at pH 7.0. The pmemd module of the Amber14 software suite [79] was used
to perform the Molecular dynamics (MD) simulations together with the Amber
ff14SB [107] force field for protein. The LEap module of AmberTools14 was used to
construct the topologies of the haspin-inhibitor complexes. The ligand parameters
were generated based on the generalized Amber force field[124] (GAFF ). To improve
the description of charge, dipole moment and geometry of halogenated compounds
in molecular mechanical calculations, the positive region (σ-hole) centered on the
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halogen atom was represented by an extra-point charge (EP). This inclusion of an EP
results in improved modeling of halogen-bonding in MD simulations[125]. The force
field parameters for this EP were taken from Ibrahim et al.[125]. For generation of
the partial atomic charges for the ligands, the RESP [106] program was used to fit the
atom-centered charges to the molecular electrostatic potential (MEP) grid computed
by the GAMESS [76] program. The system was centred and aligned with the axes
to minimize the volume. The system was then solvated using the TIP3P [126] water
model by immersing the protein-ligand complex in a cubic box of water molecules,
such that the shortest distance between the edge of the solvation box and the complex
is 10 Å. The net charge (-2e) of the system was then neutralized by adding counter
ions such as Na+ and Cl- ions. For each system, energy minimization was performed
in three 1500-cycle consecutive runs using the steepest descent minimization method
followed by switching to the conjugate gradient method after 500 cycles. Gradually
decreasing harmonic restraints with force constants of 500, 1 and 0 kcal/mol.Å2 were
used for non-hydrogen atoms in three consecutive runs. Energy minimization was
followed by 1 ns of gradual heating from 10 K to 300 K with harmonic restraints
with a force constant of 50 kcal/mol.Å2 acting on non-hydrogen atoms. Then the
system was equilibrated for 1 ns under NPT conditions at 300K, with heavy atoms
(except solvent Na+ and Cl- ions) harmonically restrained with a force constant of
50 kcal/mol.Å2. This was followed by an NPT equilibration of 2 ns without any
positional restraints. The potential energy function and atomic coordinates were
calculated using a 2 fs time step. The SHAKE [62] algorithm was used to constrain
all the bonds involving hydrogen atoms. The Particle Mesh Ewald (PME)[127]
method was used to calculate the electrostatic interactions. A cut-off of 10 Å was
set for generating the non-bonded pair list and this pair list was updated after every
100 steps. After equilibration, data were collected over 6 ns of a simulation run
for binding free energy calculations and 3000 sets of atomic coordinates were saved
every 2 ps.
Then, MMGBSA calculations of the binding free energy were performed using
the MMPBSA.py module implemented in the Amber14 analysis tools. A single-
trajectory approach was used in which receptor, ligand and complex geometries
were extracted from a single MD trajectory. All the ions and water molecules were
stripped from the trajectory snapshots. A salt concentration of 0.15 M and the
Born implicit solvent model (igb=2 ) was used. Each binding free energy was com-
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puted as the sum of a molecular mechanics term (∆Egas), a Gibbs solvation term
(∆∆Gsolvation) and an entropic contribution (T∆Ssolute). For the entropic contribu-
tion to binding free energy, we computed translational and rotational entropies with
a rigid rotor model using the MMPBSA.py module. The calculation of vibrational
entropies using normal-mode analysis with MMPBSA.py failed due to the inclusion
of the EP in the force field. The free energy of binding for some of the derivatives
is positive since vibrational and conformational entropy terms are neglected.
4.3.3 τ -Random Acceleration Molecular Dynamics
(τ -RAMD) simulations
τ -RAMD is a computationally efficient procedure that involves application of Ran-
dom acceleration molecular dynamics simulations[28], to compute relative dissoci-
ation rates for ligand unbinding from the binding site of proteins[29]. To perform
τ -RAMD simulations, X-ray crystallographic structures of haspin-inhibitor com-
plexes were used as the starting structures. The Protein Preparation wizard [104]
of the Schrodinger suite (release 2015-4, Schrödinger, LLC, New York) was used to
pre-process the structures, to add missing side chains, and to optimizing the H-bond
network. The topologies of the systems were constructed using the LEap program of
the Amber14 software. The Amber ff14SB [107] force field was used for the proteins,
the General Amber Force Field[124] (GAFF ) for inhibitors, and the TIP3P [126]
model for waters. The partial atomic charges of the ligands were calculated accord-
ing to the AM1-BCC [128, 129] method using Antechamber module of Amber14. The
systems were then solvated in a cubic box of water, with water molecules extending
at least 14Å between the complex and the edge of the box. Na+ counter ions were
added to neutralize the net charge of the system. The pmemd module of Amber14
was used for carrying out energy minimization in four 1500 cycle consecutive runs
using the steepest descent minimization method followed by switching to the con-
jugate gradient method after 500 cycles. Gradually decreasing harmonic restraint
force constants of 500, 1 and 0.005 kcal/mol.Å2 were used for heavy atoms in the
first three consecutive runs and no positional restraints were used in the final min-
imization run. Each system was then heated for 40 ps from 10 K to 300 K with a
restraint with a force constant of 50 kcal/mol.Å2 acting on the heavy atoms. Then,
the systems were equilibrated in the NPT ensemble using a Langevin thermostat and
Nosé–Hoover Langevin pressure control to maintain the system at 1 atm and 300
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K. A two-stage equilibration for 400 ps (200 ps in each stage) was performed using
the pmemd module of Amber14. In the first stage, heavy atoms except Na+ and
Cl- ions were restrained with a harmonic with a force constant of 50 kcal/mol.Å2.
In the second stage, NPT equilibration with no restraints was performed for each
system. The SHAKE algorithm was used to constrain all bonds involving hydrogen
atoms and a time step of 2 fs was used. Electrostatic interactions were calculated
using the Particle Mesh Ewald (PME) method. The atomic coordinates of the equi-
librated system generated with AMBER were used as input for the production run
with the NAMD software[80]. Then, 2 ns long standard MD simulations were run
using the NAMD software with Langevin dynamics applied for constant tempera-
ture (300K ) and pressure control (1 atm). Atom pairs that were less than 14 Å
apart were included in the pair list, and non-bonded interactions were calculated
at every step for atom pairs that were within 12 Å cut-off distance. The atomic
coordinates and velocities obtained after 2 ns of this production run were used as
the starting input for the Random Acceleration Molecular Dynamics (RAMD) sim-
ulations. The RAMD simulation procedure[28] was implemented as a Tcl wrapper
around the NAMD software[80], and recently this Tcl wrapper was modified to take
the force magnitude rather than acceleration as an input parameter and to use new
functions available from version 2.10 of NAMD onward[29].
The RAMD simulations were performed in an explicit solvent with parame-
ters identical to the standard MD simulations. A randomly oriented force (F ) of
magnitude 8.0 kcal/mol.Å was applied to the centre-of-mass of the ligand and the
movement of the ligand was assessed after every 50 MD simulation steps (100 fs).
If the change in distance r moved by the ligand in this time was less than a thresh-
old distance of rmin = 0.025 Å, a new random direction of the force was generated.
Otherwise, the simulation was continued for the next 50 simulation steps with the
same direction of the force. The simulation was stopped when the distance between
the ligand and protein centre-of-mass exceeded 30 Å or if the ligand exit was not
observed within 3 ns. Coordinates were saved at 1 ps intervals. A set of 20 RAMD
dissociation trajectories was generated for each ligand by varying the initial direc-
tion of the artificial force F. The ligand egress times of the RAMD trajectories were
recorded for all the ligands employed in this method. As in the procedure described
by Kokh et al.[29], the residence time, τ , was defined as the simulation time re-
quired for ligand dissociation in 50% of the trajectories. A bootstrapping procedure
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(200 sets, each of the sets containing 80% of the trajectories chosen randomly) was
employed to compute the final residence time, τcomp, and its standard deviation.
4.4 Results and Discussions
4.4.1 The second order Møller-Plesset interaction energies
(EMP2) between the inhibitor and the gatekeeper
residue correlate well with dissociation rate constants
and equilibrium dissociation constants determined
experimentally
The second-order Møller–Plesset interaction energies (EMP2) between the 5-iTU
derivatives and the gatekeeper phenylalanine (F605) residue were calculated at con-
secutive levels of quantum mechanical theory and are outlined in Tables 4.1. The
contributions of isolated constituent energy terms to total interaction energy are
given in Table 4.2. EMP2 energies were also calculated between 5-iTU and mu-
tated gatekeeper residues (Tyrosine and Threonine) at the 605 position (F605Y and
F605T) (see Tables 4.3 and 4.4). The coordinates for these tyrosine and threonine
gatekeepers were extracted from the resolved crystallographic structures of mutant
haspin in complex with 5-iTU. We obtained a good correlation between interaction
energies calculated at the MP2 level of theory (EMP2) and the dissociation rate con-
stants (koff ) and affinities determined experimentally (see Figure 4.4 A,C). EMP2
energies correlate well with the size of halogens substituted on the inhibitors. The
Pearson correlation coefficient (R2) between calculated EMP2 energies (kcal/mol)
for 5-iTU derivatives with the gatekeeper (F605) residue and their log(koff ) values
from SPR experiments is 0.93. Similarly, calculated EMP2 energies also correlated
well with affinities (Kd) from ITC experiments with a Pearson correlation coefficient
of 0.80. The EMP2 interaction energy calculated for 5-iTU with F605 was approxi-
mately 1.5 kcal/mol higher than the EMP2 energy calculated for tubercidin (Table
4.1).
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Inhibitor log koff
(SPR)
log koff
(BLI)
log Kd
(SPR)
log Kd
(ITC)
EEL EHL ESCF EMP2
5-iTU -2.62 -3.56 -9.10 -8.24 -1.85 2.79 2.15 -3.01
5-brTU -1.92 -3.19 -8.59 -7.76 -1.09 2.22 1.78 -2.74
5-clTU -1.84 -3.04 -8.18 -7.79 -0.52 1.91 1.58 -2.24
5-fTU -0.60 -2.20 -6.81 -7.37 0.17 1.15 0.94 -1.44
tubercidin -0.18 -1.32 -5.59 -6.62 -0.09 0.65 0.47 -1.48
Table 4.1: Total interaction energy [kcal. mol−1] between tubercidin derivatives and gatekeeper
Phe 605 residue at consecutively increasing levels of quantum mechanical theory. EEL is the
electrostatic energy only, EHL includes the Heitler-London energy, ESCF includes the Hartree-
Fock energy as well, and EMP2 is the full Moeller-Plesset second order energy. koff values were
measured by SPR and BLI, and Kd values were measured by SPR and ITC.
Inhibitor log
koff
(SPR)
log
koff
(BLI)
log
Kd
(SPR)
log
Kd
(ITC)
EEL,MTP EEL,PEN EEX EDEL ECORR
5-iTU -2.62 -3.56 -9.10 -8.24 2.48 -4.33 4.63 -0.64 -5.16
5-brTU -1.92 -3.19 -8.59 -7.76 1.03 -2.12 3.30 -0.42 -4.54
5-clTU -1.84 -3.04 -8.18 -7.79 -0.21 -0.32 2.44 -0.34 -3.82
5-fTU -0.60 -2.20 -6.81 -7.37 0.13 0.04 0.97 -0.21 -2.37
tubercidin -0.18 -1.32 -5.59 -6.62 -0.07 -0.01 0.74 -0.18 -1.94
Table 4.2: Contribution of the different interaction energy terms to the total interaction energy,
EMP2 [kcal. mol−1], between tubercidin derivatives and the gatekeeper Phe 605 residue. EEL,MTP
is the electrostatic multipole term, EEL,PEN is the penetration electrostatic term, EEX is the
exchange term, EDEL is the delocalization term, and ECORR is the correlation energy term. koff
values were measured by SPR and BLI, and Kd values were measured by SPR and ITC.
Partitioning of EMP2 into its constituent energy components (see Table 4.2) us-
ing a many-body interaction energy decomposition scheme showed that the major
contribution to EMP2 comes from the correlation energy (ECORR). ECORR describes
second-order intermolecular dispersion interactions and the correlation corrections
to the Hartree–Fock energy. Similar to EMP2, ECORR increases in magnitude with
an increase in the size of the halogen. A very high correlation was observed be-
tween ECORR and the dissociation rates measured experimentally with R2 = 0.97
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(see Figure 4.4 B). This indicates the importance of the halogen interaction with
the aromatic gatekeeper for the prolongation of residence times as the halogen size
increases. The computed ab initio energies also correlate for the interaction of 5-iTU
with the F605Y mutant but the magnitude of the interaction energy of 5-iTU with
the threonine mutant (F605T) was underestimated (see Table 4.3 and Figure 4.4).
System log koff
(SPR)
log koff
(BLI)
log Kd
(SPR)
log Kd
(ITC)
EEL EHL ESCF EMP2
Wild type -2.62 -3.56 -9.10 -8.24 -1.85 2.79 2.15 -3.01
F605Y ND -3.37 ND -8.34 -2.27 3.01 2.30 -3.13
F605T -1.72 -2.91 -7.89 -8.38 -0.78 1.38 0.99 -1.14
Table 4.3: Total interaction energy [kcal. mol−1] between 5-iTU and the gatekeeper residue for
the wild type and the two mutants, at consecutively increasing levels of quantum mechanical theory.
EEL is the electrostatic energy only, EHL includes the Heitler-London energy, ESCF includes the
Hartree-Fock energy as well, and EMP2 is the full Moeller-Plesset second order energy. koff values
were measured by SPR and BLI, and Kd values were measured by SPR and ITC.
System log
koff
(SPR)
log
koff
(BLI)
log
Kd
(SPR)
log
Kd
(ITC)
EEL,MTP EEL,PEN EEX EDEL ECORR
Wild type -2.62 -3.56 -9.10 -8.24 2.48 -4.33 4.63 -0.64 -5.16
F605Y ND -3.37 ND -8.34 0.41 -2.68 5.28 -0.71 -5.43
F605T -1.72 -2.91 -7.89 -8.38 -6.97 6.19 2.17 -0.39 -2.13
Table 4.4: Contribution of the different interaction energy terms to the total interaction energy,
EMP2 [kcal.mol−1] between 5-iTU and the gatekeeper residue for the wild type and the two mutants.
EEL,MTP is the electrostatic multipole term, EEL,PEN is the penetration electrostatic term, EEX
is the exchange term, EDEL is the delocalization term, and ECORR is the correlation energy term.
koff values were measured by SPR and BLI, and Kd values were measured by SPR and ITC.
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Figure 4.4: Correlation plots of computed quantum mechanical energies against experimental
binding parameters. A) Second-order Møller-Plesset interaction energy (EMP2) between the tu-
bercidin derivatives and the gatekeeper residue versus the experimental (SPR) dissociation rate
con-stants (koff ) of the tubercidin derivatives. B) The second-order correlation correction energy
term (ECORR) for the interaction between the tubercidin derivatives and the gatekeeper residue
versus the experimental (SPR) dissociation rate constants (koff ) of the tubercidin derivatives This
correlation energy (ECORR) includes second-order intermolecular dispersion interactions and the
correlation corrections to the Hartree-Fock (HF) energy. C) Second-order Møller-Plesset interac-
tion energy (EMP2) between tubercidin derivatives and gatekeeper residue ver-sus the experimental
(ITC) binding affinities (Kd) of the tubercidin derivatives. D) Second-order correlation correction
energy term (ECORR) for the interaction between the tubercidin derivatives and the gatekeeper
residue versus the experimental (ITC) binding affinities (Kd) of the tubercidin derivatives. The
correlation coefficients (R2) and the linear fits were computed omitting the outlier data points for
the F605T mutant. The error bars for the Kd (ITC) values are smaller than the size of the data
point symbols.
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4.4.2 Binding free energies calculated from MM/GBSA
approach correlate with experimental parameters for
the halogen-gatekeeper interaction.
In order to account for the complete protein structure, we computed the binding free
energies of the haspin–inhibitor complexes using the classical MM/GBSA approach
with an implicit solvent model (see Table 4.5). Each binding free energy was com-
puted as the sum of a molecular mechanics term (∆Egas), a Gibbs solvation term
(∆∆Gsolvation) and an entropic contribution (T∆Ssolute). Some ∆GMMGBSA values
are positive as they only include translational and rotational entropic terms and do
not include vibrational and conformational entropy contributions.
The binding free energies computed correlate well with the calorimetric data
measured by ITC, with the Pearson correlation coefficient, R2 = 0.83 between
enthalpic energies computed by MM/GBSA (∆Egas + ∆∆Gsolvation) and ITC en-
thalpies (∆HITC). Also, a good correlation (R2 = 0.62) was observed between the
binding free energies computed from MM/GBSA (∆GMMGBSA) and the ITC binding
free energies (∆GITC) of the interactions between haspin and halogenated deriva-
tives of 5-iTU. Therefore, the binding free energies computed from MM/GBSA, are
consistent with the increasingly favorable enthalpic contribution to binding as the
halogen size increases (see Figure 4.5 and Table 4.5).
Figure 4.5: Correlation of calculated binding free energies with experimental parameters for
the halogen-gatekeeper interaction. A) MMGBSA internal and solvation contributions (∆Egas
+ ∆∆Gsolvation) vs the ITC enthalpies (∆HITC) and (B) MMGBSA binding free energies
(∆GMMGBSA) vs the ITC binding free energies (∆GITC) of the interactions between haspin and
TU derivatives.
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Inhibitor
∆Egas + ∆∆Gsolvation
(kcal.mol−1)
T∆SMMGBSA
(kcal.mol−1)
∆GMMGBSA
(kcal.mol−1)
5-iTU -25.95 ± 2.93 -23.52 ± 0.02 -2.43 ± 2.95
5-brTU -26.00 ± 2.75 -23.27 ± 0.02 -2.73 ± 2.77
5-clTU -21.58 ± 3.33 -22.97 ± 0.02 1.39 ± 3.35
5-fTU -20.31 ± 3.04 -22.83 ± 0.01 2.52 ± 3.05
tubercidin -19.45 ± 2.87 -22.65 ± 0.02 3.20 ± 2.89
Table 4.5: Binding free energies calculated using the MMGBSA approach for the binding of
tubercidin derivatives with haspin.
4.4.3 Relative residence times from τ -RAMD simulations
correlate with the experimentally measured residence
times
The ligand egress times of 5-iTU derivatives from the haspin’s binding site were
recorded for the set of 20 dissociation trajectories simulated for each inhibitor using
τ -RAMD protocol. The RAMD residence time (τcomp) and its standard deviation
was computed for each of the 5-iTU derivative using a bootstrapping procedure
where bootstrapping was performed for a total 200 sets, and in each of the sets 80%
of the trajectories were chosen randomly (see Table 4.6).
Inhibitor
Experimental
residence time (SPR)
τexp (s)
Experimental
residence time (BLI)
τexp (s)
Computed
residence time
τcomp (s)
5-iTU 416.67 3623.19 1.62 ± 0.37
5-brTU 84.03 1557.63 1.29 ± 0.45
5-clTU 68.97 1084.60 0.89 ± 0.17
5-fTU 4.01 158.23 0.95 ± 0.15
tubercidin 1.52 21.10 0.64 ± 0.18
Table 4.6: Experimental residence times (τexp) and the computed residence times from τ -RAMD
(τcomp) for tubercidin derivatives.
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Figure 4.6: Correlation plot of experimental residence times (τexp) from (A) SPR experimental
assay and (B) BLI measurements versus the computed residence time (τcomp) from the τRAMD
procedure as described in Kokh et al.[29]. The solid line in both plots corresponds to a linear fit
with R2 values labelled on the plot.
A good correlation was observed between the computed RAMD residence time
(τcomp) and experimental residence times (τexp) of halogenated inhibitors of haspin
from SPR and BLI assay (see Figure 4.6 A and B). The computed residence times
(τcomp) correlated better with τexp values from BLI experiments with Pearson correla-
tion coefficient, R2 of 0.86 compared to R2 of 0.76 for τexp from SPR assay. However,
difference in residence time between 5-clTU and 5-fTU is not distinguished; suggest-
ing some effects of halogens may not be captured by the classical MM force field.
In this chapter, the biophysical and structural data presented from Heroven
et al.[118] on 5-halogen-substituted tubercidin derivatives along with our computa-
tional results using quantum chemical interaction energy calculations and MM/GBSA
binding free energy calculations, suggest that it could be a viable strategy to in-
crease the residence times of inhibitors by mediating their interactions with aro-
matic residues of proteins by incorporating heavier halogen atoms into inhibitors.
Our results provide a good basis for further research on this topic and it would be
interesting to explore the role of presence of halogen atoms to longer residence times
of drug candidates especially because many approved drugs have halogen atoms[130]
and the aromatic residues are also found frequently in the binding site of proteins,
especially kinases.
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Chapter 5
Protocol for calculation of diffusional
association rates for small molecules
using Brownian dynamics
5.1 Overview
The Brownian dynamics (BD) simulation technique is used to simulate the diffu-
sive dynamics of particles, such as proteins, that undergo Brownian motion. It
involves use of an implicit solvent model and the stochastic and friction effects
of the surrounding solvent are introduced in a separate term in the equation of
motion. BD is used to simulate protein-protein association or diffusion of mul-
tiple proteins to investigate biomolecular diffusion, binding kinetics, and the ef-
fects of macromolecular crowding. The procedure for simulating diffusional asso-
ciation of protein molecules with Brownian dynamics simulations using the SDA
software[54, 53, 131] is well established and numerous applications have been re-
ported in the past where SDA was used to compute diffusional association rate
constants (kon) for protein-protein association and the computed rates correlated
well with the experiments[131, 53, 7, 132, 6, 5, 133, 134]. However, this procedure to
compute diffusional kon rates using SDA has not been well optimized for computation
of association kinetics for binding of protein and small molecules. Considering the
increasing interest in simulating association of drug-like molecules with their target
proteins to compute kinetic parameters for binding, we decided to optimize the simu-
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lation parameters in SDA and implement a generalized protocol using SDA software
that allows calculation of diffusional kon rates for small molecules by running BD
simulations of diffusional association of protein and small molecules. We also imple-
mented new algorithms for assigning effective charge sites for small molecules and
for the systematic definition of reaction criteria as python scripts. These algorithms
differ from the algorithms already implemented for protein-protein association. The
implemented protocol was validated for several inhibitors of 4 different targets of
varying levels of structural complexity (see the following sections). While for some
of these protein-ligand systems, binding is mainly electrostatically driven, for others
short-range hydrophobic interactions play a key role in the binding as the inhibitors
are hydrophobic in nature.
5.1.1 Trypsin
Figure 5.1: 3D crystal structure of trypsin in complex with benzamidine (PDB ID: 3PTB[135]).
Trypsin is shown in ribbon representation with helices, β-sheets and loops shown in red, yellow
and green, respectively, and the bound benzamidine is shown in magenta stick representation.
Trypsin is a pancreatic serine protease and it hydrolyses proteins by cleaving peptides
on the C-terminal side of the amino acid residues, lysine and arginine. Trypsin is
characterized by the catalytic triad His57, Asp102 and Ser195. Trypsin is a globular
protein composed of 220 residues. The protein is composed of 13 beta-strands, 4
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regions of alpha-helix, and six disulfide bridges. The Ca2+-binding loop extends from
Glu70 to Glu80. Due to its relatively small size (25 kDa) and monomeric structure,
the trypsin–benzamidine complex has proven to be a popular model system for
developing and testing methods for computing protein–ligand binding kinetics.
5.1.2 Human Coagulation Factor Xa
Figure 5.2: 3D crystal structure of the Human Coagulation Factor X activated (FXa) with
rivaroxaban bound (PDB ID: 2W26[136]). FXa is shown in ribbon representation with helices, β-
sheets and loops shown in red, yellow and green, respectively, and rivaroxaban is shown in magenta
stick representation. The inset on the right shows the active site of FXa with rivaroxaban bound
and the four subpockets: S1, S2, S3 and S4 are labelled. The 2D structures of the FXa inhibitors
studied, rivaroxaban and apixaban, are also shown.
Coagulation Factor X activated (FXa) is a trypsin-like serine endo-peptidase and
an important enzyme (EC 3.4.21.6) of the blood coagulation cascade. It is formed
by the proteolysis of Factor X (FX). It is composed of two disulfide-linked subunits
that catalyze prothrombin to form thrombin (Factor IIa). Thrombin is also a serine
protease and it processes fibrinogen to form fibrin (Factor Ia). Fibrin, as the name
suggests, is a fibrous, non-globular protein which polymerizes with platelets and re-
sults in the formation of a blood clot. Because of its important role in the blood
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coagulation cascade, FXa is an important target for the treatment for thromboem-
bolic disorders and a number of selective, direct and indirect fXa inhibitors have been
approved for clinical use such as rivaroxaban[137], apixaban[138], betrixaban[139],
edoxaban[140] and fondaparinux[141]. Optimizing the kon of FXa inhibitors may be
important for the in vivo activities as kon for targeting free FXa has been identified
to influence the clinical coagulation behavior[142].
The active site of FXa can be subdivided into four sub-pockets: S1, S2, S3 and
S4[143](see Figure 5.2). Direct FXa inhibitors such as rivaroxaban and apixaban
bind in an L-shaped conformation where one part of the inhibitor occupies the
anionic S1 pocket and another part occupies the S4 pocket[136](see Figure 5.2, inset).
The S1 sub-pocket is surrounded by residues His57, Asp189, Ser195 and Tyr228, and
determines the major component of selectivity[137]. On the other hand, the S4 sub-
pocket consists of a narrow hydrophobic channel formed by aromatic residues, such
as Tyr99, Phe174 and Trp215. The first generation FXa inhibitors make direct
electrostatic interaction of a basic arginine-mimic P1 group with Asp189 at the
bottom of the S1 pocket[144, 145]. However, these basic groups are also generally
critical for oral bioavailability. A new class of oral fXa inhibitors has been developed
that does not require the presence of a basic P1 group and instead makes favourable
non-basic interactions with residues in the S1 sub-pocket. Rivaroxaban is one such
example which has a chlorothiophene moiety and its chlorine atom interacts with the
aromatic ring of Tyr228 at the bottom of the S1 pocket[145]. This chlorine–Tyr228
interaction accounts for high potency and oral bioavailability for the rivaroxaban.
5.1.3 Haspin kinase
Haspin, or germ cell-specific gene 2 protein (GSG2), is an atypical serine/threonine
kinase known for its role in cell cycle regulation[146, 147]. Haspin phosphorylates
Thr3 on histone H3 during prometaphase, which provides a signal for Aurora B
kinase to localize to the centromere of mitotic chromosomes[148]. Aurora B is part
of the chromosome passenger complex (CPC) and regulates several steps in mitotic
progression. The overall structure of the Haspin kinase corresponds to the conserved
eukaryotic protein kinase fold, which consists of two subunits: an amino-terminal
lobe (“N lobe”) and a larger carboxy-terminal lobe (“C lobe”)[149, 150]. The "N
lobe" is composed of an α-helix (helix αC) and a five-stranded β-sheet, while the
C lobe is predominantly helical[149, 150]. Both of these lobes are connected by a
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“hinge region” and the ATP binding pocket resides deeply between these lobes.
Figure 5.3: 3D crystal structure of the Haspin kinase in complex with 5-iodotubercidin (PDB
ID: 6G34[118]). Haspin is shown in ribbon representation with helices, β-sheets and loops shown
in red, yellow and green color respectively, and the 5-iodotubercidin (5-iTU) is shown in magenta
stick representation. 2D structures of haspin inhibitors studied, 5-iTU, 5-brTU, 5-clTU, 5-fTU and
tubercidin are also shown.
5.1.4 Neuraminidase
Neuraminidases are key targets for drug development against influenza because
of their significant role in the release of the virus from an infected cell. Neu-
raminidase is a homotetramer with circular symmetry and is composed of four iden-
tical subunits[151]. The four active sites (one in each subunit) are located in a deep
depression on the upper surface. The binding of its natural substrate, sialic acid, to
the active site results in the clipping of the glycosidic linkage between sialic acid re-
ceptor and sialic acid[152]. The structure of the active site depends upon a proximal
four-fold coordinated Ca2+ ion and the flexibility of the 150-loop consisting of amino
acid residues 148-151[151]. Several subtypes of Neuraminidase (N1, N4, N5, N8) are
known to have an open 150-loop structure in the unbound form, that closes upon
drug binding. The existence of Neuraminidase in an open 150-loop conformation
leads to the presence of an additional cavity also known as the 150-cavity, which is
absent in the bound closed form. Other Neuraminidase subtypes (N2, N3, N6, N7,
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N9) have been shown to exist in a closed conformation in both bound and unbound
forms, without a 150-cavity[153].
Figure 5.4: Tetrameric crystal structure of the N1 Neuraminidase (NA) complexed with os-
eltamivir (PDB ID: 2HU4[153]). NA is shown in ribbon representation with different monomeric
units shown with different colors and oseltamivir (orange stick representation) bound to each
monomer. The 150-loop is shown in red color. The 2D structures of NA inhibitors studied, os-
eltamivir and zanamivir, are also shown.
Currently, oseltamivir and zanamivir are the two FDA-approved drugs used to
battle influenza. They are transition-state analogues of the natural substrate, sialic
acid, and therefore, bind more tightly to the active site than the substrate. Both
oseltamivir and zanamivir are zwitterionic in nature and they comprise a central
ring structure with a carboxyl and an amino moiety.
5.2 Methods
5.2.1 Preparation of protein and ligand structures
The 3D coordinates of all the protein and ligand molecules studied were extracted
from the co-crystallized protein-ligand complexes available in the PDB database.
Table 5.1 lists the PDB IDs used for extracting the coordinates of the different
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protein-ligand systems studied. N1 Neuraminidase (NA) has a tetrameric structure
and each monomeric unit has a Ca2+ ion situated close to the active site and it is
tetrahedrally coordinated by backbone as well as side chain atoms. This Ca2+ ion
seemed to be important for structural stability around the active site of NA. Since
the coordinates for Ca2+ ions were missing in the PDB structures of the NA-inhibitor
complexes used in our study, they were taken from a high-resolution structure of NA
in complex with oseltamivir (PDB ID: 3TI6[154]) and modelled into all NA-inhibitor
crystal structures. The Protein preparation wizard [104] of the Schrödinger suite
(release 2015-4, Schrödinger, LLC, New York) was used for pre-processing of the
protein structures e.g. to add disulfide linkages and missing atom names, remove
crystallographic waters and for capping polypeptide chain termini. Any missing
residues or empty loops in the protein were modelled using the Prime program[155]
of Schrödinger. Then, the protein and ligand structures were protonated at pH
7.0 according to residue pKa values calculated by PROPKA[105]. The hydrogen-
bonding network of the protein-ligand complexes was optimized with the Schrödinger
suite to avoid any steric clashes and ensure favorable atom orientations. Then the
complexes were energy-minimized with a default energy minimization procedure
using the Impref [104] program of Schrödinger and OPLS3 force field. The Impref
minimization involves a two-step relaxation in which first the rotatable hydrogen
atoms are minimized with all the torsional potentials removed, and then an all-
atom minimization is performed that is terminated either when the system is fully
converged or when it reaches a heavy-atom RMSD from the initial structure of 0.30
Å. The coordinates of the protein and ligand molecules were then extracted from
the minimized complexes into separate PDB files.
Protein Ligand PDB ID
Resolution
(Å)
Trypsin benzamidine 3PTB 1.70
Coagulation Factor Xa rivaroxaban 2W26 2.08
Coagulation Factor Xa apixaban 2P16 2.30
Haspin kinase 5-iTU 6G34 1.76
Haspin kinase 5-brTU 6G35 1.55
Haspin kinase 5-clTU 6G36 1.46
Haspin kinase 5-fTU 6G37 1.48
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Protein Ligand PDB ID
Resolution
(Å)
Haspin kinase 5-hTU 6G38 1.47
Neuraminidase oseltamivir 2HTY (Neuraminidase) 2.50
2HU4 (oseltamivir) 2.50
Neuraminidase zanamivir 2HTY (Neuraminidase), 2.50
2HTQ (zanamivir) 2.20
Table 5.1: List of PDB structures of different protein-ligand complexes used for computation of
diffusional association rates using SDA.
5.2.2 Preparation of PQR files
The PDB2PQR web server[156] (http://nbcr-222.ucsd.edu/pdb2pqr_2.1.1/) was
used to generate PQR files for protein structures for being used later in contin-
uum electrostatics calculations. PQR files are PDB files where the occupancy and
B-factor columns have been replaced by per-atom charge and radius. The AM-
BER force field was used to generate PQR files with the PDB2PQR server and the
protonation states determined from PROPKA in the previous step were retained.
The PDB2PQR webserver allows the setup, execution, and analysis of Poisson-
Boltzmann electrostatics calculations. However PDB2PQR cannot perform calcula-
tions for bound ligand molecules and Ca2+ ions. Therefore, AmberTools[79] was used
to generate PQR file for ligands. Partial atomic charges for ligand molecules were
generated using the RESP [106] program of AmberTools by fitting atom-centered
charges to the electrostatic potential computed by the GAMESS [76] program with
6-31+G basis sets. The force field parameters for ligand molecules (inpcrd-and
prmtop-files) were prepared with LEaP program of AmberTools with the GAFF[124]
force field, and these parameters were then used by ambpdb program of AmberTools
to generate PQR files. Coordinates, charges (+2e) and radii (1.713 Å) for Ca2+ ions
were manually added into PQR files of corresponding proteins.
5.2.3 Grids preparation
To calculate interaction forces acting between protein and ligand molecules during
the BD simulations of diffusional association, charges and radii from PQR files were
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used to generate grids of the electrostatic potential. Electrostatic potentials were
calculated by solving the linearized Poisson-Boltzmann equation using the APBS [57]
software. APBS calculates the electrostatic potential of the solute with respect to
its environment for every grid point of a 3D system. In addition to the PQR file,
APBS requires an input file with information on grid dimensions and grid spac-
ing. The grid sizes for different systems were chosen so as to ensure electrostatic
potentials with isovalues of ± 0.01 kcal/mol/e fit into the boxes. A grid size of
129x129x129 points was used for Trypsin, Coagulation Factor Xa and Haspin ki-
nase whereas a larger grid size of 161x161x161 points was used for Neuraminidase
due to its relatively bigger size. For all the ligands, a grid size of 65x65x65 points
was used. A grid spacing of 1.0 Å was consistently used for all protein and ligand
molecules. The temperature and ionic strength used for the grid calculations were
specific to the system studied, depending upon the experimental conditions in which
rates were measured (see Table 5.2). The solvent dielectric constant, protein dielec-
tric constant, and the ionic radius were set to 78, 2, and 1.5 Å, respectively. “Single
Debye-Hückel” boundary condition (bcfl sdh) was used where the potential at the
boundary is set to the values prescribed by a Debye-Hückel model for a single sphere
with a point charge, dipole, and quadrupole. For mapping the point charges to the
grid for a Poisson-Boltzmann calculation, traditional trilinear interpolation (chgm
spl0 ) was used where each charge is mapped onto the nearest-neighbor grid points.
The dielectric and ion-accessibility coefficients (srfm parameter) were defined using
the smol flag where the dielectric coefficient is defined based on a molecular sur-
face definition, and the ion-accessibility coefficient is defined by an inflated van der
Waals model. The electrostatic potential grids calculated by APBS are in units of
kT/e and cannot be directly used with SDA. Therefore, they were rescaled and con-
verted into UHBD format (kcal/mol.e) using the convert_grid program of the SDA
package. To take the desolvation forces into account, electrostatic and hydropho-
bic desolvation grids for the protein and ligand molecules were calculated using the
make-edhdlj-grid tool of SDA. A grid size of 110x110x110 points with a 1.0 Å spac-
ing was used and ionic strength, solvent dielectric constant and ion radius were set
to 0 mM, 78 and 1.5 Å, respectively. The value of empirical scaling parameter, α,
for electrostatic desolvation grids was set to 0.36 in the SDA input file. The pa-
rameterisation is based on the work by Gabdoulline and Wade[55] to reproduce the
Poisson-Boltzmann interaction energy of plastacyanin and cytochrome f. When α is
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set to 0.36, electrostatic desolvation potential is calculated assuming that no salt is
present. Therefore, ionic strength was set to 0 in the input file used for calculation
of electrostatic desolvation grids.
Figure 5.5: Electrostatic Potential Grids of A) Trypsin, B) Human Coagulation Factor Xa, C)
Haspin and D) Neuraminidase. For each system studied, electrostatic potential from the front and
the back are shown. Isosurfaces shown in the figure correspond to the isovalue of ± 0.01 kcal/mol/e
units. The grid sizes chosen for different systems are given in Table 5.2.
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Protein-ligand
system simulated
Ionic
Strength
mM
Temperature
◦C
Electrostatics
grid size
for protein
(Å3)
Reference for
experimental
conditions
Trypsin-benzamidine 100 25 129×129×129 [157]
FXa-rivaroxaban 150 37 129×129×129 [158]
FXa-apixaban 150 37 129×129×129 [158]
Haspin-5-iTU 150 25 129×129×129 [118]
Haspin-5-brTU 150 25 129×129×129 [118]
Haspin-5-clTU 150 25 129×129×129 [118]
Haspin-5-fTU 150 25 129×129×129 [118]
Haspin-5-hTU 150 25 129×129×129 [118]
Neuraminidase-
oseltamivir 100 25 161×161×161 [159]
Neuraminidase-
zanamivir 100 25 161×161×161 [159]
Table 5.2: Different experimental conditions (Ionic strength and Temperature) used for prepara-
tion of electrostatic grids for different protein-ligand complexes simulated with SDA for computa-
tion of diffusional association rates.
5.2.4 Effective charges for protein and ligands
Effective Charges for Macromolecules in solvent (ECM) are fitted charges in a uni-
form dielectric that can reproduce the electrostatic potential of the molecule com-
puted with the use of all partial atomic charges in a heterogeneous dielectric. The
accurate evaluation of electrostatic forces and interaction free energies for protein-
ligand association is computationally very demanding for realistic systems with thou-
sands of atomic charges in an environment with a non-uniform dielectric permittiv-
ity and a solvent of non-zero ionic strength. Therefore, a small number of effective
charges are calculated for each molecule that reproduce the intermolecular elec-
trostatic interactions with high accuracy in a uniform dielectric[160]. Determining
the effective charge sites is relatively simple for proteins where the test charges are
placed on the carboxylate oxygens of Asp, Glu, and the C-terminus, and the amine
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nitrogens of Lys, Arg, and the N-terminus. However, this approach does not work
for chemical compounds, cofactors etc. Therefore, a python script was written to
pick effective charge sites for small molecules and assign appropriate test charges to
them (see Figure 5.6 for the protocol).
Figure 5.6: Algorithm to assign test charges for computing effective charges for small molecules.
The script reads in the PQR file and determines the net charge on the molecule.
Then, the N, O, S, F, Cl, Br, I , P and Fe atoms present in drug like compounds and
organic cofactors are marked as effective charge sites. The partial atomic charges
of hydrogen atoms covalently bonded to these effective charge sites are added to
the respective partial charges of the effective charge site atoms. Then, the charge
difference between the net charge of the molecule and the cumulative sum of the
partial charges of the effective charge sites is calculated. This charge difference is
then redistributed equally to all the effective charge sites, so that the total test charge
on all effective charge sites is equal to the net charge of molecule. These updated test
charges are then written to an output file in a .tcha format, which is similar to pdb
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format with occupancy column replaced by the test charge of atoms. This output
.tcha file is then used by the ecm_expand tool of SDA to generate ECM charges. The
molecular structures of inhibitors of Human Coagulation Factor Xa, Haspin kinase
and N1 Neuraminidase are given in Figures 5.8, 5.9 and 5.10, respectively. Tables
5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10, 5.11 and 5.12 list the test charges and effective
charges assigned to the polar atoms of benzamidine, rivaroxaban, apixaban, 5-iTU,
5-brTU, 5-clTU, 5-fTU, 5-hTU, oseltamivir and zanamivir, respectively.
Figure 5.7: Atomic structure of benzamidine. Benzamidine has a net charge of +1e. Test and
effective charges for benzamidine are given in Table 5.3.
Figure 5.8: Atomic structures of A) rivaroxaban and B) apixaban. Both rivaroxaban and apix-
aban are neutral. Test and effective charges for rivaroxaban and apixaban are given in tables 5.4
and 5.5, respectively.
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Atom Name Test charge (e) Effective charge (e)
N1 0.50 0.524
N2 0.50 0.534
Net effective charge (e) 1.058
Electric dipole moment (Debye) 0.02 D 0.05 D (4.84 D)
Solvent accessible surface area (Å2) 311.15
Table 5.3: Test charges and effective charges assigned to polar atoms of benzamidine. The table
also lists the solvent accessible surface area of the molecule, and the electric dipole moment of the
molecule calculated after assignment of test charges and effective charges. The net electric dipole
moment of the molecule calculated using RESP atomic charges is given in parenthesis.
Atom Name Test charge (e) Effective charge (e)
CL 0.242 0.128
N2 0.217 0.865
O5 -0.130 -0.118
O13 -0.297 -0.606
N14 0.197 0.281
O17 -0.091 -0.196
O19 -0.279 -0.455
N21 0.033 0.901
S23 0.346 -0.401
O28 -0.239 -0.377
Net effective charge (e) 0.021
Electric dipole moment (Debye) 22.21 D 8.74 D (4.11 D)
Solvent accessible surface area (Å2) 997.46
Table 5.4: Test charges and effective charges assigned to polar atoms of rivaroxaban. The positions
of these atoms corresponding to effective charge sites can be visualized on the atomic structure
of rivaroxaban shown in Figure 5.8 A. The table also lists the solvent accessible surface area of
the molecule, and the electric dipole moment of the molecule calculated after assignment of test
charges and effective charges. The net electric dipole moment of the molecule calculated using
RESP atomic charges is given in parenthesis.
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Atom Name Test charge (e) Effective charge (e)
N1 0.494 0.445
O1 -0.329 -0.611
N2 0.209 0.827
O2 -0.291 -0.735
N3 0.186 0.414
O3 -0.245 -0.966
O4 -0.072 -0.009
N5 0.189 0.785
N6 -0.143 -0.143
Net effective charge (e) 0.006
Electric dipole moment (Debye) 5.41 D 9.98 D (7.19 D)
Solvent accessible surface area (Å2) 1171.93
Table 5.5: Test charges and effective charges assigned to polar atoms of apixaban. The positions
of these atoms corresponding to effective charge sites can be visualized on the atomic structure
of apixaban shown in Figure 5.8 B. The table also lists the solvent accessible surface area of the
molecule, and the electric dipole moment of the molecule calculated after assignment of test charges
and effective charges.
Figure 5.9: Atomic structures of A) 5-iTU, B) 5-brTU, C) 5-clTU, D) 5-fTU, and E) 5-hTU. All
5-iTU derivatives are neutral. Test and effective charges for 5-iTU derivatives are given in tables
5.6, 5.7, 5.8, 5.9 and 5.10, respectively.
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Atom Name Test charge (e) Effective charge (e)
N -0.450 -0.171
O 0.092 0.481
N1 -0.399 -0.715
O1 0.041 0.008
N2 0.267 -0.059
O2 0.099 0.163
N3 0.164 0.608
O3 -0.100 0.131
I 0.285 -0.474
Net effective charge (e) 0.028
Electric dipole moment (Debye) 13.77 D 14.61 D (7.54 D)
Solvent accessible surface area (Å2) 679.64
Table 5.6: Test charges and effective charges assigned to polar atoms of 5-iTU. The positions of
these atoms corresponding to effective charge sites can be visualized on the atomic structure of 5-
iTU shown in Figure 5.9 A. The table also lists the solvent accessible surface area of the molecule,
and the electric dipole moment of the molecule calculated after assignment of test charges and
effective charges.
Atom Name Test charge (e) Effective charge (e)
N 0.254 0.060
O -0.095 -0.237
N1 0.177 0.306
O1 0.105 -0.211
N2 -0.446 -0.040
O2 0.051 0.330
N3 -0.402 -0.451
O3 0.102 0.518
Br 0.254 -0.291
Net effective charge (e) -0.016
Electric dipole moment (Debye) 13.30 D 12.48 D (7.83 D)
Solvent accessible surface area (Å2) 674.31
Table 5.7: Test charges and effective charges assigned to polar atoms of 5-brTU. The positions
of these atoms corresponding to effective charge sites can be visualized on the atomic structure of
5-brTU shown in Figure 5.9 B. The net electric dipole moment of the molecule calculated using
RESP atomic charges is given in parenthesis.
108
Atom Name Test charge (e) Effective charge (e)
N -0.449 0.305
O 0.103 0.442
N1 -0.397 -0.859
O1 0.056 0.145
N2 0.251 -0.345
O2 0.111 0.091
N3 0.187 0.236
O3 -0.088 0.207
Cl 0.225 -0.250
Net effective charge (e) -0.027
Electric dipole moment (Debye) 13.19 D 15.14 D (7.77 D)
Solvent accessible surface area (Å2) 669.62
Table 5.8: Test charges and effective charges assigned to polar atoms of 5-clTU. The positions of
these atoms corresponding to effective charge sites can be visualized on the atomic structure of 5-
clTU shown in Figure 5.9 C. The table also lists the solvent accessible surface area of the molecule,
and the electric dipole moment of the molecule calculated after assignment of test charges and
effective charges. The net electric dipole moment of the molecule calculated using RESP atomic
charges is given in parenthesis.
Atom Name Test charge (e) Effective charge (e)
N 0.238 -0.257
O -0.078 0.185
N1 0.206 0.309
O1 0.105 0.042
N2 -0.428 0.226
O2 0.077 0.180
N3 -0.386 -0.825
O3 0.111 0.433
F 0.158 -0.316
Net effective charge (e) -0.024
Electric dipole moment (Debye) 12.14 D 14.86 D (7.57 D)
Solvent accessible surface area (Å2) 658.29
Table 5.9: Test charges and effective charges assigned to polar atoms of 5-fTU. The positions of
these atoms corresponding to effective charge sites can be visualized on the atomic structure of
5-fTU shown in Figure 5.9 D.
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Atom Name Test charge (e) Effective charge (e)
O3 0.173 0.305
O -0.032 0.655
O1 0.180 0.579
O2 0.076 -0.432
N 0.327 -0.658
N3 -0.478 -0.980
N2 -0.503 0.268
N1 0.257 0.239
Net effective charge (e) -0.024
Electric dipole moment (Debye) 15.58 D 12.01 D (7.12 D)
Solvent accessible surface area (Å2) 631.48
Table 5.10: Test charges and effective charges assigned to polar atoms of 5-hTU. The positions of
these atoms corresponding to effective charge sites can be visualized on the atomic structure of 5-
hTU shown in Figure 5.9 E. The table also lists the solvent accessible surface area of the molecule,
and the electric dipole moment of the molecule calculated after assignment of test charges and
effective charges. The net electric dipole moment of the molecule calculated using RESP atomic
charges is given in parenthesis.
Figure 5.10: Atomic structures of A) oseltamivir and B) zanamivir. Both oseltamivir and
zanamivir are neutral and zwitter-ionic. Test and effective charges for oseltamivir and zanamivir
are given in tables 5.11 and 5.12, respectively.
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Atom Name Test charge (e) Effective charge (e)
O1A -0.408 -0.880
O1B -0.425 -0.571
N4 0.858 1.331
N5 0.180 0.844
O7 0.041 0.378
O10 -0.246 -1.086
Net effective charge (e) 0.017
Electric dipole moment (Debye) 20.73 D 24.50 D (22.24 D)
Solvent accessible surface area (Å2) 675.42
Table 5.11: Test charges and effective charges assigned to polar atoms of oseltamivir. The
positions of these atoms corresponding to effective charge sites can be visualized on the atomic
structure of oseltamivir shown in Figure 5.10 A. The table also lists the solvent accessible surface
area of the molecule, and the electric dipole moment of the molecule calculated after assignment
of test charges and effective charges. The net electric dipole moment of the molecule calculated
using RESP atomic charges is given in parenthesis.
Atom Name Test charge (e) Effective charge (e)
NE 0.272 0.492
NH1 0.304 0.498
NH2 0.285 0.270
O1A -0.464 -0.593
O1B -0.477 -0.674
N5 0.207 0.303
O6 0.100 0.197
O7 0.078 -0.188
O8 0.005 0.427
O9 0.037 -0.136
O10 -0.348 -0.572
Net effective charge (e) 0.024
Electric dipole moment (Debye) 25.82 D 21.11 D (25.20 D)
Solvent accessible surface area (Å2) 741.86
Table 5.12: Test charges and effective charges assigned to polar atoms of zanamivir. The positions
of these atoms corresponding to effective charge sites can be visualized on the atomic structure of
zanamivir shown in Figure 5.10 B.
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5.2.5 Calculation of diffusion coefficients
During BD simulations using SDA software, diffusional motion of a mobile solute
is modelled according to the translational and rotational Ermak-McCammon equa-
tions. Since one of the solutes (the protein) is kept fixed, SDA uses a relative trans-
lational diffusion constant D to account for diffusion of both protein and ligand. D
is calculated as the sum of the translational diffusion constant of the protein (Dprot)
and the translational diffusion constant of the ligand (Dlig). In our BD simulations,
translational and rotational diffusion coefficients for the protein and the ligand were
calculated using the HYDROPRO[82] software. A partial specific volume of 0.73
cm2mol−1, solvent density of 1.0 g/cm3, and solvent viscosity of 0.0091 poises was
used in the HYDROPRO input. The calculation mode (INDMODE parameter)
was set to 1 which corresponds to the atomic-level primary model and shell-based
methodology with up to 2000 minibeads. For proteins, the hydrodynamic radius
(AER) was set to 2.9 Å which is the recommended value to be used for proteins
when INDMODE is set to 1. The lowest (SIGMIN ) and the highest (SIGMAX )
value for sigma, the minibead radius, was set to 1.0 Å and 2.0 Å, respectively. The
NSIG parameter was set to 6 which corresponds to the number of values of the radius
of the minibead. However, for ligands, a smaller value of the hydrodynamic radius
(AER = 1.2 Å) was used. This value was optimized by Dr. Ariane Nunes-Alves,
based on control calculations on several small chemical compounds to reproduce
their experimental diffusion coefficients (data unpublished). Also, for ligands, the
NSIG parameter was set to -1 where the program estimates the two extreme values
of sigma, and therefore, there is no need to define SIGMIN and SIGMAX values.
The diffusion coefficients of the different protein and ligand molecules simulated in
this study are given in table 5.13.
Molecule
Name
Translational diffusion
coefficient
Å2/ps
Rotational diffusion
coefficient
radian2/ps
Trypsin 0.010550 0.000015
Coagulation Factor Xa 0.010460 0.000014
Haspin kinase 0.008663 0.000008
Neuraminidase 0.005707 0.000002
benzamidine 0.092250 0.009354
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Molecule
Name
Translational diffusion
coefficient
Å2/ps
Rotational diffusion
coefficient
radian2/ps
rivaroxaban 0.052000 0.001482
apixaban 0.048800 0.001173
5-iTU 0.063310 0.002976
5-brTU 0.063830 0.003063
5-clTU 0.063230 0.003080
5-fTU 0.064360 0.003165
5-hTU 0.065460 0.003408
oseltamivir 0.063450 0.002729
zanamivir 0.060030 0.002330
Table 5.13: Translational and rotational diffusion coefficients of different protein and ligand
molecules calculated using HYDROPRO.
5.2.6 Generation of Reaction Criteria
For docking and association rate calculations with SDA, the user needs to spec-
ify a set of reaction criteria that define the formation of an encounter complex.
Usually, donor-acceptor atom pairs in the bound protein-ligand complexes are con-
sidered as reaction criteria but other types of interacting atom pairs can also be
included. To generate reaction criteria for two interacting solutes automatically, we
wrote a python script ReactionCriteria.py that generates reaction criteria by tak-
ing into account the hydrogen bonding interactions, halogen-π interactions, and the
π-π interactions in the bound protein-ligand complex. It requires a total of three
mandatory parameters as input: 1) PDB file for protein, 2) PDB file for ligand, and
3) the reaction distance (in Å). The MOL2 file for the ligand can also be provided
as an optional fourth argument, if π-π interactions between the protein and ligand
also need to be considered for generating reaction criteria. In our association rate
calculations, we only considered possible donor-acceptor pairs (within 3.5 Å) and
halogen-π interactions (within 4.5 Å) between protein and ligand molecules for gen-
erating reaction criteria. Tables 5.14, 5.15, 5.16 and 5.17 lists the set of pairs of
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atoms used as reaction criteria for performing association rate calculations for the
different protein-ligand systems simulated.
Trypsin benzamidine
D171 OD1 N2
D171 OD1 N1
D171 OD2 N1
S172 OG N1
S172 O N2
S172 O N1
G196 O N2
Table 5.14: Reaction Criteria for SDA association rate constant calculations for benzamidine
binding to Trypsin.
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oseltamivir-Neuraminidase zanamivir-Neuraminidase
oseltamivir Neuraminidase zanamivir Neuraminidase
N4 E119 OE2 O1B R118 NH2
N4 D151 OD1 NH2 E119 OE1
O10 R152 NH2 NE E119 OE2
O1A R292 NH1 NH2 D151 O
O1A R292 NH2 NE D151 OD1
O1A Y347 OH O10 R152 NH2
O1A R371 NH1 NH2 R156 NH1
O1B R371 NH1 NH1 W178 O
NH2 W178 O
O9 R224 NE
O9 E276 OE1
O8 E276 OE2
O1A R292 NH1
O8 R292 NH1
O1A R292 NH2
O8 R292 NH2
O1A Y347 OH
O1A R371 NH1
O1B R371 NH2
O1A Y406 OH
O1B Y406 OH
O6 Y406 OH
Table 5.17: Reaction Criteria for SDA association rate constant calculations for inhibitors of N1
Neuraminidase (NA).
5.2.7 Association rate calculation with SDA
Simulation setup
Using trypsin-benzamidine as a model system, some of the parameters were opti-
mized to simulate protein-ligand association with SDA. For protein-ligand associa-
tion, a smaller probep radius of 1.40 Å (representative of hydrogen bond distance)
was used than the relatively larger radius of 1.7-2.0 Å used for protein-protein associ-
ation in previous studies. The value of the radius used for protein-protein association
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studies is chosen to represent the atomic radius of surface (non hydrogen) atoms and
therefore the value of this radius depends on the type of force field used, for example,
a smaller value (0.5 Å) should be used with the ProMetCS force field as it includes
a Lennard-Jones term. In the simulation setup, the protein molecules were kept
fixed at the center of a spherical system and the BD trajectories of ligand molecules
were started from a large center-to-center distance (of mass), b surface of 100 Å at
which the centrosymmetric forces acting between protein and ligand molecules are
assumed to be negligible (iso-potential values of electrostatic grids were lower than
± 0.01 kcal/mol units). A trajectory was stopped when the ligand left the outer c
surface = 300 Å. An encounter complex was considered to be formed when protein
and ligand satisfied 1 to 5 independent reaction contacts (nb-contacts parameter in
SDA input file), with the minimum distance between independent contacts (dind)
being 3 Å. Due to smaller size of the ligands and to ensure presence of at least 2
independent contacts, a smaller dind value of 3 Å was chosen for ligands compared
to 6 Å used for proteins. Due to the small size of the benzamidine, the distance
criteria for independent contacts (dind) was set to 2 Å to have at least 2 independent
contacts because having dind=3 Å resulted in only 1 independent contact.
Figure 5.11: Schematic representation of the geometric setup for the diffusional association of
protein and ligand molecules in BD simulations.
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Analysis of SDA output
Diffusional association rate constants were computed for encounter complexes satis-
fying one to five reaction contacts at different reaction distances starting from 3.0 Å
to 20.0 Å, with each reaction window separated by 0.5 Å. For each system, two sets of
simulations were run: with and without taking into account hydrophobic desolvation
(HD) potentials in simulating diffusional association (see Figure 5.12). Hydrophobic
desolvation potential grid values were multiplied by a factor of -0.013 (hdfct = -0.013)
to compute the short-range attractive nonpolar interaction forces. For each set of
simulations, four replica simulation runs were run with different starting position of
ligand at the b surface to gain statistically relevant results. 50,000 trajectories were
simulated in each run (total 4 x 50,000 = 200,000) of simulations when hydrophobic
desolvation (HD) potentials were considered. For simulations without hydropho-
bic desolvation taken into account, 500,000 trajectories were simulated for each run
(total 2 million trajectories were run). To increase the statistical significance, rate
constants from all four replica simulations of the same system were averaged and a
standard error was calculated using the SDA integrated tool nos2rates.
Figure 5.12: Schematic representation of BD simulations protocol to explore determinants of kon
rates for protein-ligand binding using SDA 7.
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For computing diffusional association rates, encounter complexes satisfying 3 in-
dependent reaction contacts between protein and ligand were considered by default.
In cases where reactions were not observed within 10 Å, rates for 2 reaction con-
tacts were taken into account (refer to Figure 5.12). However, for certain systems,
only encounter complexes with a maximum of 2 independent reaction contacts were
formed due to limited accessibility of the binding pocket due to the specific binding
mode. For such systems, encounter complexes satisfying 2 reaction contacts were
considered for computing association rates. Because desolvation interactions are
only relevant at distances less than 6 Å, for simulations run with only electrostatic
forces and no hydrophobic desolvation potentials, the reaction window starting at 6
Å (having kon > 0 and standard deviation < 25%) was used to record the association
rates.
Protein-ligand
system
simulated
Number of
reaction contacts
satisfied in
encounter
complexes
Distance
for recording
diffusional kon
(with
Hydrophobic
Desolvation)
(Å)
Distance
for recording
diffusional kon
(without
Hydrophobic
Desolvation)
(Å)
Trypsin-benzamidine 2 4.0 6.0
FXa-rivaroxaban 2 5.0 6.5
FXa-apixaban 2 6.5 8.0
Haspin-5-iTU 3 11.0 NA
Haspin-5-brTU 3 10.0 NA
Haspin-5-clTU 3 10.0 NA
Haspin-5-fTU 3 11.0 NA
Haspin-5-hTU 3 10.5 NA
Neuraminidase-oseltamivir 3 4.0 6.0
Neuraminidase-zanamivir 3 4.0 6.0
Table 5.18: Reaction criteria considered for defining successful encounter complexes and dis-
tances at which diffusional kon rates were recorded in both sets of simulations (with and without
hydrophobic desolvation forces) for different protein-ligand complexes studied.
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In simulations run with hydrophobic desolvation potentials, a smaller reaction
window of 4 Å was considered as cut-off window because short-range attractive
hydrophobic interaction leads to closer contacts. For more details on the criteria
used to record on-rates, please refer to protocol in Figure 5.12.
5.3 Results
5.3.1 Diffusional association rate constants (kon) computed
for the trypsin-benzamidine association
The Trypsin–benzamidine complex, due to its small size and monomeric structure,
is a popular model system frequently used for developing and testing the methods
for computing protein–ligand binding kinetics. Herein, we have also used the diffu-
sional association of benzamidine to trypsin for optimizing some of the SDA input
parameters used in our BD protocol to compute diffusional association (kon) rate
constants for protein-ligand association. Diffusional association rate constants were
computed for the association of trypsin and benzamidine using SDA and 2 sets of
simulations were run with hydrophobic desolvation (HD) interaction forces included
in the first set and excluded in the second set of simulations (Figure 5.13 B). The
encounter complexes between trypsin and benzamidine were formed starting at a
distance of 3.0 Å irrespective of the presence or absence of HD forces in the simula-
tion of diffusional encounter. The encounter complexes formed (in both simulations
with and without HD forces included) at 3.0 Å almost reproduced the bound state
with an RMSD of less than 1.0 Å between the orientation of benzamidine in the
encounter complex and the crystallized structure of trypsin-benzamidine complex
(Figure 5.13 A).
The computed diffusional association rate constants were consistently higher at
all reaction distances when HD forces were taken into account. A sharp decline in
the association rates was observed at distances below 8.0 Å when HD forces were not
considered. However, when HD forces were considered in the BD simulations, the
short-range hydrophobic forces become important as observed by considerably faster
on-rates, even at shorter distances (Figure 5.13 B). The HD forces within 6 Å might
result in some effective 2D surface diffusion of the ligand, thereby resulting in closer
contacts and faster on-rates. However, we did not analyse the individual trajectories
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to visualize any surface diffusion. The diffusional kon rate constant computed for
binding of benzamidine to trypsin was approximately 15 fold overestimated (45.9 ±
2.16 x 107 M−1s−1) compared to the experimental value (2.9 x 107 M−1s−1), when
HD forces were considered. When HD forces were excluded, the computed on-rate
(0.82 ± 0.14 x 107 M−1s−1) was about 3 fold lower than the experimental value (for
which no information on experimental error was given).
Figure 5.13: A) Comparison of the orientation of benzamidine (shown with stick representation
in magenta) in the co-crystallized structure (PDB Id: 3PTB) with trypsin (shown with surface
representation) and in the encounter complex formed during BD simulations with hydrophobic
desolvation potentials using SDA (stick representation in green). B) Comparison of diffusional
kon rates calculated for the association of benzamidine with trypsin with and without inclusion of
HD forces in the diffusional association. Based on the analysis protocol described in Figure 5.12,
different reaction windows were selected specific to the protein-ligand system studied and the type
of simulation, with their corresponding computed kon values marked with circles (refer to Table
5.19 for exact numbers).
Protein-ligand
system
simulated
Experimental
kon value
(×106 M−1s−1)
Computed
kon value
(with HD)
(×106 M−1s−1)
Computed
kon value
(without HD)
(×106 M−1s−1)
Reference
for
experimental
value
Trypsin-
benzamidine 29.0 459.1 ± 21.56 8.17 ± 1.43 [157]
FXa-
rivaroxaban 29.00 ± 6.0 169.6 ± 22.55 1.45 ± 0.34 [158]
FXa-
apixaban 7.30 ± 1.60 88.55 ± 11.43 0.77 ± 0.17 [158]
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Protein-ligand
system
simulated
Experimental
kon value
(×106 M−1s−1)
Computed
kon value
(with HD)
(×106 M−1s−1)
Computed
kon value
(without HD)
(×106 M−1s−1)
Reference
for
experimental
value
Haspin-5-iTU 9.39 ± 2.03 39.14 ± 6.82 NA [118]
Haspin-5-brTU 9.71 ± 2.67 31.26 ± 2.01 NA [118]
Haspin-5-clTU 2.79 ± 1.26 11.83 ± 0.71 NA [118]
Haspin-5-fTU 2.06 ± 2.07 24.25 ± 4.12 NA [118]
Haspin-5-hTU 0.20 ± 0.16 10.10 ± 2.50 NA [118]
Neuraminidase-
oseltamivir 2.52 ± 0.21 111.25 ± 6.80 3.21 ± 0.09 [159]
Neuraminidase-
zanamivir 0.95 ± 0.08 552.50 ± 2.97 9.60 ± 0.40 [159]
Table 5.19: Comparison of experimental association rate constants and computed association
rate constants from SDA for different protein-ligand complexes simulated (HD = hydrophobic
desolvation potentials).
5.3.2 Diffusional kon rate constants computed for the
inhibitors of Human Coagulation Factor Xa
Association rate constants computed for association of rivaroxaban and apixaban
to Human Coagulation Factor Xa using SDA are shown in Figure 5.14 C,D. Both
rivaroxaban and apixaban bind to Factor Xa in an L-shaped conformation where
one part of the ligand occupies the anionic S1 pocket and another part occupies the
S4 pocket (see Figure 5.14 A,B). Since both protein and inhibitor molecules were
modelled as rigid bodies and internal conformational flexibility was neglected, the
encounter complexes of rivaroxaban and apixaban with Factor Xa satisfied maximum
2 reaction contacts within 10 Å reaction distance. Due to differences in the size of
the inhibitors and the diversity of atoms contributing to the reaction criteria, the
encounter complexes and hence, the rates were computed starting from different
reaction windows. For rivaroxaban, association events were observed starting at 4.5
Å when hydrophobic desolvation forces were also taken into account, and at 5.5 Å
when hydrophobic desolvation forces were excluded in the simulation of diffusional
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encounter (see Figure 5.14 C and D). Apixaban, on the other hand, formed encounter
complexes with Factor Xa starting from 6 Å in the simulations run with hydrophobic
desolvation forces and from 7.5 Å when hydrophobic desolvation forces were ignored.
Figure 5.14: The orientations of A) rivaroxaban and B) apixaban (shown with stick represen-
tations in magenta) in the co-crystallized structures (PDB Ids: 2W26, 2P16 respectively) with
Coagulation Factor Xa (shown with surface representation, colored by polarity of residues with
positively charged, negatively charged and neutral residues shown in blue, red, and gray color
respectively) and in the encounter complex formed during BD simulations with hydrophobic des-
olvation forces using SDA (shown with stick representations in green). In the encounter complexes
of rivaroxaban with FXa, rivaroxaban did not occupy the S1 sub-pocket of FXa’s binding site
and its chlorothiophene moeity was surface exposed. On the other hand, apixaban occupied the
S1 sub-pocket in the majority of its encounter complexes with FXa formed at shorter distances.
Comparison of diffusional kon rate constants calculated for association of rivaroxaban and apixaban
with Coagulation Factor Xa: C) without HD forces included, and D) with HD forces included in
the simulation setup. The rates for shown for encounter complexes forming 2 reaction contacts.
Based on the analysis protocol described in Figure 5.12, different reaction windows were selected
specific to the protein-ligand system studied and the type of simulation, with their corresponding
computed kon values marked with circles (refer to Table 5.19 for exact numbers).
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In calculations with HD forces included, the rate constants for reaction criteria
distances between 15 Å and 20 Å remained stable at around 1.0 x 1010 M−1s−1. For
both rivaroxaban and apixaban, this value corresponds to the diffusional motion of
ligands at a distance where they are not yet influenced by the distinct conformation
and electrostatic distribution of the active site. At reaction criteria distances be-
tween 4 and 8 Å, the association rate constants dropped for both rivaroxaban and
apixaban. The rate constant values are lower at shorter distances as encounter com-
plex formation depends on the proximity and correct orientation of bound ligands.
The latter requirement prevented multiple contacts being made at short distances.
The rate constants computed from BD sumulations with hydrophobic desolvation
included, were overestimated for both rivaroxaban and apixaban, with computed kon
values almost 5 fold and 12 fold higher than the experimental values for rivaroxaban
and apixaban, respectively (see Table 5.19). The computed kon for rivaroxaban and
apixaban from BD simulations without considering hydrophobic desolvation were
underestimated by about 1 order of magnitude compared to the experiments. How-
ever, both of the simulation protocols estimated higher kon values for rivaroxaban
compared to apixaban, which is in agreement with the experimental observations
(see Figure 5.14 C,D). The logP value of apixaban (2.22, source: DrugBank[161]) is
higher than the logP of rivaroxaban (1.74, source: DrugBank[161]) suggesting it to
be more hydrophobic than the rivaroxaban.
5.3.3 Diffusional kon rate constants computed for the
inhibitors of Haspin kinase
Association rate constants computed for the association of 5-iTU derivatives to
Haspin at different reaction distances are shown in Figure 5.15 B. Lack of the con-
formational flexibility and rigid modelling of both haspin and inhibitor molecules
restricted the access to the binding site by 5-iTU derivatives, with encounter com-
plexes starting to form at only distances greater than 8 Å from the binding pocket
(see Figure 5.15 A). In the BD simulations without HD forces taken into account,
encounter complexes were observed only from distances higher than 15 Å. There-
fore, for inhibitors of Haspin, we only computed rates from BD simulations with HD
forces included in simulating diffusional encounter. Diffusional kon rate constants
observed for all 5-iTU derivatives showed huge standard deviations at smaller dis-
tances and therefore rate constants were recorded at distances starting from 10 Å
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where the conditions specified in the SDA protocol (Figure 5.12) were met (refer to
Figure 5.15 B and Tables 5.19 and 5.18 for the specfic reaction windows considered
for different 5-iTU derivatives and the corresponding rate constants computed for
these reaction windows).
Figure 5.15: A) The orientations of 5-iTU (shown with stick representation in magenta) in the
co-crystallized structure (PDB Id: 6G34) with Haspin (shown with surface representation, colored
by polarity of residues with positively charged, negatively charged and neutral residues shown in
blue, red, and gray color respectively) and in the encounter complex formed during BD simulations
with hydrophobic desolvation forces (stick representation in green). B) Comparison of diffusional
kon rates calculated for association of 5-iTU derivatives with Haspin with HD forces included in
the simulation setup. Based on the analysis protocol described in Figure 5.12, different reaction
windows were selected specific to the protein-ligand system studied and the type of simulation,
with their corresponding computed kon values marked with circles (refer to Table 5.19 for exact
numbers).
Diffusional kon rate constants computed were higher for inhibitors containing
bigger halogen atoms such as 5-iTU, 5-brTu and 5-clTU than the inhibitors with a
smaller halogen (5-fTU) or no halogen substituted (5-hTU) (see Figure 5.15 B). This
is consistent with the experimental observations that substitution of bigger halogens
on tubercidin results in mediation of halogen-π interaction between halogen of in-
hibitors and aromatic ring of phenylalanine gatekeeper residue in the binding site
of Haspin, thereby resulting in an increase of kon rates and decrease of koff rates.
Since diffusional kon rate constants of inhibitors with bigger halogens were consis-
tently higher even at large reaction distances, changes in electrostatics induced by
halogen substitutions might result in stronger long-range electrostatic interaction
between the inhibitors and Haspin, leading to faster diffusion of halogenated in-
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hibitors towards Haspin’s binding site. Although, SDA was not able to exactly rank
these 5-iTU derivatives based on their kon rate constants, it managed to capture the
effects of changes in electrostatics and non-polar interactions of inhibitors due to
substitution of bigger halogens. The diffusional kon computed for all 5-iTU deriva-
tives were overestimated compared to the experimental values (see Table 5.19) as
we computed the rates at larger reaction distances, because at shorter distances,
rates were statistically not reliable and showed large error bars (see Figure 5.15 B).
These large errors at shorter distances could be attributed to the limited access to
the binding site, with BD trajectories in only a subset of simulations satisfying the
requirements for formation of an encounter complex.
5.3.4 Diffusional kon rate constants computed for the
inhibitors of Neuraminidase
Diffusional kon rate constants computed by SDA for diffusional association of os-
eltamivir and zanamivir with Neuraminidase at different reaction distances using
the 2 different simulation protocols (with and without HD forces) are shown in Fig-
ures 5.16 B and 5.16 C. The relatively exposed binding site of Neuraminidase, the
presence of a number of charged amino acid residues in its binding site, and the
zwitter ionic nature of both inhibitors contributed to the strong electrostatic inter-
action between the protein and the inhibitors with encounter complexes observed
at smaller distances from 4 Å. Due to the differences in the size of the ligands and
the diversity of atoms contributing to the reaction criteria, oseltamivir made up to
three, zanamivir up to five reaction contacts in the encounter complexes. When only
electrostatic forces were considered and no HD forces in the association, the on-rates
computed were higher for zanamivir than for oseltamivir (Figure 5.16 B). The com-
puted kon rate constant (3.21 ± 0.09 x 106 M−1s−1) for oseltamivir was very close to
the experimental values (2.52 ± 0.21 x 106 M−1s−1). In fact, this kon value computed
for oseltamivir by our protocol is very similar to the kon value (5.17 ± 0.08 x 106
M−1s−1) computed by Sung et al.[21] with their BD simulation procedure (without
including HD term in the simulations). The kon rate constant computed (9.60 ±
0.40 x 106 M−1s−1) for zanamivir was almost 10-times higher than the experimental
value (0.95 ± 0.08 x 106 M−1s−1). The electric dipole moment of zanamivir (25.20
Debye) calculated from RESP atomic charges was higher than the electric dipole
moment of oseltamivir (22.24 Debye) suggesting it to be slighly more polar than
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oseltamivir. This additional polarity might be because of the presence of additional
polar moieties on zanamivir such as diaminomethyl and trihydroxypropyl groups
which may result in stronger electrostatics interactions with the Neuraminidase and
this could be the reason why computed on-rates for zanamivir were higher than for
oseltamivir. Or, the higher on-rates for zanamivir could be due to the fact that
it might be relatively easier for zanamivir to satisfy the criteria of formation of 3
reaction contacts in the encounter complex due to its bigger size and presence of
more number of polar atoms on the list of contacts provided as the reaction criteria.
Figure 5.16: A) The orientations of the oseltamivir (shown with stick representation in magenta)
in the co-crystallized structure with Neuraminidase (shown with surface representation, colored
by polarity of residues with positively charged, negatively charged and neutral residues shown in
blue, red, and gray color respectively) and in the encounter complex formed during BD simulations
with hydrophobic desolvation forces (stick representation in green). Comparison of diffusional kon
rates calculated for association of oseltamivir and zamamivir with Neuraminidase: B) without HD
forces included, and C) with HD forces included in the simulation setup. Rates are shown for
encounter complexes satisfying the criteria for 3 reaction contacts. Based on the analysis protocol
described in Figure 5.12, different reaction windows were selected specific to the protein-ligand
system studied and the type of simulation, with their corresponding computed kon values marked
with circles(refer to Table 5.19 for exact numbers).
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In the simulation protocol with HD forces included, computed on-rates for both
oseltamivir and zanamivir were very high (higher than 109 M−1s−1) even at shorter
distances (from 6 Å). After 7-8 Å, rates become stable at around 109 M−1s−1. This
trend was observed for both oseltamivir and zanamivir and describes the diffusional
motion of ligands in a distance, at which they are not yet influenced by the distinct
conformation and electrostatic distribution of the active site. At reaction criteria
distances between 4 and 6 Å, association rate constants dropped for both oseltamivir
and zanamivir, but the drop was higher for oseltamivir. Still, the computed kon rate
constants (111.25 ± 6.80 x 106 M−1s−1) were approximately 40 times higher for os-
eltamivir than the experiments (2.52 ± 0.21 x 106 M−1s−1). Similarly, for zanamivir,
computed kon value (552.50 ± 2.97 x 106 M−1s−1) was highly overestimated by more
than 2 orders of magnitude compared to the experimental value of 0.95 ± 0.08 x
106 M−1s−1. Also, Neuraminidase are known to have an open 150-loop structure
in the unbound form, that closes upon drug binding, and the polar residues in the
150-loop (Asp151, Arg152) interact with polar side chains of the inhibitors. This
suggests that the slower conformational changes of protein and inhibitor molecules
are associated with the formation of a fully bound protein-ligand complex and these
short-range conformational changes are not modelled in BD simulations, and we
have only used the Neuraminidase structure with an open 150-loop conformation
(PDB Id: 2HTY). Therefore, SDA results suggest that zanamivir, inspite of having
higher diffusional on-rates, has the slower experimental kon value than oseltamivir,
meaning that conformational adaptation might be slower for binding of zanamivir
to Neuraminidase than for oseltamivir.
5.4 Concluding Discussions
The current application of our protocol to different protein-ligand systems for the
calculation of diffusional association rate constants of the ligands demonstrate that
the protocol has some limitations in correctly ranking the ligands according to their
experimental on-rates. In some cases, especially for inhibitors binding to Coagula-
tion Factor Xa and Haspin kinase, the protocol managed to correctly distinguish
the inhibitors with slow and fast on-rates. However, for inhibitors binding to Neu-
raminidase, the protocol failed to capture the effects of faster binding of oseltamivir
compared to zanamivir. Since our protocol is solely based on BD simulations where
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we model the interacting molecules as rigid bodies and neglect the internal con-
formational flexibility of molecules, our protocol may not completely capture the
short-range effects of binding of small but flexible ligand molecules, especially when
the protein-ligand binding is conformation dependent. Although we have optimized
a set of parameters for the diffusional association of protein-ligand systems using
SDA software, this list is not complete and there are several other parameters that
need to be evaluated and optimized on a diverse set of systems. The short-range
desolvation forces acting between protein and ligand molecules might be sensitive
to the size of grid-spacing used for generating desolvation potentials grids. For the
generation of desolvation grid potentials, we have used the grid spacing value of 1
Å, that was used for protein-protein association studies in the past. We believe that
different values of grid spacing need to be evaluated for protein-ligand association,
especially because the rates (hence the binding) are very sensitive to the presence or
absence of short-range hydrophobic desolvation forces as observed in our calculations
when using HD term in the simulations. Moreover, the current dataset on protein-
ligand systems needs to be extended further and studied to have a well optimized
and robust protocol. As we have already discussed, this protocol, solely based on
BD simulations alone would not be sufficient to model the complete binding process
but it can serve as a good starting point for multiscale modelling, where, for exam-
ple, the less demanding BD simulations can be run using this protocol to model the
initial diffusional encounter of protein and ligand molecules, following which a more
computationally rigorous MD-based regime can be used to account for the flexibility
and conformational changes to simulate the formation of the final bound complex.
The association rates from these two different approaches can be combined using
specialized techniques such as milestoning to compute the on-rates for the complete
binding.
129

Chapter 6
KBbox: A Toolbox of Computational
Methods for Studying the Kinetics of
Molecular Binding
I have contributed to the development of KBbox (http://kbbox.h-its.org/toolbox/),
a webserver which provides information about various computational methods to
study molecular binding kinetics, and different computational tools that employ
them. It is developed as an effort to guide less experienced researchers in the use of
different computational and simulation approaches available to compute the kinetics
parameters of drug-protein binding. The toolbox lists and provides an overview of
the current state-of-the-art computational approaches for studying molecular bind-
ing kinetics, with methods ranging from relatively high-throughput regression-based
chemoinformatics methods to computationally intensive atomic-level simulation ap-
proaches. KBbox provides a curated list of published applications of the methods,
providing users with an easy-to-find reference list. For a number of methods, de-
tailed tutorials are also provided that give the user an introduction into how to
run the calculations and to reproduce some of the example cases. KBbox provides a
query interface that asks a series of questions relating to structural and kinetics data
available to them, and the data they wish to calculate, and provides them with a list
of methods found in the toolbox that match their query, sorted approximately by
the computational resources required for their application. The web server is easily
extendable, allowing us to add new methods to the toolbox as they are developed
and published.
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Figure 6.1: A snapshot of the homepage of KBbox toolbox website (http://kbbox.h-its.org/
toolbox/). The key features/content of the toolbox are highlighted in different colors.
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6.1 Technical Implementation
KBbox was developed using the high-level python web framework Django (Version
2.2, Retrieved from https://djangoproject.com) for serving dynamic HTML con-
tent created from information stored in its database (see Database Structure). The
responsive web interface of the KBbox is provided through the use of JavaScript
and CSS plugins from the Bootstrap 3[162] framework. Biopython’s[163] Bio.Entrez
module is used for programmatic access to Entrez[164], a data retrieval system
that provides users access to NCBI’s databases such as PubMed. The Bio.Entrez
parser allows for example to search PubMed or download GenBank records from
within a Python script. This functionality is used in KBbox to add new exam-
ple cases directly by providing either a valid PubMed Id or a valid DOI iden-
tifier, and the data is parsed using the Beautiful Soup parser. KBbox uses the
CKEditor rich text editor in the Django-CKEditor python package to enable writ-
ing the content directly in web pages e.g. to add and format rich text for new
methods, tools or tutorials. In addition, KBbox also uses Pillow (version 4.0, re-
trieved from https://pillow.readthedocs.io/en/stable/), a Python Imaging Library
(PIL) fork which provides image processing capabilities to the Python interpreter.
6.2 Database Structure
KBbox uses SQLite, the default database available in the Django framework. SQLite
is included in Python and it is a fast, self-contained and highly-reliable SQL database
engine. The data structure used in KBbox is shown in the Figure 6.2. The main
data table contains the computational methods that comprise the toolbox (class
CompMethod). Each entry in the table contains a short summary description of
the method and a more detailed introduction to the method. It also contains a
number of Boolean parameters that are used for querying the methods in the tool-
box, to find which methods match the user’s needs. These relate to the data that
the user wishes to obtain (association rates—kon; dissociation rates—koff ; phar-
macokinetic/pharmacodynamics predictions—PKPD), whether training or atomic
structural data is required by the method, and whether the method is able to pro-
vide absolute data, or only relative data. Finally, the table contains an integer
(comp_cost field) describing the approximate computational cost of the method
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from 1 (least expensive) to 5 (most expensive). Values of 1 or 2 relate to methods
that can be run in short time on a desktop computer. Values in the range 3 to 5 cor-
respond to longer simulation-based methods. Each method is sorted into one group
(class CompMethodGroup), to allow KBbox to organize the methods into different
classes allowing users to search for methods more easily. Currently, these groups are
molecular modeling, molecular simulation, PKPD modelling and QSKR (qualitative
structure – kinetics relationships) approaches (discussed in the following sections).
Figure 6.2: Entity relationship diagram showing the data representation used in KBbox. (http:
//kbbox.h-its.org/toolbox/). For each of the 6 classes, name of the fields and their data types are
shown. This figure was prepared by Dr. Neil J. Bruce.
Each method is linked to one or more examples of previously published research,
or a report of currently unpublished data, in which that method was either the
primary method used, or one of a set of methods applied (class ExampleCase).
Each row in the table describing these examples contains author information and a
flag to say whether the work is published or unpublished. For published examples,
citation data is also provided. For some of the examples, tutorials are also provided
these are recorded in an additional table (class Tutorial).
A separate table is used to populate the list of computational tools described
by KBbox (class CompTool). Each row of this table contains a description of the
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tool, its license and a URL to its web page. In a similar manner to the methods,
the tools are grouped into classes (class CompToolGroup). Currently, these are data
analysis tools, PKPD modelling tools, preparation and general modelling tools, sim-
ulation tools and structure visualization tools (discussed in the following sections).
A particular tool could be a member of more than one group.
6.2.1 Query Interface to choose the methods
The toolbox also provides a query interface that asks users about information on
the amount of structural and kinetic data they have, and the data they want to
calculate, and suggests them a list of appropriate methods that they could use. This
list of methods is sorted based on the amount of computational resources required
by the methods. The query is built based on the information provided by users
on the data they want to estimate (kon, koff or PKPD modelling), amount of 3D
information available on protein-ligand complexes, and whether experimental kinetic
data is available for the ligands (see Figure 6.3). The methods that match this query
are provided, with methods sorted by the computational resources required for their
application (comp_cost field in CompMethod class).
Figure 6.3: Schematic outline of the query building workflow of the Interface to suggest list of
appropriate methods to the users. Note: This schema served as the starting point for the design of
the interface, however the design evolved with time and therefore, the actual workflow implemented
on the website might be different from the one shown here.
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6.3 Group of Methods available in KBbox
The Methods webpage provides a description of a number of computational meth-
ods that can be used to investigate binding kinetics. At present, the toolbox provides
information on 19 different computational approaches that have been broadly cate-
gorized into the following 4 groups:
• QSKR Approaches
QSKR (quantitive structure-kinetic relationship) are regression or classifica-
tion models that relate a set of physio-chemical properties or molecular de-
scriptors to the binding kinetics of compounds. QSKR regression models use
regression techniques to relate a set of molecular descriptors (referred to as
"predictor variables" in Machine Learning terminology) to the kinetic parame-
ter ("response variable") and predicted parameter is a continuous value. QSKR
classification models, on the other hand, relate the predictor variables to a cat-
egorical value (e.g. slow or fast, active or inactive) of the response variable.
• Molecular Simulation
Molecular simulation is a type of N-body simulation technique used for study-
ing the physical movements of atoms and molecules. In molecular simulation,
the dynamics of the system can be studied by allowing the atoms and molecules
to interact for a fixed period of time. In the most common version, forces be-
tween the interacting particles and their potential energies are calculated using
interatomic potentials or molecular mechanics force fields, and the trajectories
of atoms and molecules are determined by numerically solving the Newton’s
equations of motion.
• PKPD Modelling
PKPDmodeling (pharmacokinetic/pharmacodynamic modeling) combines dose-
concentration relationships (pharmacokinetics) and concentration-effect rela-
tionships (pharmacodynamics) into one set of mathematical expressions, that
allows to establish and evaluate dose-concentration-response relationships and
subsequently describe and predict the effect-time courses resulting from a drug
dose.
• Molecular Modelling
Molecular modelling tools are used to create and modify the 3D structures of
136
molecules. When experimental structural data is missing, they can be used
to predict the structures of biomolecules, biomolecular complexes and of com-
plexes formed between biomolecules and small molecules. They are also used
to prepare existing structures for use in simulations.
6.4 List of Examples
The different computational methods described in KBbox are linked to one or several
of the example cases (also available under Examples webpage link) where they were
successfully applied. The toolbox currently lists total 33 example cases of which 31
are already published.
6.5 Group of Computational tools in KBbox
TheTools webpage lists a number of different computational tools that are employed
in binding kinetics studies. At the moment, there are total 18 computational tools
and software that are grouped under the following 5 categories:
• Simulation Tools
Currently, this section consists of information on 7 different simulation tools
such as Amber, Amber Tools, CHARMM, Gromacs etc.
• Preparation and General Modelling Tools
There are total 12 different tools available in this category that are generally
used for preparation and modeling of 3D structures and potential grids for use
in simulation and docking based methods.
• Pharmacokinetic and Pharmacodynamics (PKPD) Modelling Tools
This category currently lists only one PKPDmodelling tool: Berkeley Madonna,
which is a mathematical modelling software package used for numerically solv-
ing ordinary differential equations, difference equations and multi-dimensional
transcendental algebraic equation roots.
• Data Analysis Tools
This section lists tools and programming languages commonly used for analysing,
plotting and visualizing output from molecular simulations and chemoinfor-
matics methods.
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• Structure Visualisation Tools
This category lists tools such as PyMOL, VMD or MOE commonly used to
visualize 3D structures, trajectories from molecular simulations and potential
grids of biomolecules.
6.6 List of Tutorials
KBbox has list of tutorials available under the Tutorials webpage to introduce
newcomers to the different computational methods required to reproduce some of
the example cases. These tutorials are also linked to their published example cases.
These tutorials provide scripts, input dataset and input files along with detailed
instructions on using specific computational method for computing rates for binding
kinetics. Currently, KBbox has 5 different tutorials available on different methods:
• Estimation of relative residence times of protein-ligand complexes
using τ-Random Acceleration Molecular Dynamics (τRAMD)
This tutorial guides the user through the process of setting up and run-
ning RAMD simulations for estimation of the relative residence time (τ) of
a protein-small molecule complex[29]. The procedure is demonstrated for a
complex of a low molecular weight compound with the N-terminal domain of
the heat shock protein, HSP90.
• Data exploration and linear regression of a kinetic dataset using R
This tutorial guides the user through the process of doing Multiple Linear
regression and data exploration on 16 MAP38 kinase inhibitors within the
software package R. Explorative data analysis is carried out on this dataset,
containing precalculated physicochemical descriptors. Multiple linear regres-
sion and correlation analysis are utilized to identify descriptors influencing
koff .
• Compartmental modelling and simulation in Berkeley Madonna
This tutorial demonstrate the use of compartmental modelling and simulation
in Berkeley Madonna in predicting the receptor occupancy time profile in a
body tissue after intravenous administration of a receptor ligand. In this tu-
torial, the selective dopamine D2 antagonist raclopride is used as an example.
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The pharmacokinetics (PK) and dopamine D2 receptor occupancy (RO) in
brain after intravenous administration of raclopride to rat are simulated[165].
• Prediction of the rate of formation of a protein-protein complex us-
ing SDA
This tutorial describes the use of SDA to perform Brownian dynamics simula-
tions to predict the bimolecular association rate constant for the formation of
a protein-protein complex[131].
• Generation of Quantitative structure-kinetics relationships (QSKRs)
using Comparative Binding Energy (COMBINE) Analysis
This tutorial guides the user through the process of setting up and running
COMparative BINding Energy (COMBINE) analysis to derive Quantitative
structure-kinetics relationship (QSKR) for dissociation rate constants (koff ) of
inhibitors of a drug target[109]. The procedure is demonstrated for a dataset
of 70 inhibitors of heat shock protein 90 (HSP90) belonging to 11 different
chemical classes.
6.7 Example Use Cases
KBbox is useful for a variety of users with different needs and experiences. Here we
outline two potential use cases of the web server.
6.7.1 What method should I use for a given project?
A PhD student with some basic experience in computational modeling and simula-
tion, is interested in starting a new project where he has data on residence times
of a set of inhibitors for a given protein target. He also has crystallographic data
for these inhibitors bound to the target. He wants to use computational modeling
to predict the determinants of short and long residence time compounds and use
this knowledge to predict residence times of compounds with no experimental data
available. He arrives on the KBbox home page (Figure 6.4, black box), and click on
the button “Not sure what method to use for a particular problem? Click here!”, and
is then asked a set of questions relating to the data available to him, and the data
he is interested in calculating. After these questions are answered, KBbox checks
the database, and a list of methods, that match his query are presented to him
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(Figure 6.4, red boxes, anticlockwise). These methods are sorted approximately by
the computational resources required for the calculation. The student clicks on each
entry in this list, and he is taken to pages that give an overview of the methods,
along with a curated list of examples of previous applications of each method, with
links to the relevant journal articles. The student selects COMBINE analysis[46]
as the method he is interested in, and he then follows the link to the tutorial that
describes how to perform COMBINE analysis on his data (Figure 6.4, red boxes,
anticlockwise).
Figure 6.4: Representation of two of the example use cases of KBbox.
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6.7.2 Where can I find information on previous applications
of a method for studying kinetics?
A postdoctoral researcher is interested in using τ -Random Acceleration Molecular
Dynamics[29] (τRAMD) to study the unbinding of a set of compounds from a target
protein and to rank them according to their relative residence times. While he has
heard about the method, he does not have experience of running these simulations,
and is looking for more information on the method and examples of previously pub-
lished research using τRAMD. He arrives on the KBbox homepage and then clicks
on the “Methods” button at the top of the page. From here he selects “Molecular
Simulation” from the menu on the left-hand side of the page and find the entry for τ -
Random Acceleration Molecular Dynamics (Figure 6.4, green boxes, anticlockwise).
After clicking on this entry, he is presented with an overview of the method, and
a list of published examples of its application to binding kinetics studies. He/she
follows the links for the examples and is taken to the relevant journal pages.
The computation of binding kinetics is an active area of interest, and the devel-
opment and application of more robust and advanced computational approaches is
expected to increase in the future. Therefore, the KBbox will be extended continu-
ously to include data on new computational methods and their example cases. Also,
more tutorials on different computational approaches will be added in the future.
Hence, KBbox will be useful to the scientific community and will provide information
on state-of-the-art of computational methods available to investigate and estimate
kinetic parameters for molecular binding.
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Chapter 7
Summary and Outlook
A number of recent studies suggesting the better correlation of efficacy of a drug
with its residence time at its receptor than its affinity has led to widespread efforts
in both industry and academia to consider the role of drug binding kinetics in drug
discovery programs. This has resulted in a growing demand for in-silico and ex-
perimental methods that can estimate or predict kinetic parameters of drug-protein
binding. In addition, understanding the mechanistic determinants of drug-target
binding kinetics is important for aiding the design of lead molecules with optimized
kinetic properties.
One of the important aims of this thesis was to use the available information
from structures of protein-drug complexes and experimentally determined kinetic
parameters of protein-drug binding to derive Quantitative Structure-Kinetics Re-
lationships (QSKRs). For this purpose, I employed Comparative Binding Energy
(COMBINE) analysis, to derive protein-specific scoring functions for the koff rate
constants of inhibitors of HIV-1 protease and HSP90. For both of these protein
systems, I managed to derive statistical models which relate the koff rate constants
of their inhibitors to weighted selected components of the drug-receptor interaction
energy. Unlike the congeneric series of compounds normally used for training such
linear regression models, herein I have used diverse sets of inhibitors that have very
different scaffolds and binding modes. These models were found to have good predic-
tive ability as assessed using different cross-validation methods and a validation data
set. These models can therefore be used to make predictions for off-rates of novel
inhibitors of these proteins. Using COMBINE analysis, I was also able to identify
key protein-inhibitor interactions that explain the variance in the binding kinetics of
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the inhibitors. These specific components of interaction energy provide insights into
the mechanisms of specific slow and fast dissociating classes of inhibitors. My results
on two different targets with very diverse sets of inhibitors considered, suggests that
the COMBINE analysis has potential as a robust and medium-throughput QSKR
method and its scope of application is expected to grow as more data on measured
kinetic parameters becomes available.
Recent work on Haspin kinase and its halogenated inhibitors has demonstrated
that inhibitors with long residence times can be designed by introducing a halogen-
aromatic π interaction between a halogen atom which is commonly found in the
drugs, and an aromatic residue in the binding site. Substitution of an iodide moiety
in tubercidin to form 5-iodotubercidin (5-iTU), a close analogue of ATP, resulted in
the formation of a halogen-aromatic π interaction with the F605 gatekeeper residue
present in the binding site of Haspin, as confirmed from the analysis of the 3D crys-
tallographic structures of Haspin complexed with 5-iTU. 5-iTU shows a very high
affinity for Haspin and also a very long residence time compared to ATP and unsub-
stituted tubercidin. Characterization of the affinities and binding kinetics of 5-iTU
derivatives (substituted with smaller halogen atoms: Br, Cl and F) with different
experimental assays showed that the affinities as well as the residence times of 5-iTU
derivatives diminish with the decreasing size of the substituted halogen atom. I per-
formed quantum mechanical interaction energy calculations to analyze the nature of
the polarization mediated interactions of the core inhibitor scaffold with the gate-
keeper aromatic residues. I calculated the second-order Møller–Plesset interaction
energies (EMP2) between the 5-iTU derivatives and the gatekeeper phenylalanine
(F605) residue at consecutive levels of quantum mechanical theory and partitioned
the EMP2 energy into its constituent energetic components using a many-body energy
decomposition scheme. I found that the correlation energy (ECORR) makes a major
contribution to the total EMP2 interaction energy between 5-iTU derivatives and the
gatekeeper residue. Also, I observed a very high correlation between ECORR and the
experimentally measured residence times of 5-iTU derivatives with a correlation coef-
ficient (R2) of 0.97. This correlation energy explains the second-order intermolecular
dispersion interactions and the correlation corrections to the Hartree–Fock energy.
I also computed binding free energies of the Haspin-inhibitor complexes using the
classical MM/GBSA approach, to account for the complete protein structure. The
computed binding free energies correlated well with the calorimetric data obtained
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from experiments suggesting that the enthalpic contribution to binding increases
with the increase in size of the halogen atom substituted on inhibitors. In addition,
the residence times of the 5-iTU derivatives computed with the τ -RAMD procedure
correlated well with the experimentally measured residence times.
I then went on to establish a protocol for the high-throughput calculation of
diffusional association rate constants for protein-small molecule binding by running
continuum solvent and rigid-body based Brownian dynamics simulations using the
SDA 7 software. A number of simulation parameters were accessed using the associa-
tion of trypsin and benzamidine as a test system and an optimized set of parameters
was derived that should be generally applicable to simulating diffusional association
of a wide-range of protein-ligand binding pairs. I also established standard guide-
lines for recording diffusional on-rates corresponding to specific reaction conditions.
I validated this protocol on several inhibitors of different targets of varying com-
plexities. I observed that the protocol had limitations in explaining the binding
of small but flexible molecules, as well as conformation dependent protein-ligand
binding. However, this protocol can serve as a good starting point for multi-scale
approaches that combine BD with MD, where BD simulations can be run using this
protocol to model the initial diffusional association of protein and ligand molecules,
following which an MD-based regime can be used to account for the flexibility and
conformational changes to simulate the formation of the final bound complex. The
association rates from these two different approaches can be combined using spe-
cialized techniques such as milestoning, as demonstrated by Votapka et al.[22] using
their software SEEKR.
In addition, I contributed to the development of KBbox, a toolbox of computa-
tional methods, which provides access to information on state-of-the-art computa-
tional methods to study molecular binding kinetics, and example cases and tutorials
for these methods. KBbox also includes a collection of tutorials that provide the
users with an introduction into how to use different computational approaches to
compute the kinetic parameters of protein-ligand binding. Due to the growing in-
terest in evaluation of drug-binding kinetics, a plethora of computational methods
based on biomolecular simulations and chemoinformatics has emerged recently that
are designed to compute either kon or koff or both. Some of these methods can
provide absolute values of kon and/or koff whereas others can be used to get rel-
ative rates or they can rank or classify ligands according to their binding kinetics.
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Also, depending upon the complexity of the protein-ligand system being studied, the
assumptions of the methods, and the amount of data available on the system, the
computational requirement and accuracy of these methods vary to a great extent.
Therefore, the choice of an appropriate method for a specific problem is non-trivial.
To help the users in choosing appropriate methods, KBbox provides a query interface
that asks users a series of questions related to the amount of structural and kinetics
data available, data that users wish to calculate, and suggests them a list of methods
for their calculations, and these methods are sorted by the level of computational
resources required for their application. Also, KBbox is designed to be easily extend-
able, so that the data on the newly developed methods and their published examples
can be added. We therefore believe that it will be useful to continuously maintain,
and regularly update this toolbox, and that will help the researchers with an inter-
est in studying drug-binding kinetics to use different state-of-the-art computational
methods for their system of interest.
Despite a lot of progress being made in the development and application of com-
putational approaches to compute binding kinetic parameters, there are still many
different challenges for computing kon and koff rates. For computing kon rates accu-
rately, meaningful encounter states must be found. On the other hand, for correct
evaluation of koff rates, a method should be able to effectively capture the factors
determining the escape of a tightly-bound ligand and the associated transition bar-
rier. In addition, computational methods make a critical assumption that the force
fields used are able to fully represent binding and unbinding processes for computing
drug-binding kinetics. However, the employed molecular force-fields are parameter-
ized to reproduce the equilibrium populations of free-energy wells, rather than the
transition barrier heights between them. Therefore, it is important to recognize the
shortcomings in commonly-used force fields so that future force fields can provide im-
proved representations of barrier heights. Similarly, water models used in simulation
approaches also need to be significantly improved so that the computational meth-
ods are able to reproduce diffusionally-limited kinetic data. At present, there is no
method available that can calculate absolute values of both kon and koff accurately
in the same computational framework with only modest computational resources.
Since the development of computational methods to compute drug-binding kinet-
ics is a very active area of research, one can expect further testing, refinement and
validation of these methods, as well as new approaches in the next few years. More-
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over, the improvement in accuracy of computational methods will contribute to a
thorough understanding of ligand–receptor structure–kinetics relationships.
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